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Particle size reduction and solid dispersions are common strategies used to improve the 
solubility of active pharmaceutical ingredients (APIs). The Supercritical Antisolvent (SAS) 
process has been proved to be advantageous over conventional micronization techniques 
however, due to the high surface energy of fine particles, handling and post-processing of the 
micronized material remains an issue. The combination of the SAS process with fluidized bed 
is an alternative to allow simultaneous precipitation of the API and coating onto the surface of 
larger particles, so the release and flow properties of the formulation can be improved in a 
single step. The aim of this project is to extend the understanding and applicability of SAS in 
conjunction with fluidized bed and produce formulations of curcumin, a model compound 
with poor water solubility. SAS-FB was initially used to precipitate curcumin onto lactose 
particles (125 µm), producing a free-flowing powder. As the size reduction of curcumin 
achieved was insufficient to significantly enhance its solubility, curcumin was coprecipitated 
with a hydrophilic polymer, poly (vinyl pyrrolidone) (PVP). Finally, simultaneous 
coprecipitation and coating onto several particles (MCC, 175 µm; corn starch, 15 µm and 
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Curcumin is a polyphenolic hydrophobic compound with several therapeutic properties such 
as anticancer, antioxidant, anti-microbial and anti-inflammatory [1,2]. However, the use of 
curcumin in pharmaceutical formulations is limited by its very low water solubility and 
consequent poor bioavailability. 
Common approaches to improve the dissolution properties of active pharmaceutical 
ingredients (APIs) include: modifying its crystalline structure; preparing composites with 
hydrophilic excipients; and/or increasing the surface area of the material by decreasing its size 
[3]. Traditional particle size reduction techniques (micronization) are usually divided into two 
main categories, top-down and bottom-up. In the former, mechanical means are used to break 
large particles, usually requiring high energy input and resulting in unstable and cohesive 
powders with wide particle size distribution [4–6]. While in the latter, particles are 
precipitated from solution so usually high temperatures are required in the drying step and 
often a low precipitation yield is obtained [7–9].  
Particle engineering using supercritical carbon dioxide (sc-CO2) is advantageous over 
conventional micronization techniques since the mild critical conditions of CO2 enable the 
processing of thermo-sensitive compounds and the production of formulations with low or no 
residual organic solvent content, avoiding product degradation and the need for further 
drying, which is especially important for the processing of pharmaceuticals. Moreover, by the 
manipulation of the process operating conditions (such as pressure and temperature), the fluid 
density and solvation power can be adjusted, allowing the control of the solute supersaturation 
and precipitation [10]. Thus, particle properties can be tuned and narrow particle size 




In the supercritical antisolvent (SAS) process, sc-CO2 acts as an antisolvent for the material to 
be micronized. This technique has been employed for several years to precipitate a wide 
variety of APIs  alone or in conjunction with excipients [14,15]; however, due to the high 
surface energy of fine particles, handling and post-processing of the micronized material 
remains an issue, especially in the case of nanometric particles. 
The combination of the SAS process and fluidized beds has been proposed more recently as 
an alternative [16]. In this way, APIs can be simultaneous precipitated and coated onto the 
surface of carrier particles in a single step, addressing the aforementioned issues of poor 
solubility and flowability. Such process integration also reduces the number of processing 
steps and the need for transfer of the product between equipment, lowering the risk of 
workers’ exposure to nanoparticles. Moreover, high-pressure fluidization with sc-CO2 avoids 
the agglomeration of the bed particles, since no liquid bridges are formed between them, and 
eliminates the possibility of forming explosive vapour phase mixtures, as is the case when air 
and organic solvents are employed as fluidizing medium [17,18]. 
1.2. Thesis Aims and Outline 
This work aims to employ different formulation strategies to improve the dissolution and flow 
properties of curcumin, exploring the advantages offered by supercritical fluid (SCF)-based 
precipitation in conjunction with fluidized beds, while extending the applicability and 
understanding of such techniques. In order to do that, the study was divided into steps, which 
are covered in the objectives of Chapters 3-5 described later in this section.   
This thesis has an alternative format in which publication-style chapters are integrated in the 
body of the text. In Chapter 1, the motivation, aims and overview of the work are given, 




following chapters, and basic principles and limitations of the analytical techniques used. 
Then, four publication-style chapters are presented (Chapter 2-5). Chapter 6 closes the study 
with a general discussion about the work, showing the main findings and recommendations 
for future work. A more detailed description of the content of each publication-style chapter 
and how they are connected is provided below. Visual representation of the thesis structure 
and main objectives of each chapter is shown in Figure 1-1.  
Chapter 2 
The applicability of SCFs to prepare a wide variety of pharmaceutical formulations is 
presented in Chapter 2. The fundamentals of well-known SCF-based processing techniques 
are discussed and recently developed processes are classified, and their differences and 
similarities discussed. Strategies to improve dissolution and flow properties of API 
formulations are also presented, giving insights into the selection of the most suitable 
formulation and processing method. 
Chapter 3  
In this chapter, simultaneous curcumin precipitation and coating on carrier particles (lactose, 
125 µm) is performed via SAS-FB (SAS integrated with a fluidized bed) aiming to improve 
the dissolution and flowability properties of the formulation. The characteristics of curcumin 
precipitation by SAS and SAS-FB are evaluated and the effect of several process parameters 
are investigated, with focus on correlating the morphology of the curcumin crystals obtained 
with the position of the operational point in the binary vapour-liquid equilibrium phase 
diagram of the system solvent-CO2. Pulmonary delivery is the proposed route of 










Further development of the work showed that the size reduction achieved by SAS and SAS-
FB in the previous chapter was not enough to significantly improve the aqueous solubility of 
curcumin. Therefore, Chapter 4 focuses on improving the solubility of curcumin by 
coprecipitation with a hydrophilic polymer, poly (vinyl pyrrolidone) (PVP), by SAS. Several 
operating conditions are tested and different solvent mixtures are employed to understand 
their effect on particle size and product recovery.    
Chapter 5 
Although successful in enhancing curcumin dissolution properties, the particles produced in 
Chapter 4 are aggregated due to their small size (327-51 nm). For this reason, Chapter 5 aims 
to combine improved dissolution and flow properties in the same formulation, which was the 
ultimate objective of this project. SAS-FB was used to coat free-flowing carrier particles 
(MCC, 175 µm) with curcumin/PVP coprecipitates in a single step and then the experimental 
rig was adapted to allow the coating of finer particles (corn starch, 15 µm and lactose, < 5 
µm) in a stirred vessel. The properties of fluidization in tapered beds and stirred vessels are 
discussed and, depending on the particle size of the carrier particles, oral or pulmonary 
delivery administration routes would be suitable.  
Although the published articles are the result of collaborative work, it is important to clarify 
that Ravenna Lessa Matos was responsible for designing and performing all experiments and 
analyses, interpreting the data, writing and editing the manuscripts in full. Tiejun Lu helped 
with adapting the experimental rig, interpreting the data and revising the manuscripts, 
Valentina Prosapio, Christopher McConville, Gary Leeke and Andrew Ingram helped with 




Elaine C. M. Cabral Albuquerque and Neil R. Foster helped with revising the manuscript 
(Chapter 2). 
1.3. Theoretical Background 
1.3.1. Supercritical Fluid Technology 
1.3.1.1. Properties of SCFs 
The phase diagram of pure CO2 is given in Figure 1-2a, showing the solid, liquid, gas and 
supercritical regions, depending on the pressure and temperature. The equilibrium between 
two phases is observed on the saturation curves and, at the triple point, solid, liquid and 
vapour coexist. The supercritical region is found at the end of the vaporization curve, above 
the critical pressure (Pc) and critical temperature (Tc), where the liquid and vapour phases 
became identical. Therefore, a fluid is said to be supercritical when it is compressed beyond 
its Pc and heated beyond its Tc [10] (Figure 1-2a).  
 
Figure 1-2. a) P-T diagram of CO2 (adapted from [19]); b) variation in density and viscosity of CO2 
with pressure at 310K (adapted from [20]). 
In the supercritical region, unique properties are observed, including liquid-like density, gas-
like viscosity and diffusivity (Table 1-1) and zero surface tension. In the proximity of the 




fluid density and viscosity, as exemplified in Figure 1-2b. These properties can be easily 
tuned by adjusting pressure and/or temperature, giving process flexibility to obtain products 
with varied characteristics. 
Table 1-1. Comparison of the order of magnitude of different thermo-physical properties of fluids in 



















































The critical properties of commonly used SCFs are given in Table 1-2. The most used is CO2 
since it has moderate critical pressure (7.39 MPa) and low critical temperature (31.1°C); it is 
non-toxic, non-flammable, inexpensive and considered environmental-friendly if compared 
with organic solvents. It can also be easily separated from the final product and recovered in 
the end of the process just by reducing the pressure to atmospheric conditions.  








carbon dioxide 44.0 31.0 7.4 
water 18.0 374.2 22.1 
methane 16.0 -82.8 4.6 
ethane 30.1 32.2 4.9 
propane 44.1 96.7 4.3 
ethylene 28.1 9.3 5.0 
propylene 42.1 91.8 4.6 
methanol 32.0 239.5 8.1 
ethanol 46.1 240.8 6.1 
acetone 58.1 235.0 4.7 




1.3.1.2. Supercritical Antisolvent (SAS) Process 
Antisolvent methods are based on the high solubility and diffusivity of sc-CO2 in organic 
solvents. In a typical Supercritical Antisolvent (SAS) process (Figure 1-3), the solute is 
dissolved in an organic solvent and then sprayed into a high pressure vessel through which sc-
CO2 is passed continuously. The instantaneous mixing of the phases leads to the 
supersaturation of the liquid solution and consequent precipitation of the solute, which is 
collected on a filter (detailed description of the experimental setup and procedure are given in 
Chapters 3 - 5). In a supersaturated solution, the solute concentration exceeds that of the 
saturated one. The degree of supersaturation is defined as the ratio between the concentration 
of the refered solutions (supersaturated/saturated), which is  the driving force for 
crystallization/precipitation (rapid crystallization). Therefore, it is the most important factor 
affecting the rate of precipitation and the characteristics of the final particles [23–25]. Within 
this thesis, the words crystallization and precipitation are used interchangeably. 
 
Figure 1-3. Simplified diagram of the SAS process. 
The SAS process is affected by a number of variables including, pressure, temperature, 
solution flow rate, solution initial concentration, CO2 flow rate, duration of the precipitation 




successful precipitation by SAS, two basic requirements must be met: complete miscibility 
between solvent and antisolvent (sc-CO2) at the operating conditions and insolubility of the 
solute in the solvent/antisolvent mixture. 
1.3.1.2.1. Selection of operating conditions 
The knowledge of the phase diagram of the components involved is crucial for understanding 
the precipitation mechanisms and appropriate selection of operating conditions. As 
experimental high-pressure phase equilibria data of ternary systems (solid-organic solvent-
CO2) of interest for SAS are scarce, usually the binary vapour-liquid equilibrium (VLE) 
diagram of solvent and CO2 is used to analyse the ternary system and select the operating 
point. Insignificant effect of solute is expected in the solvent-CO2 VLE diagram when the 
initial concentration of the liquid solution is very low or the solute is considered insoluble in 
the supercritical phase, which is not always true. 
Mixtures of CO2 and organic solvents usually have a typical VLE diagram, classified as type I 
by Van Konynenburg and Scott [26]. The shape of the curve showing pressure versus the 
molar fraction of CO2 (P-XCO2) at a fixed temperature is shown in Figure 1-4, where the 
saturated liquid and saturated vapour lines meet at the mixture critical point (MCP). The 
different regions of the diagram are presented in Figure 1-4a, for the system CO2-DMSO at 
329K [27], while Figure 1-4b presents the VLE of ethanol-CO2 [20], showing how the MCP 
of the system varies with temperature: at higher temperature, Pc increases and Xc decreases. In 
order to benefit from the previously mentioned properties of SCFs, the operating point is 
usually chosen in the supercritical region, that is, above the critical point of the mixture 





Figure 1-4. Binary vapour-liquid equilibrium of a) CO2-DMSO at 329K (adapted from [28], 
equilibrium data from [27]); b) CO2-ethanol at two different temperatures: 308K and 333K (adapted 
from [20]). 
Once P, T and XCO2 have been selected, the flow rate of the organic solution needs to be 
chosen. Usually a capillary tube is employed to disperse the solution inside the vessel and 
liquid jet atomization can happen depending on the velocity of the jet and position of the 
operating point [14]. In the proximity of the solvent-CO2 MCP, atomization can occur 
because the time required for the jet break-up to happen is shorter than the time taken for 
complete vanishing of the liquid surface tension (multi-phase mixing) [29]. Near above the 
MCP, jet velocities of 0.33-0.42 m/s (critical atomization velocity) were found to be enough 
to promote the atomization of different solvents in sc-CO2 [30]. On the other hand, at 
completely developed supercritical conditions, the surface tension vanishes before the jet 
break-up so no droplets are formed and the jet spreads as an expanding gas plume (single-
phase mixing) [29].  
There have been attempts to correlate the morphology of particles precipitated by SAS with 
the position of the operating point in the solvent-CO2 VLE phase diagram and the fluid 
dynamics of the solution jet when injected into CO2. It has been reported that nanoparticles 




microparticles are precipitated near above the MCP, expanded microparticles (EMP) are 
produced in the subcritical vapour region, while crystals are formed when the solute has very 
fast crystallization kinetics or the operating point is within the biphasic region [28]. Other 
authors, on the other hand, believe that the level of supersaturation achieved determines if the 
solute precipitates (as amorphous particles) or crystallizes: moderate solution supersaturation 
would lead to crystallization, while high supersaturation would lead to precipitation [31,32]. 
Figure 1-5 summarizes the two possible mechanisms of amorphous particle formation 
proposed by Reverchon and De Marco [28]. In the proximity of the MCP, particles are formed 
by drying of the atomized jet (mass transfer in and out of each droplet), so particles keep the 
spherical shape of the initial droplets. Far above the MCP, as no droplets are formed, the very 
fast mixing of the fluids (single-phase mixing) leads to a very high supersaturation and 
formation of a large number of nuclei which will develop into nanoparticles [28]. Other 
researches have proved that such morphologies can also be obtained by the manipulation of 
the initial concentration of the liquid solution since at higher concentrations the time required 
for the liquid surface tension to vanish increases, leading to an increase in particle size [32]. 
 




Besides considering the MCP of the binary system to select the operating point based on the 
intended morphology, it also important to know that the properties of the solvent (viscosity 
and surface tension) will determine the required increment in pressure to move from the 
transition region (near above the MCP) to completely developed supercritical conditions (far 
above the MCP). Ethanol and acetone, for example, present a narrower pressure transition 
range than DMSO [33]. 
In the SAS process, particle growth happens mostly by condensation (deposition of molecules 
onto particles) and in minor extent by coagulation (collision of particles) [34]. Due to the 
interactions of many physical phenomena (thermodynamics, fluid dynamics, mass transfer 
and precipitation kinetics) and the number of operating parameters involved, prediction of 
particle characteristics remains a difficult task [34,35]. In order to demonstrate the complexity 
of the process, possible effects of changing some of the operating parameters are summarized 
in Figure 1-6, where an increase in the nucleation rate is associated with a decrease in particle 
size, and vice versa (deeper discussion is provided in Chapters 3 and 4). As it can be seen, 
variations in any of the parameters has at least two opposite effects on supersaturation and 
nucleation rate. Therefore, experimental work remains a very important part of the research 







Figure 1-6. Effect of changing SAS operating parameters in the solution supersaturation and 
nucleation rate. 
1.3.2. Curcumin – problems and promises 
Curcumin is an orange-yellow polyphenolic compound traditionally used as a spice and food 
additive. It is extracted from the rhizome of turmeric (Curcuma longa) in association with 
smaller quantities of other compounds (curcuminoids), namely: demethoxycurcumin, bis-





Figure 1-7. Chemical structures of curcuminoids: a) curcumin, b) demethoxycurcumin, c) bis-
demethoxycurcumin, d) cyclocurcumin (adapted from [36]). 
Curcumin is an attractive compound for the pharmaceutical industry since it has a wide range 
of biological activity, including anti-inflammatory, antioxidant, antibacterial, antiviral, 
antiarthritic, antifungal and anticancer so potentially it could be used to treat numerous 
diseases [1,2].  
However, the bioavailability of curcumin is limited by its poor solubility in aqueous media, 
low absorption and fast intestinal metabolism [37]. In addition, curcumin undergoes 
degradation when exposed to light, heat and alkaline pH [38,39]. For those reasons, extensive 
research in the past years has focused on finding appropriate processing methods and delivery 




1.3.3. Pulmonary delivery formulations 
Pulmonary delivery is one of the proposed routes for the administration of curcumin 
formulations. Besides being a non-invasive route, other advantages of lung delivery for the 
treatment of systemic diseases are: rapid onset of therapeutic action due to the enormous 
alveoli surface area, thin epithelial barrier and high blood supply, enabling a great mass 
transfer between air and blood and avoidance of first-pass metabolism which can increase 
drug bioavailability [43]. 
Developing formulations for inhalation is challenging due to the specific flowability 
requirements. It is generally accepted that in order to reach the lungs, particles should have an 
aerodynamic diameter between 1-5 µm. In order to avoid particle aggregation and improve 
the handling of the material, active pharmaceutical ingredients (APIs) are usually combined 
with larger excipient or carrier particles [44–46], as shown in Figure 1-8. By the inspiratory 
airflow force, drug and carrier should dissociate, small drug particles travel towards the lungs, 
while coarse carrier particles are deposited in the upper airways [47,48]. This is the 
formulation strategy used in Chapter 3.  
A more innovative approach consists of preparing nano-on-micron formulations by coating 
fine drug particles (1-5 µm) with nanoparticles of excipients, as reviewed elsewhere  [49]. In 
this case, the nanoparticles work as spacers between the microparticles, improving their flow 
properties [49]. In Chapter 5, the same concept (nano-on-micron) is employed however the 
excipient/carrier is in the form of microparticles while the drug is dispersed within 





Figure 1-8. Examples of formulation strategies for pulmonary delivery [49]. 
1.4. Fundamentals and limitations of analytical techniques 
In this section the fundamentals and limitations of the analytical techniques used to 
characterize the formulations produced are briefly discussed. Detailed methodology was 
covered in each chapter where appropriate references for each method were given. 
1.4.1. Scanning electron microscopy (SEM) and particle size measurements 
Scanning electron microscopy (SEM) was employed to observe the morphology of the 
particles produced.  In brief, the SEM works by delivering a beam of electrons to scan the 
sample and registering the pattern created by them when bounced off from the surface of the 
material. The signal obtained from the scattered electrons is then converted into a magnified 
picture.   
The common limitations of the SEM are the difficulty in observing a representative sample of 
the material since only small amounts can be analysed at a time and the fact that the images 
taken can be subject to the user’s intentions. Samples were usually unchanged by the 




a few occasions (some curcumin crystals being removed from the surface of lactose and 
damage of the surface of uncoated corn starch at high magnification). 
Particle size distribution was assessed using Image J analysis software with particles being 
measured one by one, manually. Automatic measurements using techniques based on laser 
diffraction, for instance, were not possible due to the difficulties in finding a proper dispersing 
medium for the samples. In the case of Chapter 3 where the samples were composed of fine 
curcumin crystals and lactose, water was tested as a dispersing medium which would dissolve 
the lactose and allow the measurements of curcumin size by Mastersizer 2000. However, due 
to the poor wetting of the curcumin crystals, most of them ended up floating and aggregating 
on the surface of the liquid, making accurate measurements impossible. Surfactants were also 
added to the medium as an attempt to improve the wetting and dispersion of the samples, but 
then the crystals were solubilized. Coprecipitates of curcumin and PVP are soluble in water 
and most known organic solvents so particle size was also only assessed by measuring their 
diameters from SEM pictures.  
1.4.2. UV-visible spectrophotometry 
UV-visible spectrophotometry is a simple and fast method to obtain the concentration of a 
solute in solution by measuring the variation of intensity of a light beam when passing 
through it. This variation is related to the solution absorbance, which is directly proportional 
to the solute concentration (Beer-Lambert Law). A calibration curve is hence necessary to 
correlate absorbance and concentration of a certain material at fixed wavelength. The 
calibration curve used to obtain the concentration of curcumin in 50% (v/v) water-acetone 





Figure 1-9. a) Calibration curve to quantify curcumin in 50% (v/v) water-acetone by UV-vis; b) 
standard addition method to determine the mass of curcumin added to a solution of CURC/PVP in 
water + 0.25% SDS (red triangle). 
It is important to notice that the linear relationship between absorbance and concentration is 
valid when the dissolved molecules do not interact with each other, which should be the case 
of low concentrated solutions. Another fact limiting the range of concentrations to be used is 
the detection limits (upper and lower) of the instrument. Proper determination of the solute 
concentration can only be done when the solution concentration is within the range used in the 
calibration curve. Therefore, sometimes multiple dilutions of the sample prior to analysis are 
required, which can introduce errors in the measurements. 
When more than one solute is present in solution, interferences in the absorbance might occur 
(matrix effects). The standard addition method [50,51] was then employed to check for 
interferences caused by PVP and SDS on the measurement of curcumin absorbance (since the 
medium used in the dissolution rate measurements was water + 0.25% SDS). The method is 
represented in Figure 1-10. It basically works by preparing a standard solution of curcumin in 
50% water-acetone (known curcumin concentration) and another solution of CURC/PVP 
coprecipitate in water + 0.25% SDS (unknown curcumin concentration). The latter solution is 




ml) of the standard solution. The unspiked and spiked solutions are diluted to the same final 
volume (25 ml) with water + 0.25 SDS and their absorbances are determined.  
 
Figure 1-10. Schematic representation of the standard addition method.  
When the values of absorbance are plotted as a function of the mass of curcumin added (or 
volume of the standard solution added), it is possible to determine the mass of curcumin 
present in the unspiked sample, as shown in Figure 1-9b, by extrapolating the curve to the 
point on the x-axis at which y = 0 (red triangle in Figure 1-9b). The mass of curcumin was 
also determined using the calibration curve of curcumin in 50% water-acetone (Figure 1-9a) 
for comparison. The relative difference between the values obtained from Figure 1-9a and 
Figure 1-9b was below 1%, showing that SDS and PVP do not interfere in the absorbance of 




1.4.3. High Performance Liquid Chromatography (HPLC) 
High Performance Liquid Chromatography (HPLC) is a more robust and sensitive technique 
capable of determining the concentration of several solutes in solution based on the time 
required (retention time) for the molecules to move throughout a column filled with an 
adsorbent (stationary phase). High pressure is employed in on side of the column to force the 
movement of the sample (dispersed in a mobile phase) to the other side, in which a detector 
(such as UV, infrared, refractive index, etc.) identifies each substance. Due to the different 
interactions between the molecules of distinct materials and the stationary phase, different 
retention times can be obtained but method development is usually an arduous task, involving 
the adjustment of several parameters. 
HPLC was used to quantify curcumin in coprecipitated samples and verify if the proportion 
between curcumin and other curcuminoids varies after processing due to curcumin 
degradation (Chapter 4). The calibration curve is given in Figure 1-11. 
 
Figure 1-11. Calibration curve to quantify curcumin by HPLC. 
1.4.4. Fourier Transform Infrared spectroscopy (FTIR)  
Fourier transform infrared spectroscopy (FTIR) is a simple and fast technique employed to 
identify functional groups in a material. When the sample is exposed to infrared light, 
y = 101536x 

















different wavelengths are absorbed, corresponding to the frequencies in which the bonds 
between the atoms constituting the molecules vibrate [52]. A mathematical technique (Fourier 
Transform) is then applied by the computer to convert the raw absorbance signal captured by 
the detector in an absorbance spectrum (absorbance/transmittance versus wavenumber). The 
Attenuated Total Reflectance (ATR) is an accessory used to enable the direct analysis of solid 
or liquid samples in their original state [53].  
FTIR-ATR was used in this work as a qualitative tool to check for the generation of molecular 
interactions between the components of the formulation and solvents used during processing.  
1.4.5. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) is a technique largely employed in the 
pharmaceutical industry to identify physical and chemical events in a sample by analysing 
variations in its enthalpy or heat capacity [54]. It works by employing two identical sensors to 
measure the difference in the amount of heat required (absorbed or released) to change the 
temperature of the sample and reference at the same rate. 
Identification of thermal transitions can sometimes be difficult when more than one thermal 
event is happening at the same temperature. Therefore, deciding on a suitable operating mode 
and developing an appropriate method can be challenging. Although a destructive technique, 
a great advantage of DSC is the requirement of only small amounts of sample (few 
milligrams).  
1.4.6. X-ray diffraction (XRD) 
X-ray diffraction (XRD) is a technique used to characterize the crystal lattice of solid 
samples. The material is exposed to a beam of X-rays which interacts with the atoms of a 




technique enables the identification of a material and its polymorphic forms by comparison 
with reference spectra and the assessment of its degree of crystallinity [55]. 
XRD was used in this work as an additional method to distinguish between amorphous and 
crystalline samples (qualitative analysis). It is advantageous over DSC since it is a non-
destructive technique (no heating required) with straight-forward interpretation of the spectra; 
however a much greater amount of powder is needed. 
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Dense carbon dioxide technology is promising for the processing of drug compounds and 
development of varied pharmaceutical formulations through micronization, coprecipitation, 
encapsulation and coating techniques. The main advantages of this technology are the 
possibility to process thermo-sensitive compounds at low temperatures and using no/low 
amounts of organic solvents. Many processes have been developed and modified throughout 
the years to allow the production of composite materials with the desired characteristics. In 
this review, various processing methods using dense CO2 and recent process modifications 
are classified, and their differences and similarities are discussed. Formulation strategies to 
improve dissolution and flow properties of active compounds are also presented, giving 
insights into the selection of the most suitable formulation strategy and processing method. 
 






Drug formulation development is a challenging field. Depending on the delivery route and 
target site of action, specific requirements of particle size, morphology, density and surface 
properties can pose a great challenge in the development of the formulation. The selection of 
the most suitable formulation strategy requires an understanding of the physico-chemical 
properties of the active pharmaceutical ingredients (API) and their interaction within the 
body. This information will also be the input for the selection of the processing method, 
which should ensure the preservation of the chemical structure of the API and the acquisition 
of the desired features.  
Traditionally used techniques for drug processing such as spray drying, solvent evaporation 
and jet milling usually require the use of large amounts of solvent, and time/energy-
consuming processing steps to remove residual solvent from the product. Additional issues 
are the use of high temperatures and the difficult control of particle size and particle size 
distribution. Supercritical fluid (SCF) or dense gas (DG) technology is an emerging and 
promising field in the development of pharmaceuticals. In the near-critical region, i.e. 
relatively close to the critical point of the system, liquid-like properties, such as high density, 
and gas-like properties such as low viscosity and high diffusivity, coexist. These properties 
can be easily tuned by adjusting pressure and temperature, giving process flexibility to obtain 
products with varied characteristics. Supercritical carbon dioxide (scCO2) is selected in most 
applications due to its relatively low critical conditions (Tc = 31.1C° and pc = 73.9 bar). It is 
also non-toxic, non-flammable and inexpensive. These properties make scCO2 especially 
attractive in the pharmaceutical field because the processing of labile compounds can be done 
at low temperatures and in many cases without the aid of organic solvents, which can be 




produce lipid-based formulations [1,2], polymeric composites [3], and also to sterilize 
biomaterials [4–6] has been reviewed in the past years. SCF-based processing techniques, 
such as extrusion [7], coprecipitation [8] and encapsulation [9,10] have also been investigated.  
This review aims to classify existing techniques for drug processing by DGs/SCFs, exploring 
the most recent developments in the field rather than discussing the selection of operation 
conditions. Insights on the selection of the processing method are provided from a 
formulation point of view. 
2.3. Formulation strategies for drug delivery 
Many reviews have focused on describing different formulation strategies for drug delivery 
[11–13], some of them represented in Figure 2-1. The association of active pharmaceutical 
ingredients (APIs) with excipients and/or additives can improve the API release kinetics and 
flow properties, and provide stability and protection against external conditions. In the 
following sections, an overview of SCF-based techniques for producing such formulations is 
presented. 
2.4. Principles of well-known SCF-based techniques for pharmaceutical 
processing 
A short description of the principles and common modifications of the most used SCF-based 
processes is shown in this section while detailed information regarding their operation can be 
found elsewhere [14–17]. Table 2-1 summarizes the main characteristics of the processes. 
2.4.1 SCF as solvents 
The Rapid Expansion of Supercritical Solutions (RESS) explores the significant 
modification of the solvent power of SCFs with changes in pressure. It operates in a batch 




depressurization of the solution through a heated nozzle/capillary, as shown in Figure 2-2a. 
The solvent power of scCO2 is reduced, leading to supersaturation of the solution and 
instantaneous precipitation of the solute in small particles [18]. The main advantages of the 
RESS process are its simplicity and the absence of organic solvents. However, its use and 
scaling up are restricted by the mandatory solubility of the API in scCO2 (> 10
−3
 kg/kgCO2 
[14]), nozzle clogging during depressurization and particle agglomeration [19]. 
 
 
Figure 2-1. Formulation strategies for drug delivery. Drug particles are represented in orange, 





Table 2-1. Characteristics of SCF-based processes 
Process 









RESS solvent batch saturation precipitation 
Solute-CO2 solution is depressurized; solvent-free; might 
require large amounts of CO2 [18]. 
RESOLV solvent batch saturation precipitation 
Solute-CO2 solution is depressurized into a liquid solvent; 
particle agglomeration and growth is avoided; extra step 
required to dry the suspension [20,21]. 
RESAS solvent batch saturation precipitation 
Solute-CO2 solution is depressurized into a water-surfactant 
solution; particle agglomeration and growth is avoided; extra 
step required to dry the suspension [22,23]. 
RESS-N solvent batch saturation precipitation 
A co-solvent is added to improve solute solubility in scCO2; 
extra step required to remove the co-solvent [24]. 
RESS-SC solvent batch saturation precipitation 
Use of a solid co-solvent to improve solute solubility in sc CO2; 
particle agglomeration and growth is avoided [25,26].  




scCO2 is added to a organic solution. Difficult removal of 
residual solvent from the powder [27]. 






Solution is sprayed into scCO2, improving the mass transfer 
compared to GAS [28–30]. 




Use of a co-axial three-component nozzle, improving the mass 


















Use of an ultrasonic vibrating surface, improving the mass 







Depressurization of a melted material containing scCO2 leads to 
cooling and particle formation; easy scale-up; solvent-free [33–
35]. 





An ELS (scCO2 + solvent + solute) is depressurized; high 
temperature needed to remove the solvent at ambient pressure 
[39]. 





An ELS (scCO2 + solvent + solute) is generated using sub-
critical CO2 to avoid the use of high pressure pumps; high 
temperature needed to remove the solvent at ambient pressure 
[40,41]. 





An ELS (scCO2 + solvent + solute) is generated in a packed 
tower and then depressurized; N2 is used to induce solvent 
evaporation; high temperature needed to remove the solvent at 








An emulsion containing the solute and scCO2 contact in T 
forming microbubbles and microdroplets; N2 is used to induce 
solvent evaporation [44–46]. 




Organic solution-water emulsion contact scCO2 in counter-
current; particle agglomeration and growth is avoided; extra 


















The pecipitator is a small tube (cheaper than large vessels); 
improved local fluid mixing; easy scale-up; difficult sample 
collection [53,54]. 




The jets of scCO2 and solution impinge inside the precipitator, 
improving mass transfer [55]. 




Addition of a polar organic solvent to act as co-antisolvent for 
aqueous solutions; facilitate the processing of hydrosoluble 
compounds; more energy consuming [59]. 





Integration of SEDS and RESS processes; continuous 
operation. Facillitates the processing of compounds with partial 
solubility in scCO2 [63]. 
SEA co-solvent semi-continuous mixing 
atomization; 
precipitation 
The fluids are pre-mixed to improve the liquid jet breakup 
[66,67]. 




The fluids are pre-mixed and precipitation happens before 
atomization; the precipitator is a small tube (cheaper than large 
vessels; particles are recovered in cyclones [68]. 





The precipitator is operated below atmospheric pressure 












A ultrasound device is placed inside of the high-pressure 
precipitator to fluidize preloaded particles; the SAS jet is 


















The atomization is promoted by pressure difference; nozzles are 
not required; Easier scale-up [77]. 





Introduction of a hydrodynamic cavitation mixer to improve the 
mass transfer between the fluids [83]. 





The ELS is sprayed into water (act as antisolvent).  particle 
agglomeration and growth is avoided; extra step required to dry 
the suspension [89]. 















A Wurster coater is placed inside of the high-pressure 
precipitator to receive the SAS jet [97]. 
RESS-WTS solvent semi-continuous saturation precipitation 
The RESS jet is depressurized inside a Wurster coater 





semi-continuous saturation precipitation 
The RESS jet is depressurized inside a fluidized bed preloaded 










A fluidized bed is placed inside of the high-pressure 























A stirrer is placed inside of the high-pressure precipitator to 
fluidize preloaded particles; the SAS jet is delivered inside of 
the fluidized bed. Small particles can be fluidized [104]. 
*





Some of these limitations have been addressed by other similar processes. In RESOLV 
(Rapid Expansion of a Supercritical Solution into a Liquid Solvent), the supercritical 
solution is expanded into a liquid solvent, instead of air, to prevent particle agglomeration 
[20,21]. Similarly, in RESAS (Rapid Expansion from Supercritical Solution to Aqueous 
Solution), a water-surfactant solution receives the supercritical jet and stabilizes the particles 
preventing their aggregation and growth [22,23]. RESS-N (Rapid Expansion from 
Supercritical Solution with a Non-solvent) uses a compound that improves the solute 
solubility at supercritical conditions but acts as a non-solvent at atmospheric conditions [24]. 
In these processes a suspension is formed. Therefore, the solute must not be soluble in the 
liquid used. In RESS-SC (Rapid Expansion of Supercritical Solutions with a Solid Co-
solvent), the addition of a solid co-solvent, which can be removed from the system by 
sublimation, improves the solute solubility and inhibits particle growth by coagulation 
[25,26]. Although the modifications cited can be useful for certain applications, these 























a) RESS b) SAS c) PGSS
Figure 2-2. Process diagram of main SCF-based techniques: a) RESS, b) SAS and c) PGSS. 
 
2.4.2 SCF as antisolvent 
Antisolvent methods are based on the high solubility and diffusivity of SCFs in organic 




contact with the scCO2. The diffusion of scCO2 into the liquid phase decreases the solvation 
power of the organic solvent, leading to the precipitation of the solute. A final washing step 
with pure scCO2 needs to be carried out to remove residual solvent from the powder. 
Therefore, the basic requirements to allow precipitation via antisolvent techniques are: 
complete miscibility between solvent and antisolvent (CO2) at the operating conditions and 
the mixture solvent/antisolvent must not solubilize the solute. 
Different antisolvent processes follow the same principles but with distinct ways of mixing 
the organic solution and the supercritical fluid. In the Gas Antisolvent (GAS) process [27], 
first the solution is loaded in the precipitation vessel and then the scCO2 is added to reach the 
operating pressure. In Supercritical Antisolvent (SAS) (Figure 2-2b), the scCO2 is pumped 
into the precipitation vessel until the operational pressure is reached, after which the solution 
enters the vessel through a nozzle. This process is also known as Aerosol Solvent Extraction 
System (ASES) [28] or Precipitation by Compressed Antisolvent (PCA) [29,30]. Solution 
Enhanced Dispersion by Supercritical Fluids (SEDS) uses a co-axial three-component 
nozzle that enables a turbulent flow and better mixture before the components enter the 
precipitation vessel [31]. In Supercritical Antisolvent Precipitation with Enhanced Mass 
Transfer (SAS-EM), the solution atomization is improved by contacting an ultrasonic 
vibrating surface [32].  
2.4.3 SCF as solute/plasticizer/co-solvent/atomizing or nebulizing agent 
Supercritical or dense CO2 can play other roles in particle generation including co-solute, co-
solvent, dispersing agent and plasticizer. In Particles from Gas Saturated Solutions 
(PGSS), scCO2 is dissolved in a substance (or mixture of substances) at high pressure, acting 
as a plasticizer. The viscosity and melting point (or glass transition temperature) of the 




depressurization, the gas evaporates, and the system is cooled drown (Joule-Thomson effect) 
below the melting point of the material, leading to the solidification of the droplets and 
formation of fine particles [33–35]. PGSS can be operated in batch mode or continuously 
feeding the materials into the precipitator through a static mixer (Figure 2-2c) [36]. 
Variations of PGSS are: Continuous Powder Coating Spraying Process (CPCSP) applied 
for the manufacture of powder coatings  [37] and Gas Assisted Melting Atomization 
(GAMA) which uses air to improve the atomization [38].   
In other processes organic solvents and scCO2 are used to generate expanded liquid solutions. 
In Depressurization of an Expanded Liquid Organic Solution (DELOS), the material to 
be micronized is dissolved in an organic solvent, and then the solution is mixed with scCO2 to 
form an expanded liquid solution. Undesirable particles possibly formed at this stage (GAS 
process) are collected in a filter and finally, the pressure is decreased to ambient leading to the 
cooling of the solution and particle precipitation [39]. The Precipitation by Pressure 
Reduction of Gas-expanded Liquids (PPRGEL) follows the same steps as the DELOS 
process, however, ambient temperature and sub-critical CO2 are employed, avoiding the use 
of high pressure pumps [40,41]. While DELOS and PRRGEL operate in a batch mode, in 
Supercritical-Assisted Atomization (SAA) the organic solution and scCO2 are mixed in a 
packed tower, forming an expanded liquid which is then atomized near atmospheric pressure 
in a semi-continuous operation. Nitrogen is also delivered to the vessel to induce liquid 
evaporation [42]. Still, high temperatures in the precipitator are usually applied to dry the 
particles.  
Other PGSS-based processes are used to dry solutions in which the solvent has low solubility 
in scCO2, such as aqueous solutions. In PGSS-drying, the solution to be dried and scCO2 




spray tower (no nitrogen used). The post-expansion temperature have to be carefully selected 
(above the dew point of the solvent-CO2 mixture) in order to obtain a dry powder [43]. In 
Carbon Dioxide-Assisted Nebulization with a Bubble Dryer® (CAN-BD) the contact of 
near-critical or supercritical CO2 with aqueous or aqueous-organic solution is promoted in a 
low volume tee. The emulsion generated is then expanded, forming microbubbles and micro-
droplets dried by hot N2 [44–46]. In these processes scCO2 acts as a co-solute and 
nebulization agent. 
2.4.4 Miscellaneous  
In Supercritical Fluid Extraction of Emulsion (SFEE) [47,48] and Continuous 
Supercritical Emulsions Extraction (SEE-C) [49,50] the solute is dissolved in an organic 
solvent, and then an emulsion in water is prepared. The emulsion is atomized in counter-
current with scCO2, so that the organic phase is extracted generating a suspension in water. 
SFEE/SEE-C is said to offer more flexibility to tune particle characteristics, enhanced 
reduction in particle size compared to SAS and the ability to avoid particle agglomeration due 
to the presence of water, however, drying of the product needs to be carried out afterwards. In 
Supercritical Reverse Phase Evaporation (scRPE), scCO2 is mixed with an organic 
solution containing a phospholipid and then an aqueous solution is introduced in the resulting 
homogeneous mixture to generate liposomes in a batch mode [51]. Later, the same group 
developed the Improved Supercritical Reverse Phase Evaporation (IscRPE), a completely 
solvent-free method in which the liposomes are formed by first mixing the water solution and 




2.5. SCF-based processes for drug formulations development 
In this section, novel/modified processes developed by using SCFs or DGs are analysed. The 
type of formulation produced and some examples of compounds processed are summarized in 
Table 2-2. 
2.5.1. Micronization of single compounds 
Drug only formulations (excipient-free) (Figure 2-1a) can be advantageous in the delivery of 
APIs that require high dosage while avoiding the possible side effects of excipients. The 
applicability of recently developed/modified processes is usually demonstrated by the 
processing of single compounds, such as APIs or polymers. This section discusses the 
features of these processes and their use to micronize materials of interest for the 
pharmaceutical industry. 
In SAS-type processes, the mixing of the fluids is of great importance to achieve high 
supersaturation and produce small and uniform particles. Recently, two different injection 
systems have been tested by the same research group. The Concentric Tube Antisolvent 
Reactor (CTAR) is simpler, and hence easier to scale up than the typical SAS process, as the 
reactor is composed of a small tube to which the scCO2 is delivered, and a capillary for the 
atomization of the organic solution (Figure 2-3). The authors propose an industrial scale 
setup made of several injection systems with the same size as the lab scale to control 
turbulences locally, avoiding poor fluid mixing which can happen when several solution jets 
are sprayed into the same bulk CO2. L-PLA was used as model compound and the 
micronization results were similar or superior to the conventional SAS process. However, 
difficulties in collecting the powder deposited in the annular part of the reactor, plugging and 




later, Impinging Jets Technology (IJT) was associated with the SAS process. In this 
configuration, jets of organic solution and scCO2 collide face to face improving the mass 
transfer (Figure 2-3). Griseofulvin [55] and sulfathiazole [56] have been processed using this 
technique. A comparison between these injection devices on the processing of L-PLA and 
griseofulvin reveals that the IJT can be more efficient in decreasing the particle size of the 
API, while CTAR is simpler and provided better results in terms of process intensification 
[57].  In all the systems evaluated, IJT and CTAR produced smaller particles compared to the 
classical SAS process, but usually larger than those obtained by more complex processes such 
as SAA and SAS-EM. Modelling of the crystallization process was later proposed [58]. 
Table 2-2. SCF-based processes and examples of drug formulations recently developed. 
Process Purpose API Excipient Reference 
CTAR, IJT 
micronization - L-PLA [53,57] 
micronization griseofulvin - [55,57] 
IJT micronization sulfathiazole - [56] 
ELAS 
micronization yttrium acetate, BSA - [59] 
micronization BSA - [60] 
micronization lysozyme - [61] 
micronization - sodium alginate and PVA [62] 
RESS-C 
micronization - PLA–PEG–PLA [63] 
micronization lonidamine - [64] 
SEA 






saccharin (cocrystal former) [66,67] 








micronization - PLLA, BSA [69] 
micronization - PEG [70] 
micronization - PLA–PEG copolymer [71] 
coprecipitation rotenone 









coprecipitation curcumin PLGA [74] 
ARISE 
 
micronization levothyroxine sodium - [75] 





coprecipitation curcumin HP-β-CD and PVP [78,79] 
coprecipitation insulin HPMCP [80] 
coprecipitation curcumin methyl-b-cyclodextrin [81] 
SAS with 
swirl mixer 
coprecipitation curcumin PVP [82] 
SAA-HCM 
 
micronization BSA - [83] 





micronization - chitosan [86] 
coprecipitation trypsin chitosan [87] 
coprecipitation insulin N-trimethyl chitosan [88] 
SAILA 
micronization - Polycaprolactone [89] 




Process Purpose API Excipient Reference 







coprecipitation coenzyme Q10 PEG6000 [93] 
coprecipitation ibuprofen PEG6000 [94] 
coprecipitation curcumin 
tristearin and soy 
phosphatidylcholine 
[95] 
coprecipitation vitamin B2 
fully hydrogenated canola oil 











encapsulation curcumin PLGA [98] 
SpEDS 
encapsulation methotrexate Fe3O4, PLLA-PEG-PLLA [99] 








acid and vitamin K3 
MCC [101] 
SAS-FB 
coating naringin MCC [102] 
coating curcumin lactose [103] 
SAS-DEM 
 
coating nevirapine lactose and MCC [104] 
coating itraconazole lactose [105] 






Figure 2-3. Injection systems for CTAR and IJT processes [58]. 
Another modification of the SAS process consists of using a supercritical mixture of a polar 
organic solvent and CO2 as the antisolvent to precipitate hydrosoluble compounds from 
aqueous solutions.  This technique was called Expanded Liquid Antisolvent (ELAS) by 
Reverchon’s group in 2012 [59], although other researchers had already used the same 
technique for many years [107–110]. The ELAS process is more complex than the SAS 
process as it requires an understanding of multiple components phase diagrams. It is also 
more energy intensive because an extra pump is required for the delivery of the organic 
solvent (co-antisolvent), which is premixed with scCO2 before entering the precipitator 
(Figure 2-4a), and an additional washing step with the antisolvent mixture needs to be carried 
out to remove residual water from the system followed by the washing with pure scCO2. 
Different materials have been processed by ELAS, including yttrium acetate and bovine 




The precipitation of composite materials is challenging due to the number of compounds 
possibly affecting the phase equilibrium. 
CO2/N2




























CO2+ H2O + 
co-antisolvent
CO2+ solvent CO2/N2 + solvent
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Figure 2-4. Principles of micronization by: a) ELAS, b) RESS-S, c) SEA and ASAIS [61,63,64,68]. 
For compounds with partial solubilitity in scCO2, the precipitation yield by either RESS or 
SAS is usually low, therefore Continuous Rapid Expansion of Supercritical Solution 
(RESS-C) was proposed (Figure 2-4b), consisting of a combination of the SEDS and RESS 
processes, operating in a continuous mode. Here the organic solution and scCO2 are sprayed 
together in a high pressure vessel using a coaxial nozzle and then the resulting mixture is 
sprayed into ambient conditions. This setup was used to produce microparticles of 
polylactide–poly(ethylene glycol)–polylactide (PLA–PEG–PLA) at 12 MPa and with the 
temperature of extraction and expansion vessels controlled by a gas bath at 33°C. When 
processed by SEDS and RESS in similar conditions, particles could not be obtained [63]. 
Further improvements in the rig, such as the addition of a mechanical stirrer in the extraction 
vessel to ensure solubilization of the solute in scCO2 and carefully designed expansion vessel 




recently proposed as illustrated in Figure 2-4b. In this last work, nanoparticles of lonidamine 
were produced at 20 MPa and 55°C with the expansion vessel being kept at 50°C by a water 
bath [64]. RESS-C configuration is similar to SAA, differing on the internal structure of the 
extraction vessel/saturator and also no nitrogen flow is used for RESS-C.  
By combining the concepts of antisolvent precipitation and atomization due to 
depressurization, Azevedo and co-workers developed the Supercritical Enhanced 
Atomization (SEA) process [67], also named Atomization and Anti-solvent (AAS) [66], 
and the Atomization of Supercritical Antisolvent Induced Suspensions (ASAIS)  process 
[68]. In the SEA process, CO2 and the organic solution are mixed in a coaxial nozzle before 
atomization in order to improve the liquid jet breakup that will then happen in the next stage 
at near-atmospheric conditions (Figure 2-4c). This process has been employed to precipitate 
lysozyme from water-ethanol solutions by using either supercritical CO2 (antisolvent and 
atomizing agent) or N2 (atomizing agent) between 8 MPa and 25 MPa and 40-60°C to study 
the precipitation mechanisms governing the process. It was found that spherical particles were 
formed when the precipitation happened after atomization by spray-drying mechanism. On 
the other hand, when the antisolvent effect was high enough, antisolvent crystallization 
happened in the mixer before atomization, leading to the formation of fibres and 
compromising the enzyme activity [65]. The applicability of the SEA process to produce 
cocrystals of APIs (indomethacin, theophylline, caffeine, sulfamethazine, aspirin, 
carbamazepine) with saccharin (cocrystal former) has also been investigated [66,67]. The 
ASAIS process differs from the SEA process in the way the fluids are mixed before the 
nozzle orifice and on the mechanism of particle separation after precipitation: SEA uses an in-
line filter and ASAIS uses a cyclone. In ASAIS, the conditions are selected in order to 




atmospheric vessel to remove the solvent (Figure 2-4c). This reduces the cost of the high-
pressure vessel, which is a small tube (similar to the CTAR). Microparticles of theophylline 
have been produced using this technique with scCO2 and N2 at 5-10 MPa and 45°C and 
computational fluid dynamics (CFD) simulations were carried out to determine the 
distribution of the solute concentration in the high pressure vessel [68]. 
2.5.2. Coprecipitation (matrix systems) 
Coprecipitates are composite materials usually obtained by the simultaneous precipitation of 
drug and excipient from the same solution. Ideally, drug molecules should be well dispersed 
in a matrix of excipient (Figure 2-1d), usually a polymer or a lipid. This configuration can 
deliver the API to a specific target with controlled release, avoiding its degradation and also 
improving the handling and flowability of the formulation when a larger structure containing 
the API is produced. When a hydrophilic polymer is used, molecular interactions between the 
compounds during precipitation might change the solid state of the drug, improving its 
solubility and dissolution properties in aqueous media. However, successful coprecipitation is 
not always achieved due to the formation of two distinct phases prior to precipitation 
(polymer-rich and drug-rich) so the compounds precipitate separately.  
Even though the solubility of the API and excipient in the selected solvent is a preliminary 
requirement, the final drug loading will depend on the process conditions rather than on the 
initial solution composition. Coprecipitates of several materials can be obtained by employing 
SCF-based processes. Recently developed experimental setups which have been used to 
coprecipitate drug and excipient using SCF technology are discussed below. 
Atomised Rapid Injection for Solvent Extraction (ARISE) is an antisolvent batch process 




nozzle blockage which hinders process scale-up. In this process, the precipitation chamber is 
filled with scCO2, and then the organic solution is loaded in the injection chamber and 
pressurized by an inert gas (nitrogen/argon) with a pressure higher than the one in the 
precipitation chamber (Figure 2-5a). After equilibration, the valve connecting the vessels is 
opened and the pressure difference promotes rapid atomization of the solution and effective 
mixing between the fluids. The ARISE process has been applied to micronize APIs such as 
levothyroxine sodium [75] and curcumin [76]. Composite materials combining curcumin, 
polyvinylpyrrolidone (PVP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) for pulmonary 
delivery have also been obtained through coprecipitation [78,79] and the improvement in 
curcumin dissolution properties has been demonstrated [81]. Coprecipitates of insulin and 
hydroxypropyl methyl cellulose phthalate (HPMCP) were also produced and a comparative 
study with other antisolvent precipitation methods showed that ARISE usually leads to higher 
recovery (84.4%) than GAS (50.9%) and ASES  (72.6%) processes [80]. Recently, a study of 
the scale-up of the ARISE process and an economic evaluation demonstrated its viability to 
produce pharmaceutical formulations [77]. 
In 2014, Zabihi et al.[74] modified the operational procedure of SAS-EM to produce 
curcumin-PLGA nanoparticles (20 - 808 nm). In this procedure, the precipitator is initially 
loaded with scCO2, then the inlet and outlet valves are closed at the desired pressure. The 
ultrasound starts to operate, and a certain amount of solution is pumped into the precipitator. 
After some time of mixing, fresh scCO2 flushes the vessel to remove the solvent. Fresh 
solution can be pumped several times into the precipitator and the mixing and washing steps 
are repeated (Figure 2-6). The authors claim that the sequential replacement of scCO2 
increased the supersaturation of the organic phase leading to high yield (23 - 96%) and 


























+ solvent  
Figure 2-5. Principles of coprecipitation by: a) ARISE and b) SAILA [89,111]. 
In order to improve the mixing and mass transfer between the fluids, Chhouk et al. [113] 
prepared coprecipitates of curcumin and PVP by the SAS process using a micro swirl mixer 
device. Although sub-microparticles and nanoparticles (25-342 nm) were obtained, the 
material was highly coalescing and a comparison of the particle size obtained by using a 
typical capillary or nozzle was not provided. 
The use of mixing devices has also been reported for the SAA process to improve the mass 
transfer between the liquid solution and scCO2. In SAA-HCM, a hydrodynamic cavitation 
mixer was used. Levofloxacin hydrochloride was first micronized with the aid of the mixer 
and the use of a vacuum pump to keep the precipitator below atmospheric pressure was 
reported [85]. In further works, BSA [83], lysozyme [84], chitosan [86] were micronized. 
Recently, the authors studied the coprecipitation of trypsin with chitosan [87] and insulin with 
N-trimethyl chitosan [88]. The typical SAA process has been applied to coprecipitate a 




technique is not suitable for the processing of thermo labile compounds due to the high 
temperature required in the precipitator to dry the particles. The operation of the precipitator 
below atmospheric pressure allows the precipitation at lower temperatures as confirmed by 
Adami et al. [69] through the micronization of PLLA and BSA using pressures of 0.5 - 0.87 
bar and temperatures as low as 30°C. The vacuum system was also employed to micronize 
PEG  [70],  PLA–PEG copolymer [71] and to produce coprecipitates of rotenone with PEG, 
PVP and sodium alginate [72] and lincomycin hydrochloride dispersed in BSA [73]. 
 
 




The configuration of Supercritical Assisted Injection in a Liquid Antisolvent (SAILA) is 
similar to the SAA process; however, the expanded solution obtained by contacting the 
organic solution and scCO2 is sprayed into water (possibly containing a surfactant) rather than 
air. The water acts as an antisolvent leading to the precipitation of the solute, generating a 
suspension (Figure 2-5b). Naturally, the organic solvent and water must be miscible while the 
solute must be insoluble in water. The authors claim that the use of expanded liquids would 
improve the mixing and produce smaller particles compared to a typical antisolvent 
precipitation using ordinary liquids. This process can be advantageous to avoid particle 
coalescence (in a similar way to RESOLV and RESAS), nevertheless, a post-processing step 
is required to separate the organic solvent from the suspension. Polymeric particles of 
polycaprolactone [89], Polymethylmethacrylate (PMMA) [90], PLGA and PLA [91] have 
been produced using this technique. The production of composite materials for controlled 
release purposes has also been reported for the coprecipitation of PLGA with some anti-
inflammatory drugs. Successful coprecipitation was achieved only for a very low 
drug/polymer ratio (1/20) while the encapsulation efficiency varied between 50 and 97% [92]. 
High temperatures in the saturator (60-100°C) were used in the previously reported works, 
limiting the application of SAILA for the processing of thermo-sensitive compounds. 
Although largely used to produce a variety of composite materials, adaptations in the 
experimental setup of the PGSS process have been reported, such as the introduction of a 
coaxial nozzle for the delivery of the gas-saturated solution (inner side) and CO2 (outer side) 
to prevent the blockage of the nozzle by solid particles; and addition of a high pressure pump 
after the mixer to control the flow rate of the solution into the precipitation vessel [93]. In the 
reported work, the coprecipitation of coenzyme Q10 with PEG6000 (a water-soluble 




solidified when precipitated alone. Then, PEG6000 was dissolved in water to obtain the 
intended nanoparticles of coenzyme Q10 in a suspension, following centrifugation and freeze-
drying to separate the aqueous solution from the nanoparticles. In another work, the authors 
used the same approach to prepare ibuprofen nanoparticles [94]. More recently, São Pedro et 
al. [95] used a coaxial nozzle to deliver nitrogen together with a gas-saturated lipid solution 
into the precipitator, also to avoid particle coalescence and agglomeration. Curcumin-loaded 
solid lipid nanoparticles containing tristearin and soy phosphatidylcholine (PC) were 
produced. Another modification of the PGSS process consisted in depressurizing the gas-
expanded solution of the materials to be micronized in counter-current with an aqueous PEG 
solution stream, as an attempt to decrease the size of the particles. This process was used to 
encapsulate vitamin B2 in solid lipid nanoparticles of fully hydrogenated canola oil (FHCO), 
using sodium lauryl sulfate (SLS) as surfactant [96]. Other PGSS-based techniques have been 
used to produce varied formulations, such as metal loaded lipid microparticles [121], hollow 
[122] and oil-loaded hollow solid lipid particles [123,124]. 
2.5.3. Encapsulation (film-on-particle) 
The encapsulation of active ingredients is widely applied in the pharmaceutical industry for 
different purposes, such as to protect the API against humidity, light and oxidation, to 
improve appearance and/or taste of formulations, to tailor the surface properties and particle 
size, to avoid caking during transportation and storage and to develop delayed or controlled 
release systems [125]. A film of the coating material is usually precipitated onto the surface of 
previously existing API particles (Figure 2-1c). Therefore, if a specific particle size of the 
API is required, a previous micronization step needs to be carried out, increasing the overall 
operational costs. The dissolution properties of hydrophobic APIs can be improved by 




coprecipitation since the API is well dispersed in an excipient matrix. The solvent used should 
be able to dissolve only the coating material, keeping the API particles unchanged. 
Supercritical fluid technology has been used to encapsulate APIs under mild temperature 
conditions. Recently developed SCF-based encapsulation processes and formulations are 
discussed in this section. 
The combination of fluidized bed coating and supercritical fluid-based precipitation has been 
reported for many years. In 1995, Tsutsumi et. al. [126] precipitated paraffin by RESS onto 
the surface of microspheroidal catalyst particles (56µm) in a circulating fluidized bed. The 
coating rate was found to be constant and particle agglomeration was avoided due to the 
absence of liquid droplets. Other core materials such as glass beds, ceramic beads, plastic 
granules and proteins have also been coated with paraffin or wax by similar processes [127–
131].   
In the previous year, Benoit et al. [132] had developed a simple batch process to coat 
microparticles of APIs with lipids or polymers soluble in scCO2. Initially, the coating material 
and API are loaded in a high pressure mixed chamber which is then pressurized with CO2. 
After some time, when the scCO2 has solubilized the coating material, depressurization leads 
to its precipitation and coating onto the surface of the suspended API particles. This process 
was used to encapsulate a model protein, bovine serum albumin (BSA), within two different 
lipids: trimyristin and Gelucire® 50-02. While trimyristin was crystalized producing a 
discontinuous coating and burst release of BSA, Gelucire® 50-02 precipitated as a film and 
hence, a sustained release was observed [133]. Later, other aspects of this technique were 
further discussed [134–136].  
It is important to notice that for a successful encapsulation, the SCF should be able to dissolve 




soluble in scCO2, an antisolvent method can be employed. Niu et al. [97] used a Wurster-type 
coater (Figure 2-7a) to encapsulate glass beads (1-2 mm), stents (< 20 mm long) and 
caffeine-loaded MCC beads (1-1.4 mm) and tables (3.2-7.9 mm) within polymer films using 
near-critical CO2 (52-66 bar) as antisolvent and fluidizing medium. After coating with ethyl 
cellulose, the initial burst release of caffeine from MCC beads was delayed, and the release 
rate decreased. Slower release could be achieved by increasing the coating time, 
demonstrating the applicability of process in preparing controlled-release formulations. The 
mild conditions used and the safety of the process compared to conventional coating 
techniques is highlighted by the authors; because air is replaced by dense CO2, a flame 
































Figure 2-7. Principles of encapsulation by: a) SAS-Wurster and b) SAS-EM [97,98]. 
A similar process, based on SAS-EM, was used to encapsulate nanoparticles of curcumin in 
PLGA. Previously precipitated by SAS-EM, curcumin nanoparticles were fluidized in batch 
mode for 15 seconds by an ultrasonic vibration probe placed on the top of the precipitator 
(Figure 2-7b).  The PLGA solution was then sprayed onto the fluidized nano-curcumin. The 
ultrasonic power (100-350 W) could be adjusted to enhance drug loading (4-38%), however, 
the precipitation yield was still very low (12-51%). Based on the sustained release profile of 




initially formed and then attached to each other to form a porous structure around curcumin 
particles [98]. As the mean size of the final formulation increased up to 84 times compared to 
the size of the initial curcumin particles, PLGA probably encapsulated curcumin 
agglomerates, rather than individual nanoparticles. It is also important to note that, although 
the removal of the organic solvent by scCO2 is fast, some curcumin could have been 
solubilized by the organic solvents used (ethanol and ethyl acetate).  
In order to increase the loading efficiency of microencapsulation, a modification of the SEDS 
process, named Suspension-Enhanced Dispersion by Supercritical Fluid (SpEDS), has 
been developed. It consists of introducing an injector to allow the delivery of a suspension to 
the precipitator, instead of a solution. The setup was tested to produce magnetic microspheres 
by microencapsulation and coprecipitation processes. For the microencapsulation, 
nanoparticles of Fe3O4 were suspended in an organic solution containing the API 
(methotrexate) and then sprayed into scCO2 to precipitate the API encapsulating the Fe3O4. 
The resulting material (API-loaded Fe3O4) was suspended in an organic polymeric (PLLA–
PEG–PLLA) solution and then sprayed again into scCO2 generating a second layer of 
microencapsulation. Unlike the previously cited encapsulation processes, in SpEDS, there is 
no need to preload the material to be coated in the precipitator. For the coprecipitation, the 
Fe3O4 was suspended in an API-polymer organic solution and then sprayed into scCO2. In the 
same operational conditions, the microencapsulation was able to produce microspheres with 
higher drug load (8.9%) and loading efficiency (60.8%) than the coprecipitation and improved 
release kinetics for sustained release of methotrexate [99]. In another work, the 
coprecipitation and microencapsulation of methotrexate by PLLA-PEG-PLLA using SpDES 




to encapsulate silica nanoparticles with Eudarit. The polymer solution contacting suspended 
silica nanoparticles was sprayed into scCO2 (SAS process).    
APIs can also be encapsulated in liposomes (Figure 2-1g) in a more complex structure as 
already reviewed elsewhere [1,2]. Recently, a continuous process to produce liposomes has 
been reported [138–140].  
2.5.4. Coating (particle-on-particle) 
Powder flowability is an important parameter in pharmaceutical processing. Micronization, 
often required to improve the dissolution properties of APIs, usually generates aggregates due 
to the intense inter-particle attraction force existing between fine particles. To improve the 
stability, handling and flowability of powder formulations, APIs are combined with larger 
carrier/excipient particles. However, drug content uniformity and further aggregation in 
downstream processing steps remain a concern [141]. 
The simultaneous precipitation of fine API particles and coating onto the surface of larger 
excipient particles can be an alternative to avoid such issues. When supercritical fluid-based 
micronization is used, the API particle size and morphology can be tuned for the intended 
application. In addition, the association with a hydrophilic excipient can improve the 
dissolution properties of poorly water-soluble APIs, by increasing its wettability, while 
enhancing its flow properties. However, the type of formulation produced (Figure 2-1e,f) is 
not ideal for applications in which prolonged/controlled release and protection of the API are 
required since the drug particles are exposed to the environment. In general, coating processes 
are limited by the fact that the solvent used must not solubilize the excipient particles, which 




This section illustrates examples of novel SCF-based techniques for particle-on-particle 
coating in which the API is the coating material. 
Taking advantage of the solvent properties of scCO2, Leeke et al. [101] adapted the RESS 
process for coating purposes using two different configurations: Wurster coater (RESS-WTS) 
and fluidized bed (RESS-BFB), as demonstrated in Figure 2-8a,b. In both solvent-free 
processes, the jet of scCO2 saturated with the API is expanded upwards in a bed of excipient 
particles. For RESS-WTS the fluidization is aided by the flow of hot air passing through a gas 
distributor. Nanoparticles of six different APIs (< 30 nm) were precipitated onto the surface 
of microcrystalline cellulose (MCC, 300 µm) close to their point of origin, inhibiting further 
particle growth and agglomeration. Therefore, the flowability and handling of the final 
formulations were improved while keeping the advantageous features of nanoparticles. The 
drug content, however, was very low (0.01-0.54 wt% for 10 minutes coating time) with 
process yield varying from 14-74%.  
As the main limitation of the RESS process is the mandatory solubility of the API in scCO2, 
recently, the same group integrated the SAS process with a fluidized bed (FB) under pressure 
(SAS-FB) to process APIs with low solubility in scCO2. In this single-step process, the 
fluidized bed is placed inside the precipitator and the jet of drug solution is sprayed from the 
bottom into a bed of excipient particles fluidized by the upward flow of scCO2 delivered 
through a gas distributor (Figure 2-8c). Nanoparticles of narigin (< 200 nm) were coated onto 
MCC particles (175-444 µm) and a faster drug release rate was obtained when compared with 
a formulation of the same materials prepared by a conventional fluidized bed coating process.  
The authors claim that the formulation could be directly administered orally since the drug 
content was around 2.5 wt% [102]. The same rig was used by Matos et al. [103] to coat 




and formulations potentially suitable for pulmonary delivery were produced with a curcumin 
content of around 1-6 wt% and drug yield between 71-93%. Due to the improved mixing and 
collection of particles close to their origin, SAS-FB produced smaller and less aggregated 











































Figure 2-8. Scheme of coating by: a) RESS-BFB, b) RESS-WTS, c) SAS-FB and d) SAS-DEM 
[102,101,104]. 
As the fluidization occurs inside the precipitator, the CO2 flowrate selected for SAS-FB 
processing should be high enough to ensure particles are fluidized and precipitation happens 
under supercritical conditions. High-pressure fluidization can be used to investigate different 




degree of mixing and high rates of heat and mass transfer, typical of fluidized beds, to achieve 
uniform coatings. 
A common weakness of conventional fluidized beds is the difficulty of fluidizing small 
particles (< 30 µm, group C) [143]. Therefore, the bed material must be composed of large 
particles, which limits the surface area available for particle deposition and, consequently, the 
amount of drug that can be loaded in the formulation. Consequently, RESS-WTS, RESS-BFB 
and SAS-FB are more useful in the preparation of formulations of highly potent drugs that 
require low dosages.  
If fine excipient particles are desired, a possible solution is to mix them with surfactants 
(additives), known as force control agents [144], in a previous processing step to decrease the 
attraction force between excipient particles, hence improving their flowability. Then a drug-
additive-excipient formulation (Figure 2-1f) can be obtained, however, the administration 
route restricts the number of additives. Additives are also used to improve the bulk density 
and flow properties of the formulation by changing the API surface properties (Figure 2-1b). 
This allows direct tablet compaction without the need for prior granulation [141,145].  
In the Supercritical Antisolvent-Drug Excipient Mixing (SAS-DEM) process, a stirrer 
placed in the high-pressure precipitator provides the extra energy source needed to allow the 
fluidization of fine particles (Figure 2-8d). This process has been used to coat lactose (100 
µm) and MCC particles (50 µm) with nevirapine (10-54 wt% loading). It was found that by 
increasing the drug loading, the API particle size increased and the configuration of the API-
excipient mixture changed from ordered to ordered-random [104]. In another work, SAS-
DEM was used to precipitate itraconazole (6-50 wt% loading) onto lactose (100 µm) in the 
presence of two surfactants, sodium dodecyl sulfate and polaxamer 407, to improve the 




the drug were obtained in both works, sometimes with a similar surface area to a SAS-
processed drug, improved dissolution properties were attributed to the efficient 
deagglomeration and wetting of drug particles in the presence of the excipients. Ober et al. 
[106] prepared pulmonary delivery formulations of micro-sized rifampicin particles onto 
lactose microfine (< 10 µm) with drug loading between 1.2–25.7%. As the particle size of the 
precipitated API is similar to the lactose, the formulation resembles more a solid mixture 
rather than a coated material. It is worth noting that, depending on the characteristics of the 
core particles, their attrition with the impeller and walls of the vessel might lead to undesired 
particle breakage when specific size and morphology are required. Additionally, the extra 
energy input might increase operational costs. 
For the mixing of nanoparticles, the rapid expansion of high pressure or supercritical 
suspensions (REHPS) can be used. This simple technique consists of suspending insoluble 
compounds in scCO2 and then depressurizing the suspension through a nozzle. REHPS has 
been initially used to mix different species of nanoparticles and several analytical techniques 
have demonstrated its improved efficacy when compared with conventional mixing 
techniques, especially for compounds with similar densities [146]. The effective break up of 
particle agglomerates was attributed to the shear stress in the nozzle and the posterior 
collision of the agglomerates with the mach disc [147]. The efficiency of this process was 
later demonstrated by deagglomeration and mixing of alumina and titania nano-powders 
[148]. This technique can potentially be applied to mix/coat pharmaceutical compounds and 
excipients, although no reports of such application have been found so far. 
2.6. Conclusions 
This review has demonstrated the applicability of SCF/DGs to prepare a wide variety of 




density with pressure and/or temperature and low viscosity, the processing of thermo-labile 
compounds is possible while keeping their molecular integrity. Additionally, they are 
considered environmentally friendly technologies since the use of large amounts of organic 
solvents is avoided. Many modifications in previously existing processes have been 
developed in recent years, showing the interest in the improvement of these techniques to 
bring them to an industrial scale. Insights into the selection of the most appropriate processing 
technique have also been provided considering different types of formulation strategies. 
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Dry powder formulations with potential application in pulmonary drug delivery were 
produced by integrating the Supercritical Antisolvent (SAS) process with a fluidized bed (FB) 
under pressure. The simultaneous precipitation and coating of curcumin on lactose was 
performed in a single step combining the advantages of both processes. Ethanol and acetone 
were used as solvents. The effects of operating parameters: pressure, temperature, drug-
lactose mass ratio, solution flow rate and solution concentration on the drug size, morphology 
and yield were investigated. Due to the high degree of mixing in the fluidized bed, a uniform 
coating of curcumin onto lactose was achieved with drug yield varying from 71.0 to 93.3% 
and curcumin crystals with length between 0.41 – 12.08 µm. The formulations produced were 
solvent-free and the crystallinity of curcumin was reduced.  







 Single-step precipitation and coating was performed via SAS-FB. 
 SAS-FB particles are smaller and less aggregated than SAS particles. 
 Solvent-free formulations with very good flow properties were produced. 
 The location of the operational point affects particle size distribution. 
3.3. Introduction 
In the recent decades, there has been a considerable investigation of the potential use of the 
lungs as a non-invasive drug delivery route. The large surface area of the alveolar region, high 
blood supply, thin epithelial barrier and lack of first pass metabolism contributes to a rapid 
onset of therapeutic action and enhances drug bioavailability [1]. The main factor controlling 
the efficiency of particle deposition in the lungs is the aerodynamic diameter which should be 
between 1-5 µm [2]. However, due to the high Van der Waals interactions, particles within 
this size range tend to be aggregated causing poor flowability, irregular dispersion and 
formulation instability. For those reasons, active pharmaceutical ingredients (APIs) are 
usually combined with larger excipient or carrier particles improving drug flow properties, 
handling and metering [3–5]. By the inspiratory airflow force, drug and carrier dissociate. 
While small particles of drug travel towards the lungs, coarse carrier particles are deposited 
and cleared in the upper airways [6,7]. 
There are several traditional methods for micronizing APIs such as: wet milling, high pressure 
homogenization and spray drying [8]. Particle engineering using supercritical fluid (SCF) 
technology has demonstrated advantages over conventional micronization processes as 
control of particle morphology, size and particle size distribution can be easily achieved with 




sensitive compounds can be processed at mild temperatures and formulations with low or no 
residual solvent can be obtained. The Supercritical Antisolvent (SAS) process is widely used 
to produce a variety of materials with different morphologies [11–15]. In a typical SAS 
process, the API is dissolved in an organic solvent, which is highly miscible with the SCF, 
and this solution is sprayed inside a high-pressure vessel (HPV) through which the SCF flows 
continuously. Upon contact, the SCF diffuses into the liquid phase, decreasing the solvation 
power of the organic solvent and leading to the precipitation of the API.  
To generate particles in the size range required for deep lung deposition while avoiding 
agglomeration issues, single-step SAS precipitation and coating in a fluidized bed (FB) under 
pressure was employed. In SAS-FB, the particles of the API precipitated by SAS process are 
simultaneously coated on the surface of carrier particles which comprise the fluidized bed 
material. Due to the high degree of mixing in the fluidized bed, a uniform coating of fine drug 
particles onto the excipient surface can be achieved while preventing aggregation of the drug 
precipitate, hence leading to a high drug dissolution rate and bioavailability [16]. Curcumin 
was selected as a model API for pulmonary delivery. Known for a long time as a spice and 
food additive, it also has many therapeutic properties including antioxidant, antimicrobial, 
anticancer and anti-inflammatory. However, the use of curcumin in drug formulations is 
limited by its poor water solubility, fast intestinal metabolism and low bioavailability after 
oral administration [17]. Therefore, pulmonary delivery is proposed as a non-invasive route 
for improving curcumin absorption in the body. Lactose was chosen as the carrier for being 
stable, inexpensive, available in several sizes and morphologies and approved by the Food 
and Drug Administration (FDA)  [6].  
The combination of supercritical precipitation and fluidized bed coating has been reported 




the Rapid Expansion of a Supercritical Solution process (RESS) [18–24].  The association of 
fluidized bed with supercritical antisolvent processes is more recent. Previous work of Li et 
al. [16] successfully coated nano-sized naringin onto microcrystalline cellulose via SAS-FB 
and the effects of several operational parameters on subsequent drug release were analysed. A 
similar rig was used to coat nanoparticle agglomerates of titanium dioxide with polymer 
Pluronic F-127 [25]. In this case, the coating material is deposited as a film rather than 
individual particles. Niu et al. [26], also precipitating polymer films, coated several materials 
using dense CO2 as antisolvent and fluidizing medium in a Wurster coater. Other researchers 
encapsulated nano-curcumin on PLGA by using ultrasonic vibration to fluidize the 
agglomerates [27]. The supercritical antisolvent-drug excipient mixing process uses a stirred 
vessel to fluidize and coat drug particles produced by SAS on excipients [28–30]. However, 
none of the previously reported works aimed to precipitate and coat curcumin on lactose by 
SAS-FB to prepare pulmonary drug delivery formulations.  
This work also attempts to understand how SAS-FB operational conditions affect the 
characteristics of the final drug formulation including curcumin morphology, particle size and 
drug yield. The operational parameters analysed were: pressure, temperature, drug-carrier 
mass ratio, curcumin solution flow rate and solution concentration. The effect of solvent was 
investigated by comparing the use of ethanol and acetone. 
3.4. Materials and Methods 
3.4.1. Materials 
All materials were used as-received from the suppliers without additional purification. 
Curcumin (purity ≥ 90%) was purchased from Cayman Chemical, UK, α-lactose monohydrate 




Pharma, Germany, ethanol (HPLC grade > 99.8%) and acetone (purity > 99.8%) were 
purchased from Scharlau and Sigma-Aldrich Company Ltd., UK, respectively. Carbon 
dioxide (purity ≥ 99.8%) was purchased from BOC, UK.  
3.4.2. SAS and SAS-FB Experimental Procedure 
SAS-FB process, using the sc-CO2 flow and the solution jet of SAS to fluidize lactose 
particles, instantly precipitates and coats nano/micro-sized curcumin particles onto the 
lactose.  A complete description of SAS-FB apparatus was previously done by Li et al. [16]. 
A schematic flowsheet of the process is shown in Figure 3-1. For a typical SAS-FB 
experiment, the conical fluidized bed is initially preloaded with 1 g of lactose and placed 
inside the 0.5 litre high pressure vessel (HPV). The system is pressurized via the top port (not 
shown in figure; shown in Appendix I) with CO2 until the desired pressure is reached. Then 
the CO2 feed is switched to the bottom of the high pressure vessel (HPV), to fluidize the 
preloaded lactose. A filter cap on the top of the fluidized bed prevents the loss of particles.  In 
order to obtain quasi-steady state composition of solvent and CO2, pure solvent is pumped 
through a nozzle (127 µm) located at the bottom centre of the fluidized bed for 10 minutes 
(see Appendix III). Following this, the pump feed is switched from solvent to drug solution 
to start SAS-FB precipitation and coating. When the solution injection is completed, the pump 
is switched back to pure solvent to purge the pipe lines and guarantee the designed amount of 
drug was delivered to the HPV. Pure CO2 then flushes the system to remove any remaining 
solvent dissolved in the supercritical phase (see Appendix III). Finally, the pressure is 
gradually decreased and the sample collected. For the SAS experiment the same procedure 




3.4.3. SAS and SAS-FB Operational Conditions 
In this study, the simultaneous precipitation and coating of curcumin on lactose generating a 
formulation with potential application for pulmonary drug delivery is presented. The final 
formulation is obtained with no further drying or mixing steps. The organic solvents were 
chosen due to their ability to solubilize curcumin, their high miscibility with sc-CO2 in the 
range of conditions studied, and their safety toward pharmaceutical applications. In addition, 
the solvents should not dissolve the lactose in the fluidized bed, and therefore, ethanol was 
selected as the standard solvent, although some experiments with acetone were also 
performed. 
 
Figure 3-1. SAS-FB experimental apparatus [16]. HPV = high pressure vessel, MPV = middle 
pressure vessel, BPR = back pressure regulator. 
Considering that at low concentrations the presence of curcumin does not significantly change 




























behaviour of the ternary system (ethanol-CO2-curcumin). Figure 3-2 shows the region of 
interest of the VLE for ethanol-CO2 at 40°C obtained from Joung et al. [32]. The figure also 
includes the location of different SAS-FB experiments performed at the same temperature. In 
the literature, it has been observed that microparticles are generally produced if the 
operational pressure is located in the proximity of the mixture critical point of solvent-CO2 
[10,12]. Once the aim of this work is to precipitate microparticles suitable for inhalation, a 
pressure of 9.0 MPa was selected for the standard experiment, as it is slightly higher than the 
critical pressure of the system ethanol-CO2 at 40°C (pc = 8.16 MPa; xcCO2 = 0.963 [32]). The 
standard operational conditions are then fixed at: temperature T = 40°C, pressure p = 9.0 
MPa, initial solution concentration C = 2 mg/ml, solution flow rate f = 1 ml/min and CO2 
mass flow rate fCO2 = 40 g/min, giving a CO2 molar fraction of xCO2 = 0.981 to ensure the 
precipitation happens in the supercritical region (Figure 3-2). The mass flow rate of CO2 was 
kept constant at 40 g/min for all experiments, thus the CO2 molar fraction was varied by 
changing the organic solution flow rate only. For the SAS-FB experiments 1 g of lactose was 
loaded in the bed and a curcumin-lactose mass ratio of MR = 2% was set as standard, while in 
the SAS experiments no lactose was loaded in the bed. A 127 µm ID capillary was used as the 
nozzle in all experiments. 
3.4.4. Fluidized Bed Behaviour 
Tapered beds are employed in several processes and applications preventing some problems 
of conventional cylindrical beds such as slugging, entrainment of particles and channelling. 
Due to the increase in the cross-section area with bed height, the fluid velocity decreases 
gradually,  improving the mixing and enabling the fluidization of materials with a wide 






Figure 3-2. Vapor-liquid equilibrium of ethanol-CO2 at 40°C obtained from Joung et al. [32] and 
operational points. Experiments that produced one population of particles are shown in green while the 
experiment with two populations is in red. 
A conical fluidized bed with base diameter of 5.9 mm was used in this work. The selected 
CO2 mass flow rate of 40 g/min resulted in a CO2 velocity ranging between 2.4 cm/s (at 16 
MPa) - 6.9 cm/s (at 8 MPa) calculated considering the base diameter. A precise determination 
of the minimum fluidization velocity by observation of the bed behaviour through the 
sapphire window on the HPV was difficult since the top of the bed at minimum fluidization 
flow rate was not high enough to be completely seen. However, observations of the bed 
behaviour during fluidization showed that the CO2 velocities used are high enough to fluidize 
the lactose particles, but not so high that particles are blown out of the bed. This was true also 
in the presence of the jet of solvent. For all conditions tested, a fully fluidized bed was 
obtained, characterized by the upward movement of particles in the centre and downward 
movement of particles with lower speed outside of the core [35]. Although there are 
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significant difference on the fluidization was noticed probably because the fluid velocities 
used are much higher than the minimum fluidization velocities in each condition.  
3.4.5. Preparation of the Physical Mixture 
For comparison with the standard SAS-FB experiment, the physical mixture of curcumin and 
lactose was prepared with the same curcumin-lactose mass ratio (2%). The sample was hand-
mixed by shaking the powder in a sealed vial for 5 minutes. 
3.4.6. Analyses and Observations 
3.4.6.1. Scanning Electron Microscopy (SEM) and Particle Size Measurements 
The morphology of particles was accessed by Scanning Electron Microscopy (SEM) model 
Philips XL-30 FEG at 10 kV and 10 mA. Samples were placed on a double-sided adhesive 
carbon tape and sputter coated with platinum at 25 mA for 3 min in an Emscope SC500 
coating machine prior to the analysis. For the calculation of particle size distribution, at least 
300 particles of different SEM images were measured for each sample using Image J analysis 
software. Due to the elongated nature of the particles, measurements of length and width were 
taken. The results are expressed as mean length ± standard deviation and the aspect ratio 
(mean length/mean width) was also calculated. 
3.4.6.2. Drug Yield and Formulation Uniformity 
Drug yield (Y) is defined as the percentage ratio of the mass of drug precipitated to the mass 
of drug introduced. The mass of precipitated drug was determined using an ultraviolet (UV)–
visible spectrophotometer (Jenway, Genova Plus) at λ = 450 nm. The absorbance of lactose at 
this wavelength can be neglected. A known mass of sample (circa 1 mg) was dissolved in 10 
ml 50% water-acetone solution and the corresponding curcumin concentration was obtained 
using a calibration curve (R
2




the mean values are shown. The uniformity of the formulation was investigated by calculating 
the relative standard deviation (RSD) of drug content in each batch.  
3.4.6.3. Solubility Measurements 
Equilibrium solubility of curcumin in the solvents used at the temperatures of the experiments 
were determined. Tests were carried out at 35°C and 50°C for ethanol and at 40°C for ethanol 
and acetone. Excess amount of curcumin was added in vials containing the solvent and kept in 
a water bath at the desired temperature until equilibrium was reached. The supernatants were 
filtered through a 0.22 μm pore size membrane filter and diluted to be further analysed via an 
ultraviolet (UV)-visible spectrophotometer (Thermo Scientific Orion AquaMate). 
3.4.6.4. Thermogravimetric Analysis (TGA) 
Solvent residue was analysed by Thermogravimetric Analysis (TGA, Exstar 6000, Seiko 
Instruments Inc, UK, coupled with a 1G/DTA6300). Fresh made samples of approximately 5 
mg were heated from 20°C to 120°C at a rate of 2°C/min. Nitrogen was used as a purge gas 
with a flow rate of 20 ml/min.  
3.4.6.5. Fourier Transform Infrared Spectroscopy (FT-IR) 
The infrared spectra of the samples and raw compounds were taken with a Fourier Transform 
Infrared (FT-IR Jasco-6300) Spectrometer in a range of 800-4000 cm
-1
. The spectra are 
composed of 64 scans with a resolution of 4 cm
-1
. 
3.4.6.6. X-Ray Diffraction (XRD) 
XRD patterns of processed and unprocessed curcumin were obtained using a powder 
diffractometer (Bruker D8, UK) to investigate the crystallinity of the samples. Powder 
samples were packed in the sample holder and characterized with a beam angle from 5° to 40° 




3.5. Results and Discussion 
3.5.1. Scanning Electron Microscopy (SEM) 
A summary of the operational conditions tested and the results obtained is shown in Table 
3-1. In the preliminary experiments, curcumin was precipitated via SAS from an ethanol 
solution (experiment SAS-Et) at standard conditions (i.e. p = 9.0 MPa, T = 40°C, C = 2 
mg/ml, f = 1 ml/min and fCO2 = 40 g/min). SEM images of SAS-Et can be seen in Figure 
3-3c, while raw curcumin, as-received from the supplier, is illustrated in Figure 3-3a. It is 
clear that after SAS processing at standard conditions curcumin morphology changed from a 
rod-like shape with a wide size distribution (18 ± 11 µm) to a filament/dendritic-like 
structure. Acetone was also tested as solvent (experiment SAS-Ac) in the same conditions and 
a similar morphology was obtained (Figure 3-3d). The formation of dendritic structures 
might be the result of non-uniform supersaturation and uncontrolled nucleation and particle 
growth [36]. The interconnected nature of the filaments of SAS processed samples made the 
particle size distribution measurements from the SEM images unfeasible. In the literature, 
curcumin has been previously processed by SAS using dichloromethane [37] and acetone, 
acetonitrile, and methanol [38] as solvents. The morphologies obtained are highly dependent 
on the operational conditions used, varying from irregular, rod, needle and spherical with 
sizes from 90 nm to 8.3 µm. 
The agglomerated drug particles produced by SAS are too cohesive for pulmonary delivery 
hence their combination with larger excipient or carrier particles to improve drug flow 
properties, handling and metering is required. SAS-FB process is proposed to allow 
simultaneous drug precipitation and coating on an excipient, avoiding an additional mixing 

























SAS-Et 9.0 40 1.0 2.0 2 ethanol - - - - unimodal 
filament/ 
dendritic 
SAS-Ac 9.0 40 1.0 2.0 2 acetone - - - - unimodal 
filament/ 
dendritic 
STD 9.0 40 1.0 2.0 2 ethanol 4 ± 1 5.8 89.2 4.6 unimodal 
rectangular, 
needle 
P1 8.0 40 1.0 2.0 2 ethanol 




90.0 2.9 bimodal irregular 
P2 13.0 40 1.0 2.0 2 ethanol 12 ± 5 7.3 76.6 2.4 unimodal 
rectangular, 
needle 
P3 16.0 40 1.0 2.0 2 ethanol 11 ± 5 8.2 80.4 4.2 unimodal 
rectangular, 
needle 
Pf 8.0 40 0.5 2.0 2 ethanol 4 ± 2 6.3 85.3 4.6 unimodal 
rectangular, 
needle 
T1 9.0 35 1.0 2.0 2 ethanol 
5 ± 3 
0.5 ± 0.2 
6.5 
4.9 
71.0 3.5 bimodal needle 
T2 9.0 50 1.0 2.0 2 ethanol 
6 ± 2; 
0.8 ± 0.2 
5.7 
4.9 


























Tf 9.0 35 0.5 2.0 2 ethanol 3 ± 2 3.7 87.1 2.4 unimodal 
rectangular, 
needle 
MR1 9.0 40 1.0 2.0 1 ethanol 3 ± 1 4.7 83.4 4.7 unimodal 
rectangular, 
needle 
MR6 9.0 40 1.0 2.0 6 ethanol 6 ± 2 5.3 86.4 4.7 unimodal 
rectangular, 
needle 
f1 9.0 40 0.5 2.0 2 ethanol 4 ± 1 5.7 91.5 2.8 unimodal 
rectangular, 
needle 
f2 9.0 40 1.5 2.0 2 ethanol 6 ± 2 5.7 82.7 4.1 unimodal 
rectangular, 
needle 
S1 9.0 40 1.0 2.0 2 acetone 5 ± 2 4.7 85.2 3.0 unimodal 
rectangular, 
needle 
C1 9.0 40 1.0 8.0 2 acetone 4 ± 2 3.7 93.3 3.3 unimodal 
rectangular, 
needle 







Figure 3-3. a) Raw curcumin; b) uncoated lactose; c) Ethanol processed curcumin (SAS-Et); d) 
Acetone processed curcumin (SAS-Ac); e) curcumin coated lactose from ethanol (STD); f) curcumin 
coated lactose from acetone (S1) . The experiment ID and conditions used are listed in Table 3-1. 
Curcumin was then processed by SAS-FB under the standard conditions, as used in SAS-Et 
above, with lactose (125-145 µm) being fluidized inside the HPV (experiment STD). For 
comparison, the uncoated lactose surface, as-received from the supplier is shown in Figure 
3-3b. After SAS-FB processing, it is clear the deposition of curcumin particles on the lactose 




(Figure 3-3c).  There was also a change in morphology from the filament/dendritic-like 
structure in SAS-Et to a rectangular and needle shape in STD. Similarly, curcumin processed 
by SAS-FB using acetone (experiment S1) also at standard conditions yielded smaller and 
less agregated particles (Figure 3-3f) than SAS-Ac (Figure 3-3d). It is believed that the 
collection of curcumin particles onto lactose close to their point of origin inhibited further 
particle growth and aggregation [16]. The smaller particle size in the SAS-FB compared to the 
SAS may be attributed to the movement of lactose particles inside the fluidized bed, 
improving the mixing and turbulance which caused higher degree of supersaturation, and 
hence higher nucleation rate. Another benefit of SAS-FB is to facilitate the removal of 
curcumin particles from the HPV as it was observed that  most of the particles attached on the 
free-flowing lactose. This clearly shows the advantages of SAS-FB at improving the handling 
of the product. 
3.5.2. Effect of Process Parameters 
In antisolvent processes, particle size is strongly related with the degree of supersaturation 
promoted by sc-CO2 in the liquid solution. The supersaturation levels may vary with the 
density of the fluid phase, which determines the equilibrium solubility of the drug in the fluid 
phase, the initial solution concentration, and the solvent molar fraction in the fluid mixture. In 
the case of drug yield, it is determined by the amount of drug that stays dissolved in the fluid 
phase [39,40]. The effect of operational parameters on particle size, morphology and drug 
yield were analysed by changing the conditions from the standard SAS-FB experiment (STD). 
It can be seen in Table 3-1 that three levels of pressure (experiments P1, P2 and P3) and two 
levels of temperature (experiments T1 and T2), curcumin-lactose mass ratio (experiments 
MR1 and MR6) and solution flow rate (experiments f1 and f2) were tested. The effect of 




curcumin concentration in ethanol in STD (2 mg/ml) was already close to its saturated 
solution [41]. The combined effect of pressure and solution flow rate was analysed in the 
experiment Pf, while the effect of temperature and solution flow rate was tested in Tf keeping 
all the other operational parameters as standard. Process recovery was calculated as a 
percentage of the final mass recovered compared to the total mass introduced in the vessel 
(curcumin and lactose) and ranged between 93% and 97% for the entire set of experiments. 
Small amount of sample was clearly lost attached to the walls of the bed and gas distributor. 
3.5.2.1. Effect of Pressure 
To investigate the effect of pressure on the final formulation, three different experiments were 
run and compared with STD performed at 9.0 MPa. The following pressure values were used: 
8.0 MPa (P1), 13.0 MPa (P2) and 16.0 MPa (P3), while all the other operational parameters 
were fixed at standard conditions (i.e. T = 40°C, C = 2 mg/ml, f = 1 ml/min, fCO2 = 40 g/min 
and MR = 2%). The effect of pressure on the length of curcumin particles is shown in Figure 
3-4a.  
Pressure has a high impact on the CO2 density and consequently on the density of the fluid 
phase formed by the mixture ethanol-CO2 once it contains around 98% (in mole) of CO2. At 
8.0 MPa (P1) a complete coverage of lactose surface is observed in Figure 3-5a,b due to the 
formation of a large amount of irregular small particles (0.4 ± 0.2 µm). A few large particles 
were also formed, however, due to their low number, reliable particle size distribution 





Figure 3-4. Variations of curcumin length compared to the experiment STD (p = 9 MPa, T = 40°C, C 
= 2 mg/ml, f = 1 ml/min, fCO2 = 40 g/min and MR = 2%) at different: a) pressures - P1 (8 MPa), P2 
(13 MPa), P3 (16 MPa); b) temperatures - T1 (35°C), T2 (50°C); c) curcumin-lactose mass ratios - 
MR1 (1%), MR6 (6%); d) solution flow rates - f1 (0.5 ml/min), f2 (1.5 ml/min); e) solution 





Figure 3-5. SEM images of curcumin coated lactose via SAS-FB at different pressures and solution 
flow rates: a) P1 (8 MPa, 1 ml/min), Mag 1500; b) P1, Mag 15000; c) Pf (8 MPa, 0.5 ml/min), Mag 
1500; d) P2 (13 MPa, 1 ml/min), Mag 1500; e) P3 (16 MPa, 1 ml/min), Mag 1500. 
In this experiment (P1), the operational point of the system is presumably located below the 
supercritical region on the boundary between the vapour and liquid-vapour regions of the 
ethanol-CO2 VLE diagram (see P1 in Figure 3-2). The ethanol-rich phase, capable of 
solubilizing more curcumin, would form a solution with low supersaturation, and 




supersaturation, due to the low solubility of curcumin in CO2, generates submicron particles 
[42]. To verify this hypothesis, another experiment (Pf) was performed away from the 
boundary of liquid-vapour region at the same pressure but with higher CO2 molar fraction 
(0.991), by decreasing the solution flow rate to 0.5 ml/min and keeping fixed the CO2 flow 
rate in 40 g/min. The operational point is now located in the vapour region (see Pf in Figure 
3-2) and a uniform distribution of particles was produced as demonstrated in Figure 3-5c. 
Therefore, one can attribute the formation of two different populations of particles in P1 to the 
existence of two phases. By having an increment of 1.0 MPa in pressure, at 9.0 MPa (STD) 
the CO2 density becomes 75% higher [43] and the mean particle length is around 10 times 
higher than at P1. When the pressure increases to 13.0 MPa (P2), the CO2 density is 53% 
higher than that at 9.0 MPa [43] and particle length increases further to 12 ± 5 µm. A small 
number of rectangular and needle-like particles with a wide size distribution were formed 
(Figure 3-5d). Finally, at 16.0 MPa (P3, Figure 3-5e) the CO2 density is only 7% higher than 
at 13.0 MPa [43]. The particles measure 11 ± 5 µm, and therefore, no further increase in 
length was observed. As with STD, only one population of particles was detected in P2 and 
P3 as the operational points are far away from the biphasic region (Figure 3-2). The aspect 
ratio (L/W = length/width) increased with pressure with values equal to 3.3, 5.8, 7.3 and 8.2 
in P1, STD, P2 and P3, respectively. It has been demonstrated that particles with high aspect 
ratio have improved aerodynamic properties, favouring drug detachment from the carrier`s 
surface and deep lung deposition [4]. Therefore, the formulation originated in P3 should have 
the best properties for pulmonary delivery.  
The results of increasing the operational pressure on particle size can be explained by the 
competition of two opposite effects caused by the rise in CO2 density: i) the ability of CO2 to 




liquid solution which causes a high nucleation rate and fast particle grow. This leads to the 
formation of a large number of small particles [39,44] and, ii) the ability of ethanol-CO2 to 
solubilize the solute (cosolvent effect) is increased, diminishing the solution supersaturation 
and consequently the nucleation rate. The higher the concentration of ethanol in the fluid 
phase, more significant is the increase in drug solubility with pressure [45]. If the fluid phase 
is still supersaturated after nucleation, the solute may continuously migrate to the solid phase, 
leading to particle growth [39]. The increase in particle size observed (Figure 3-4a) when the 
pressure increased from 8.0 to 13.0 MPa leads to the conclusion that the cosolvent behaviour 
of CO2 is favoured at higher pressures. Two recent papers [45,46] support this conclusion 
through the measurement of curcumin solubility in ethanol-CO2 mixtures. They found out that 
for a given temperature and ethanol composition, the solubility of curcumin in the fluid phase 
increases with pressure. At 16.0 MPa, the antisolvent effect would probably start to 
compensate the cosolvent effect as no further increase in length occurred. Similar effect of 
pressure was observed by Jia et al. [37] in the precipitation of curcumin from a 
dichloromethane solution: at 8.0 MPa irregular and rod morphology was observed, whereas at 
12.0 MPa much larger rod and needle-like particles were produced. These results evidence 
that the supersaturation of the dichloromethane solution decreased with pressure, likewise the 
ethanol solution studied here, although quantitative measurements of particle size were not 
shown. Conversely, Anwar et al. [38] noticed a decrease in the mean particle size of curcumin 
processed by SAS with methanol, acetonitrile and acetone when the pressure was increased. 
Curcumin processed with acetone by SEDS (Solution Enhanced Dispersion by Supercritical 
Fluids) also showed a decrease in particle size with pressure [47].  
With respect to drug yield, negligible change was observed from 8.0 MPa (Y = 90.0%) to 9.0 




obtained probably due to the high drug solubility in the fluid phase (cosolvent effect), as 
discussed before. At 16.0 MPa, as the CO2 density change became not significant with the 
change of pressure, the cosolvent effect intensity was weaker, giving a yield of 80.4%. In 
general, in the range of CO2 density distinctly affected by pressure, for the curcumin-ethanol-
CO2 system, the cosolvent effect probably dominated the competition with the antisolvent 
effect, leading to large particle size and low yield at high pressures.  
3.5.2.2. Effect of Temperature  
Tests of curcumin coating lactose using SAS-FB process at temperatures 35°C (T1) and 50°C 
(T2)  with all other conditions constant (i.e. p = 9.0 MPa, C = 2 mg/ml, f = 1 ml/min, fCO2 = 
40 g/min and MR = 2%) were carried out to be compared with STD performed at 40°C. SEM 
images of curcumin coated lactose at 35°C and 50°C are shown in Figure 3-6a,b and Figure 
3-6c,d, respectively. Two populations of particles were obtained in both tests with lengths 
shown in Figure 3-4b. 
Considering the VLE of ethanol-CO2 at 35°C obtained from Tanaka and Kato [48], T1 was 
probably performed in the liquid region (Figure 3-7a). The lower diffusivity of liquids 
compared with supercritical fluids may have caused a non-uniform mixing and 
supersaturation which lead to the formation of two populations of particles. To understand the 
influence of the fluid phase behaviour on the morphology of curcumin particles, another 
experiment (Tf) was performed at the same temperature but with higher CO2 molar fraction 
(0.991) by decreasing the solution flow rate to 0.5 ml/min and keeping the CO2 flow rate at 40 
g/min. In Tf (Figure 3-7a), the operational point is located in the border of the supercritical 
region (xcCO2 = 0.994, [48]) and only one population of particles was observed (Figure 
3-6e,f). In this case, the higher concentration of CO2 might have increased the diffusivity of 





Figure 3-6. SAS-FB results of curcumin coated lactose at different temperatures and flow rates: a) T1 
(35°C, 1 ml/min), Mag 1500; b) T1, Mag 3500; c) T2 (50°C, 1 ml/min), Mag 1500; d) T2, Mag 3500; 
e) Tf (35°C, 0.5 ml/min), Mag 1500; f) Tf, Mag 3500.  
At 50°C (T2), taking the VLE data from Joung et al. [32] as reference, the operational point 
should be located in the vapour region (Figure 3-7b), albeit very close to the boundaries of 
the biphasic region where liquid and vapour can be found. Thereby, small oscillations on the 
process conditions could easily lead to precipitation in the biphasic region. The large particles 




rate occurred. At immiscible conditions, the mechanisms of supersaturation are more complex 
than in miscible systems so they cannot describe properly the precipitation process [39].  
  
Figure 3-7.  a) Vapor-liquid equilibrium of ethanol-CO2 at 35°C obtained from Tanaka and Kato [48]; 
b) vapor-liquid equilibrium of ethanol-CO2 at 49.4°C obtained from Joung et al. [32]. The dashed 
lines limit the supercritical region. The experiment that produced one population of particles is shown 
in green while the experiments with two populations are in red. 
The temperature affects the SAS precipitation process in different ways: it changes the vapour 
pressure of the drug and densities of CO2 and solvent which influence the solid solubility in 
the fluid phase and, ultimately, the degree of supersaturation; the viscosity of the liquid 
solution can also change which influences the nucleation rate. The most significant impact on 
drug yield was observed at 35°C (T1), where the fluid density is the highest among the three 
temperatures tested. As discussed previously in Section 3.5.2.1, high ethanol-CO2 density 
enhances drug solubility in the fluid phase (cosolvent effect), decreasing the supersaturation. 
Cunico et al. [46] observed that the effect of temperature on the solubility of curcumin in 
ethanol-CO2 is substantially higher than the effect of pressure and this might explain why at 




concluded that high temperature improves curcumin recovery from ethanol and ethanol-
acetone solutions processed by Gas Antisolvent (GAS) and  Atomized Rapid Injection of 
Solvent Extraction (ARISE) [36]. At 50°C, the yield (Y = 82.3%) was not higher than at 40°C 
(Y = 89.2%), despite the decrease in the fluid density. In this case, the increase in the vapour 
pressure of the drug might have compensated the effect of density. Also, the equilibrium 
solubility of curcumin in ethanol increased from 7.5 mg/ml to 10.4 mg/ml when the 
temperature changed from 40°C to 50°C which could decrease the supersaturation of the 
liquid solution.  
3.5.2.3. Effect of Drug-Carrier Mass Ratio 
In order to analyse the surface area available for drug deposition two tests were performed: 
the first at 1% curcumin-lactose mass ratio (MR1) and the second at 6% curcumin-lactose 
mass ratio (MR6), with all the other conditions constant as the experiment STD (i.e. T = 
40°C, p = 9.0 MPa, C = 2 mg/ml, f = 1 ml/min and fCO2 = 40 g/min). The mass of lactose in 
the bed was kept constant (1 g) so only the amount of drug pumped inside the HPV was 
varied. Figure 3-8 shows the lower mass ratio results (MR1) in the lefthand column and  the 
higher mass ratio (MR6) in righthand column.   
It is clear that in the lower mass ratio test (MR1) the lactose surface is not completely covered 
as some free space can be observed. Conversely, increasing the mass ratio to 6% (MR6) 
resulted in the formation of agglomerated particles and mutiple layered coating with many 
curcumin particles not attached to the carrier surface. In this case, the relative surface area of 
lactose particles available is much lower so the chance of forming drug agglomerates is 
higher. As the solution flow rate and concentration were kept constant, the coating time was 
varied to reach the desired curcumin-lactose mass ratio. In addition to these changes in 




significant) that increasing the drug-carrier mass ratio leads to an increase in the mean size of 
the curcumin partcles.  If true, this may be explained by the increase in residence time of 
partices in the HPV [39]: in MR1, STD and MR6 the respective coating times were 5, 10 and 
30 minutes. 
 
Figure 3-8. SAS-FB results of curcumin coated lactose at different curcumin-lactose mass ratios. 
Lefthand column: mass ratio of  1% (MR1); righthand column: mass ratio of 6% (MR6). 
As expected, no significant changes in drug yield could be observed comparing the STD (Y = 
89.2%), MR1 (Y = 83.4%) and MR6 (Y = 86.4%) experiments. Once pressure, temperature, 
solution initial concentration and flow rate were kept constant, the yields were not 




3.5.2.4. Effect of Solution Flow Rate 
The effect of changing the solution flow rate from the experiment STD (1 ml/min) was 
analysed for two different values: 0.5 ml/min (f1) and 1.5 ml/min (f2). All the other 
operational conditions were kept constant (i.e. T = 40°C, p = 9.0 MPa, C = 2 mg/ml, fCO2 = 
40 g/min and MR = 2%). There is a suggestion of an increase in curcumin length with the 
solution flow rate (Figure 3-4d), but the data is not statistically significant. In f1, rectangular 
and needle-like particles were formed (Figure 3-9a). As the solution flow rate increased to 
1.5 ml/min, the morphology of particles (Figure 3-9b) was kept similar to the experiments 
before, however there may be an increase in the mean particle length. In both experiments (f1 
and f2), only one population of particles was obtained as the operational points are located in 
the supercritical region (see f1 and f2 in Figure 3-2).  
Drug yield decreased from 91.5% in f1 to 82.7% in f2. The possible reason is that the 
presence of more solvent enabled more curcumin to be solubilized in the fluid phase [45,46]. 
Furthermore, there was a small decrease in the contact time between solution and sc-CO2, 
thus the solution supersaturation could decrease. Other authors [38,47] have reached the same 
conclusions regarding flow rate and supersaturation of curcumin solutions,  however the 
opposite effect has been also reported justified by the fact that high solution flow rate 
improves the mixing [44]. 
3.5.2.5. Effect of Solvent 
The effect of solvent on particle size can be observed by comparing the experiment STD, in 
which ethanol was used as solvent, to the experiment S1 that used acetone with all the other 
conditions constant (i.e. T = 40°C, p = 9.0 MPa, C = 2 mg/ml, f = 1 ml/min, fCO2 = 40 g/min 




than in STD (Figure 3-3e) while the morphology was similar. Therefore, in the case of this 
work, the choice of organic solvent has little impact on particle size and morphology if the 
same concentration is used. 
There was a small decrease in drug yield from 89.2% in STD to 85.2% in S1. Since the ability 
of acetone to solubilize curcumin at 40°C is much higher (67.5 mg/mL) than ethanol (7.5 
mg/ml), the supersaturation in the ethanol solution was probably higher. To increase the 
supersaturation of the acetone solution, other tests were performed with acetone at higher 
concentrations. 
3.5.2.6. Effect of Solution Concentration 
Acetone solution concentrations of 8 mg/ml (C1) and 20 mg/ml (C2) were tested with all the 
other conditions fixed as standard (i.e. T = 40°C, p = 9.0 MPa, f = 1 ml/min, fCO2 = 40 g/min 
and MR = 2%). Increasing the solution concentration effectively increases the supersaturation 
of the liquid at the prevailing conditions and would appear to result in smaller curcumin 
particles (Figure 3-4e). The morphology of curcumin particles in C2 was changed to irregular 
and agglomerated (Figure 3-9d) while C1 particles still kept the rectangular shape (Figure 
3-9c) as S1 (Figure 3-3f). The aspect ratio also decreased with concentration, measuring 4.7, 
3.7 and 2.6 in S1, C1 and C2, respectively.  
Drug yield increased from 85.2% in S1 to 93.3% in C1 due to the higher supersaturation 
attained. In fact, C1 delivered the highest yield in this work. Increasing the concentration even 
more, drug yield was equal to 86.0% in C2. No further increase in yield probably resulted 
from the increase in the viscosity of the liquid solution at  the elevated concentration, leading 
to a poor diffusion between sc-CO2 and acetone and thus a non-uniform supersaturation [44]. 




using ethanol (STD), it is possible to see that acetone with an intermediate concentration (8 
mg/ml) provides higher drug yield than the standard ethanol solution (2 mg/ml), however the 
aspect ratio is larger in the latter. These results regarding drug yield are in agreement with the 
observations of Kurniawansyah et al. [36]. 
 
Figure 3-9. SAS-FB results of lactose coated curcumin at different solution flow rates a) f1 (0.5 
ml/min); b) f2 (1.5 ml/min) and different solution concentrations c) C1 (8 mg/ml); d) C2 (20 mg/ml). 
3.5.3. Formulation Uniformity 
An indication of the uniformity of the formulation can be analysed by calculating the relative 
standard deviation (RSD) of the curcumin yield in each sample based on 3 to 4 measurements. 
The FDA [49]  recommendation is that the RDS should not exceed 6%. Due to the high 
degree of mixing in the fluidized bed, highly uniform samples were obtained once the RSD 




3.5.4. Thermogravimetric Analysis (TGA) 
In the pharmaceutical industry, the amount of residual organic solvent existing in the final 
formulation is critical. Not only are they harmful to the human health, but also high levels of 
organic solvents can affect the formulation physicochemical properties [50]. According to the 
USP 467 for residual solvent, ethanol and acetone belong to class 3 and therefore the 
maximum concentration recommended is 5000 ppm or 0.5%. The sample STD was analysed 
immediately after processing to investigate possible mass loss due to solvent evaporation. 
Solvent-free curcumin-lactose physical mixture was also tested as reference for comparison. 
Figure 3-10 demonstrates that the thermal behaviour of curcumin-lactose physical mixture 
and STD have very similar weight loss curves with no significant mass loss (about 0.1%) 
before 90°C. The boiling point of ethanol is 78°C so it would have started to evaporate below 
90°C, leading to the conclusion that there is only trace residual solvent in the samples 
processed by SAS-FB. As acetone (boiling point = 56°C) is even more volatile than ethanol, it 
is likely than even lower amounts of residual solvent would be found in SAS-FB samples 
processed by acetone.  
These results show the ability of the process in producing solvent-free formulations without 
the need for an extra drying step. Proper quantification of residual solvent content can be 
obtained by employing a headspace sampler coupled to a gas chromatograph with a flame 





Figure 3-10. TGA thermograms of curcumin coated lactose via SAS-FB (STD) and curcumin-lactose 
physical mixture. 
3.5.5. X-Ray Diffraction (XRD) 
The XRD patterns of raw curcumin and curcumin processed by SAS with ethanol (SAS-Et) 
are shown in Figure 3-11. It can be seen that after SAS processing the intensity of the peaks 
is decreased. This means that there was a reduction in the crystallinity of SAS-Et samples 
compared with raw curcumin. Moreover, changes on its crystal structure are observed since 
the peaks appear in different positions, as previously observed after curcumin processing by a 
similar supercritical antisolvent technique [36]. 
3.5.6. Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR was performed to analyse possible chemical interactions among lactose, curcumin, CO2 
and ethanol after SAS and SAS-FB.  As can be seen from Table 3-1, similar IR spectra were 
obtained for raw curcumin and SAS-Et. The spectra of STD and lactose also show high 
similarity once STD contains around 98% of lactose. No new peaks were observed when 























indicating that there is no chemical interaction among the compounds and their 
physicochemical properties remained unchanged. 
 
Figure 3-11. XRD patterns of raw curcumin and SAS processed curcumin (SAS-Et). 
 
Figure 3-12. IR spectra of processed and raw materials: raw curcumin; SAS processed curcumin 
(SAS-Et); raw lactose; curcumin coated lactose via SAS-FB (STD).  























SAS-FB process successfully precipitated and coated curcumin particles on the surface of 
lactose in a single step. Due to the improved mixing and collection of drug particles close to 
their point of origin in the fluidized bed, SAS-FB precipitates are normally smaller and less 
aggregated than SAS particles. The coating also gives the formulation better handling 
properties and flowability with potential application for pulmonary drug delivery. In the range 
of conditions tested, the operational pressure showed the highest impact on curcumin particle 
size, which varied between 0.41 and 12.08 µm. Drug yield varied from 71.0 to 93.3% with the 
highest value obtained when acetone was used as solvent. By careful use of the operational 
point in the multiple component phase diagram, a bimodal particle distribution could be 
obtained or avoided. 
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4.1.  Abstract 
The poor solubility of curcumin (CURC) in aqueous media leads to a low bioavailability, 
which prevents its application in pharmaceutical formulations. In this work, the Supercritical 
Antisolvent process (SAS) was used to produce coprecipitates of CURC and poly (vinyl 
pyrrolidone) (PVP) from mixtures of ethanol and acetone. The effects of operating 
parameters: pressure, temperature, solution concentration, drug/polymer mass ratio and 
solution flow rate were analysed for a 70-30 (v/v) acetone-ethanol mixture. It was found that 
the composition of acetone in the solvent mixture is the parameter that affects particle size 
and curcumin recovery the most. The thermal behaviour, crystallinity, molecular interactions, 
apparent solubility, release profile of the coprecipitates and possible degradation of curcumin 
were investigated. The results showed that the SAS process is effective in preparing 
amorphous formulations of CURC/PVP with an apparent solubility of more than 600 times 
higher than that of the physical mixture of the raw compounds. 
Keywords: coprecipitation; curcumin; PVP; supercritical antisolvent process; dissolution 
4.2. Highlights 
 Curcumin/PVP coprecipitates were produced from acetone-ethanol mixtures by SAS 
 Acetone percentage has great influence on particle size and product recovery 
 Nanoparticles (51–96 nm) and sub-microparticles (117–327 nm) were obtained 
 Curcumin recovery,  crystallinity, release profile and degradation were measured 






Curcumin (CURC) is a polyphenolic hydrophobic compound extracted from the roots of 
Curcuma longa and traditionally used as a spice and food additive. It has been demonstrated 
that curcumin has a wide range of therapeutic properties such as anticancer, antioxidant, 
antimicrobial and anti-inflammatory [1,2]. However, the use of curcumin in drug formulations 
is still not approved by the Food and Drug Administration (FDA), limited by several reasons 
including its low oral bioavailability caused by its poor solubility in aqueous media, low 
absorption and fast intestinal metabolism. In addition, curcumin undergoes degradation under 
light, heat and alkaline pH [3,4].  
In recent decades, several curcumin formulations have been developed to address these issues 
including nanoparticles, liposomes, polymeric micelles, dendrimers and hydrogels [5–7]. The 
coprecipitation of active pharmaceutical ingredients (API) with hydrophilic polymers is 
advantageous because it can improve the API dissolution properties while protecting it against 
degradation. Poly(vinyl pyrrolidone) (PVP) was selected in this work because it is a 
biodegradable polymer approved as an inactive ingredient by the FDA and hence widely used 
in pharmaceutical applications. Several studies have demonstrated its ability in modifying the 
crystallisation kinetics of poorly water-soluble compounds by producing amorphous 
formulations with improved dissolution profile [8–10]. PVP is also expected to inhibit drug 
recrystallisation in the gastro-intestinal tract after oral administration [11,12], giving time for 
drug molecules to be absorbed into the systemic circulation, thus increasing its bioavailability 
[13].  
The preparation of solid dispersions of curcumin and PVP with different molecular weights 
has been reported using conventional micronization techniques, such as spray drying [14] and 




temperature, which causes the degradation of thermo-sensitive compounds, low yields and 
high residual solvent content in the formulation, often requiring an extra processing step. 
Moreover, the control of particle morphology, particle size and size distribution is difficult 
[18–20]. In smaller quantities, PVP has been used as a stabilizer for curcumin nanoparticles 
prepared via liquid antisolvent methods followed by freeze drying [21–23].   
Supercritical fluids (SCFs) are attractive for particle precipitation as they combine liquid-like 
properties, such as high solvation power, and gas-like properties, including high diffusivity 
and compressibility. SCF-based micronization has demonstrated advantages over 
conventional techniques since particle size can be controlled through the manipulation of the 
operating parameters, the use of  relatively low temperatures and formulations with low or no 
residual solvent can be obtained [24,25]. Carbon dioxide is a usual choice for SCF-based 
micronization processes since it is inexpensive, non-toxic, non-flammable, environmentally 
benign and it has a relatively low critical pressure (7.39 MPa) and critical temperature 
(31.1°C). Depending on the role played by the supercritical carbon dioxide (sc-CO2) in 
relation to the solute, it can act as solvent, co-solute, antisolvent, dispersing agent, plasticizer 
or reaction medium.  
In the Supercritical Antisolvent (SAS) process, the solute is typically dissolved in an organic 
solvent and then sprayed into a high pressure vessel through which sc-CO2 is passed 
continuously. The instantaneous diffusion of sc-CO2 into the liquid solution and, in minor 
extent, the evaporation of the liquid to the supercritical phase leads to the supersaturation of 
the liquid solution and precipitation of the solute, which is collected on a filter. Solvent and 
antisolvent are then separated via simple depressurization in a separator located downstream 
the precipitation vessel [26]. Although studied for many years, the SAS process is still not 




involved in each step is required to allow the selection of the most appropriate operating 
conditions and enable process control. Extensive use of SAS at industrial scale to process 
pharmaceutical and food ingredients is believed likely in the future, especially due to the need 
of finding more environmentally friendly technologies, as recently discussed [27]. A key 
feature of SAS is its ability to process a wide variety of compounds to obtain several 
morphologies and sizes including crystals, nanoparticles, microparticles and expanded 
microparticles [28–30]. However, the use of SAS to produce coprecipitates has not always 
been successful. In some works, irregular and coalescing particles with wide particle size 
distribution [31] and low encapsulation efficiency [32] were obtained and the demonstration 
of an effective coprecipitation through the improvement of the drug dissolution properties is 
hardly reported [33].  
In our recent work, curcumin was simultaneously precipitated and coated on the surface of 
lactose particles by the integration of the SAS process with a fluidized bed under pressure 
(SAS-FB) to improve the flow properties of the formulation [25]. In this work, the aim is to 
improve also the dissolution properties of curcumin through its coprecipitation with PVP by 
SAS, which is a suitable technique to treat thermo- and light-sensitive compounds, since low 
temperatures can be used and the experiments are carried out away from light.  
Other SCF-assisted processes have been used to produce CURC/PVP coprecipitates. Adami et 
al. [34] obtained spherical and collapsed particles with mean size ranging from 220 - 380 nm 
by the supercritical assisted atomization (SAA), using ethanol as solvent. The issue here is the 
use of high temperature (80 °C) since curcumin degradation is known to be  intensified above 
60˚C [4,35]. The quantification of product recovery and possible degradation of curcumin 
were not presented by the authors. The atomized rapid injection solvent extraction (ARISE) 




PVP and cyclodextrins, with very few experiments being carried out with the binary 
CURC/PVP. As the intended application was pulmonary delivery, microparticles were 
produced and in some of the images presented it was possible to distinguish curcumin crystals 
in a porous structure, which indicate that the materials precipitated separately [36–38]. 
Although there are similarities between the SAS and ARISE processes in terms of the role of 
sc-CO2, differences between the mixing mechanism can lead to different results. The use of 
SAS process to produce CURC/PVP coprecipitates for pharmaceutical application has been 
reported once by Chhouk et al. [39]. They used a micro-swirl mixer, a patented device, to 
process curcumin and PVP from a 90-10 acetone-ethanol mixture. Highly coalescing 
nanoparticles (25 - 342 nm) were obtained while very relevant information such as total 
product recovery, curcumin recovery and drug dissolution kinetics was not presented. Only 
samples with low curcumin content (3-9%) were produced and no explanation was given for 
the selection of the solvent mixture used.  
Therefore, it is clear that a deeper study and understanding of the coprecipitation of curcumin 
and PVP by SAS is necessary, which is the aim of this work. It is also the intention of this 
work to test if it is possible to obtain non-coalescing nanoparticles of the composite material, 
with high curcumin content (up to 25%) and improved dissolution properties, without the aid 
of a complex mixing device, as reported in the aforementioned work [39]. For the first time, 
different organic solvent mixtures were studied to understand how adjusting the solvent 
properties (solvation power) can modulate particle size and recovery of CURC/PVP 
coprecipitates. The effects of operating parameters, pressure, temperature, initial solution 






Curcumin (CURC, purity ≥ 90%) was purchased from Cayman Chemical and poly (vinyl 
pyrrolidone) (PVP, Mw = 10 kg/mol), sodium dodecyl sulphate (SDS) and acetic acid (glacial 
class 8, purity ≥  99%) were purchased from Sigma Aldrich, UK and Ireland. Ethanol (EtOH, 
purity = 99.97%) and carbon dioxide (purity ≥ 99.8%) were purchased from VWR Chemicals 
and BOC, UK, respectively. Acetone (Ac, purity = 99.99%) and acetonitrile (purity = 
99.99%) were purchased from Fisher Chemical, UK. All materials were used as-received. 
4.4.2. SAS equipment 
Figure 4-1 shows the diagram of the SAS process. CO2 is delivered to the precipitator or high 
pressure vessel (HPV) by an air driven pump (PowerStar 4; Model: P464, Sprague). Before 
entering the pump, the CO2 line passes through a cold bath (Grant C1G) operated below 0°C 
to promote the condensation of CO2 and avoid pump cavitation. After the pump, the CO2 is 
heated in a hot water bath (Tecam open bath TECAM1 + Grant Type ZA Grant bridge control 
unit) to achieve the desired operating temperature and then it enters the precipitation vessel 
via a tube of 1/4 inch OD. The solvent/solution is delivered by an HPLC pump (Waters M-
6000). Detail of the precipitation vessel and injection device can be seen in the supplementary 
material. A stainless steel capillary with internal diameter of 100 µm, external diameter of 
1/32 in and 20 cm in length (Thames Restek UK), placed concentric with the CO2 delivery 
tube, is used as a nozzle to promote the atomization of the solvent/solution. The nozzle end, 
where the solution is sprayed out, is placed 2.4 mm lower than the end of CO2 inlet tube to 





The high pressure vessel (HPV) used as precipitator is a 500 ml cylindrical jacketed autoclave 
(Baskerville Scientific, UK) containing three saphire windows. Hot water is continuously 
supplied to the heating jacket to keep the HPV at the desired operating temperature by the 
same heat exchanger used to heat up the CO2 line. The precise reading of the temperature and 
pressure inside the vessel is enabled by a thermocouple (RS PRO Type K) and pressure 
transducer (GE Druck PTX 1400) displayed in a digital process indicator (GE Druck DPI 
282). The HPV is protected against overpressure by a safety valve (Swagelok SS-4R3A). 
Precipitated particles are collected by a cellulose thimble (43 mm x 123 mm, Whatman) 
installed inside the HPV, allowing the flow of CO2 + organic solvent mixture. The chamber 
pressure is controlled by a pressure regulator (Tescom 26-1752-24) located in the by-pass of 
the CO2 pump. A middle pressure vessel (MPV) of approximately 300 ml (Swagelok double-
ended sample cylinder, 316L-HDF4-300-PD) is connected to the precipitator through a 
micrommetric valve (MMV) (Hoke 1335G4Y), which enables the manual control of the CO2 
flow rate, which is displyed by a mass flow transmitter (Rheonik RHE08) placed in the CO2 
inlet to the HPV. The MPV pressure is controlled by a pressure reducing regulator (GO BP3-
1A11I5J114) at around 1 MPa. It is also protected against overpressure by a safety valve 
(Swagelok SS-4R3A). Due to the pressure drop, the MPV enables the separation of the 
phases: the organic solution is condensed and collected in bottom of the vessel, while gaseous 
CO2 flows out from the top. The CO2 then passes through the pressure reducing regulator, 
decreases its pressure to ambient, enters a cyclone to remove fine droplets of solution possibly 
entrained in the gas phase and is finally directed to vent. A third heat exchanger and pump 
(Tecam circulator C-400) supply hot water through a flexible pipe which surrounds the MMV 




966GP) are placed in the outlet of the CO2 cylinder, outlet of the CO2 pump, inlet of the 
precipitation vessel and inlet of the MPV. 
4.4.3. SAS experimental procedure 
Firstly, the precipitator is pressurized with CO2 until the desired pressure is achieved. At this 
point, the outlet micrometric valve (MMV) is opened to give a constant flow of sc-CO2 (40 
g/min for all experiments), whilst maintaining pressure (Figure 4-1).  
Solvent is then pumped into the precipitator through the 100 µm capillary nozzle for enough 
time to reach quasi-steady state composition of solvent and CO2, before the pump is switched 
to a solution of curcumin, PVP or curcumin and PVP. As the precipitation happens inside of 
the cellulose thimble and glass connector (dimensions shown in the supplementary material), 
rather than in the whole volume of the vessel, the mean residence time of the materials varies 
between 2 and 5 minutes, being close to 3 minutes at 40°C and 9.0 MPa (see Appendix III), 
which is the condition used in most experiments. Assuming the behaviour of an ideal stirred 
tank, at least three residence times of CO2 and solvent were allowed to flow before the drug 
solution was injected so the CO2/solvent ratio in the vessel was at least 95% of the inlet 
composition. 
After the desired amount of curcumin and/or PVP has been injected into the precipitator 
(usually 400 mg of solute in 40 ml of solution), the pump is reverted to solvent to purge the 
line (10 ml) and assure all the solution inside the dead volume has been delivered. Then the 
solvent pump is stopped and fresh CO2 runs through the system to remove any residual 
solvent. Finally, the pressure is gradually decreased to ambient, the thimble is removed from 
inside the high pressure vessel and then the powder is collected with a spatula. Some material 




powder can be collected. No powder is found outside the thimble or inside the vessel, 
however possible loss of nanoparticles might occur in the first minutes of particle generation 






































Figure 4-1. SAS experimental setup. 
4.4.4. Preparation of the physical mixture 
Physical mixtures (PM) of curcumin (CURC) and PVP, obtained by shaking the powders in 
sealed vials for 5 minutes, were prepared with mass ratios of 1:3 and 1:10 CURC/PVP for 





4.4.5.1. Scanning Electron Microscopy (SEM) and Particle Size Measurements 
Scanning Electron Microscopy (SEM - model Philips XL-30 FEG) was used to observe the 
morphology and particle size of raw materials and coprecipitates at 10 kV and 10 mA. 
Samples were initially fixed on a double-sided adhesive carbon tape and sputter coated 
(Polaron SC 7640) with gold for 3 min at 25 mA. Image J analysis software was used to 
measure particle size and size distribution. Usually 500 particles of each sample in SEM 
images with different magnifications were accounted. The results are presented as mean 
diameter ± arithmetic standard deviation. 
4.4.5.2. Total product recovery 
The total product recovery (Rec.) is an important parameter to assess the efficiency of a 
process. It was defined as the percentage ratio of the final mass of precipitates collected to the 
initial mass delivered to the precipitator, as shown below: 
𝑅𝑒𝑐. =  
𝑚𝑎𝑠𝑠 (𝐶𝑈𝑅𝐶 +  𝑃𝑉𝑃) 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑
𝑚𝑎𝑠𝑠 (𝐶𝑈𝑅𝐶 +  𝑃𝑉𝑃)𝑓𝑒𝑒𝑑
 × 100% 
4.4.5.3. Curcumin content and recovery 
Accurately weighed samples were dissolved in 50% v/v water-acetone solution and curcumin 
concentration was determined using an ultraviolet (UV)–visible spectrophotometer (Thermo 
Scientific Orion AquaMate) to measure the solution absorbance at λ = 425 nm. At this 
wavelength the absorbance of PVP is negligible (as reported in the supplementary material), 
while that of curcumin is proportional to its concentration (R
2
 = 0.999). All the measurements 
were taken within few minutes of sample dissolution so the effect of curcumin degradation in 




mean values are reported. Curcumin content (Cont.) was obtained by dividing the mass of 
curcumin in the analysed sample by the total sample mass, as follows: 
𝐶𝑜𝑛𝑡. =
𝐶𝑈𝑅𝐶 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝑡𝑜𝑡𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑚𝑎𝑠𝑠
× 100% 
Curcumin recovery (CURC Rec.) was calculated as shown below: 
𝐶𝑈𝑅𝐶 𝑅𝑒𝑐. =
𝑅𝑒𝑐.× 𝐶𝑜𝑛𝑡.
𝐶𝑈𝑅𝐶 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑓𝑒𝑒𝑑
 
The use of the cellulose thimble described here very conveniently facilitates the recovery of 
the powder without requiring the precipitator to be completely disassembled from the rig and 
cleaned after each run. The amount of curcumin retained in the pores of the cellulose thimble 
(filter) was quantified by washing each filter with a known volume of 50% v/v water-acetone 
and analysing the resulting solution by (UV)–visible spectrophotometer.  
4.4.5.4. High Performance Liquid Chromatography (HPLC) 
Raw curcumin and processed samples were analysed by HPLC to investigate possible 
degradation of curcumin after processing. A gradient elution was employed using an 
Accucore C18 column (30 mm x 2.1 mm, 2.6 µm, Thermo Scientific) starting with a mobile 
phase containing acetonitrile and 2% acetic acid initially at 10:90 (v/v). The proportion of the 
materials was gradually changed to 50:50 by 10 minutes with each run lasting 16 minutes in 
total.  A flow rate of 0.85 ml/min, a column temperature of 30°C, a detection wavelength of 
425 nm and an injection volume of 20 μl were employed [40]. Sample solutions were 
prepared in 50:50 acetonitrile-2% acetic acid and filtered with a 0.22 µm PTFE syringe filter 




4.4.5.5. X-ray diffraction (XRD) 
Raw materials and coprecipitates were analysed by X-ray diffraction (XRD, Bruker D8, UK) 
at 40 kV and 30 mA to determine the degree of crystallinity before and after processing. 
Patterns were obtained with a beam angle varying from 5° to 40° and a step size of 0.023°. 
4.4.5.6. Differential Scanning Calorimetry (DSC) 
The thermal behaviour of the samples and unprocessed compounds were assessed by 
Differential Scanning Calorimetry (Discovery DSC 25, TA Instruments) working with a 
nitrogen purge of 50 ml/min. A heat-cool-heat cycle  was employed to eliminate possible 
interference of moisture and relieve stress allowing a proper determination of the glass 
transition temperature (Tg) of the materials [41–43]. First, the samples were placed in 
aluminium pans and accurately weighed. A hole was made on each lid, allowing the removal 
of moisture with the purge gas. They were then heated from 50°C to 160°C (above the glass 
transition of PVP and below the melting point of curcumin) at 20°C/min and after that quench 
cooled (100°C/min) to the initial temperature. Finally, they were heated to 250°C at 
20°C/min. The results presented correspond to the final heating stage in which the glass 
transition temperature, melting point and enthalpy of fusion were measured. TA Instruments 
Universal Analysis Software was used to estimate the glass transition temperature (Tg, 
midpoint of the change in heat capacity) and melting point (Tm, onset temperature) of the 
samples. 
4.4.5.7. Fourier transform infrared spectroscopy (FTIR)  
Fourier transform infrared spectroscopy (FTIR, Jasco-6300) equipped with an attenuated total 




possible molecular interactions generated after processing. 64 scans were taken in a range of 
800-4000 cm
-1
 with a resolution of 4 cm
-1
 [44,45].  
4.4.5.8. Drug apparent solubility 
The apparent solubility of the materials was analysed by adding excess sample to 2 ml of 
distilled water and then sonicating the suspension at 25°C for 15 minutes. Then the 
suspension was filtered with a 0.22 µm PTFE syringe filter. Curcumin concentration was 
determined via UV–visible spectrophotometer. Experiments were performed in triplicates and 
the mean values are shown. 
4.4.5.9. In vitro dissolution studies 
In vitro dissolution studies were performed using a USP 2 dissolution apparatus (rotating 
paddles). Samples were accurately weighed with equivalent amount of curcumin (5 ppm) and 
incubated at 37 ± 0.5°C in 200 ml of water and 0.25% w/v sodium dodecyl sulphate (SDS). 
The rotation of the paddles was set to 100 rpm.  2 ml of the solution was withdrawn at 
different time intervals and replaced with the same volume of fresh medium. Curcumin 
concentration was then analysed by UV–visible spectrophotometer. Curcumin release was 
calculated as follows: 




where mt represents the mass of curcumin released at time t and m100% is the mass of 





4.5. Results and discussion 
In the SAS process, the selection of the operational conditions is crucial in the success of the 
precipitation [46,47]. Knowledge of thermodynamics, jet hydrodynamics, mass transfer and 
crystallization kinetics is required to properly understand the results. Supersaturation is the 
driving force for precipitation and can be defined as the ratio between the solute concentration 
in the solvent-CO2 system and the equilibrium concentration (solubility). Particle size is 
dependent on the degree of solution supersaturation achieved. High initial solution 
concentration and low equilibrium concentration of the solute in the fluid phase leads to high 
supersaturation. Additionally, the supersaturation can be affected by the flow rate of the 
materials used, responsible for the turbulence and mixing between the phases. The yield of 
precipitation is especially influenced by the concentration of solute present in the effluent 
solution [48–50]. 
For most experiments, pressure, temperature and CO2 flow rate were kept constant at 40°C, 
9.0 MPa and 40 g/min, giving a CO2 molar fraction (XCO2) between 0.98 - 0.99. According to 
the literature [51], these conditions would ensure that the precipitation happens in the 
supercritical region of the mixed solvent-CO2. 
4.5.1. Precipitation of single compounds 
Prior to coprecipitation experiments, the compounds were processed separately to compare 
with their precipitation behaviour (morphology and size) when processed at the same 
conditions of the coprecipitates. This information is useful to evaluate the success of the 
coprecipitation and any possible changes in morphology that can occur when the two 




PVP is a biocompatible polymer commonly used in drug delivery applications and has been 
previously precipitated by SAS [24,52,53]. In this work, the experiments were carried out 
initially using ethanol as solvent, solution concentration of 10 mg/ml and solution flow rate of 
1 ml/min, resulting in a CO2 molar ratio of XCO2 = 0.98.  
Table 4-1 summarises the operational conditions and the results obtained. In run #1 a 
negligible amount of powder was recovered. Since PVP is highly soluble in ethanol [24], the 
concentration used might have not been high enough to achieve the minimum supersaturation 
required for particle generation. In an attempt to increase the supersaturation, in run #2, the 
solution concentration was increased to 20 mg/ml and the other parameters were kept 
constant; however this concentration was still not enough and the precipitation was again 
unsuccessful.  
Another way to affect the supersaturation, while keeping the initial solution concentration 
constant, is by changing the solubility (equilibrium concentration) of the solute in the fluid 
phase. As the solubility of PVP in ethanol is much higher than in acetone (315 mg/ml versus 7 
mg/ml), solvent mixtures of acetone-ethanol (Ac-EtOH) were used. As a consequence of the 
addition of a poor solvent to PVP (acetone), higher supersaturation levels can be achieved and 
a higher proportion of the solute precipitates, increasing product recovery. In fact, the addition 
of acetone into ethanol to produce a 50% v/v mixture allowed a successful precipitation in run 
#3 and the increase in acetone content to 90% v/v further improved PVP recovery in run #4 
from 2.0 to 87.0% (Table 4-1). These results demonstrate the significant impact of changing 
the solute solubility in the fluid phase by the manipulation of the solvent power of the organic 
solution. Pure acetone was not used to process PVP since PVP solubility in acetone is below 




The precipitation of PVP from acetone-ethanol mixtures has been previously investigated. 
However, contrary to what has been demonstrated here, De Marco et al. [24] reported a 
process yield of around 90% for experiments with several acetone-ethanol mixture 
compositions, while Rossmann et al. [52] did not discuss product recovery. Figure 4-2a,b 
shows the comparison between raw and processed PVP obtained from run #4. It is clear that 
there is a decrease in particle size and a narrowing of the particle size distribution after SAS 
processing.  
Curcumin was then processed at the same conditions used for PVP. The solubility of 
curcumin in acetone was estimated to be around 58 mg/ml, while in ethanol it was below 5 
mg/ml. In the experiment with pure ethanol (run #5), a concentration of 2 mg/ml was used; 
however no powder could be recovered. When curcumin was processed by a 50-50 Ac-EtOH 
solution (run #6) and by pure acetone (run #7) at 10 mg/ml, product recovery was 23.4% and 
34.8%.  Despite the higher initial saturation of the ethanol solution in comparison to the 
acetone solution, when CO2 is present in the system a co-solvent effect seems to be taking 
place with ethanol, as already observed for other systems [54,55]. This explains the lower 
product recovery when ethanol was used.  The lower recovery of curcumin produced by 
similar processes from alcoholic solutions compared to acetone have also been observed 
elsewhere [56]. The authors explained that the higher volume expansion and consequently 
more efficient reduction in solvent power are achieved in the case of acetone possibly leading 
to higher recovery. In runs #5, #6 and #7, the amount of curcumin retained in the filter 
decreased from 56.4% to 48.2% and 33.0%, respectively (Table 4-1). Figure 4-2c shows rod-
like crystals of raw curcumin with a wide size distribution, while curcumin processed by a 
50% Ac-EtOH (Figure 4-2d, run #6) and by pure acetone (Figure 4-2e, run #7) has an 




PVP and curcumin precipitate in completely different morphologies when processed at the 
same conditions. This underlines the complexity of the SAS process and its compound-
dependent characteristic. 
 
Figure 4-2. SEM images of: a) raw PVP; b) PVP processed by SAS (run #4); c) raw curcumin; d) 
curcumin processed by SAS from 50% Ac-EtOH (run #6); e) curcumin processed by SAS from 




Table 4-1. Experimental conditions and results (p = pressure; f = solution flow rate; CTOT = total solute concentration; m.d.: mean diameter; s.d.: standard 

































1 9.0 40 1 10 EtOH 0-100 pure PVP ≈ 0 - - - - - 
2 9.0 40 1 20 EtOH 0-100 pure PVP ≈ 0 - - - - - 
3 9.0 40 1 10 Ac-EtOH 50-50 pure PVP 2.0 - - - - - 
4 9.0 40 1 10 Ac-EtOH 90-10 pure PVP 87.0 - - 123 27 SMP 
5 9.0 40 1 2 EtOH 0-100 pure curcumin ≈ 0 ≈ 0 56.4 - - - 
6 9.0 40 1 10 Ac-EtOH 50-50 pure curcumin 23.4 23.4 48.2 - - - 
7 9.0 40 1 10 Acetone 100-0 pure curcumin 34.8 34.8 33.0 - - irregular 
8 9.0 40 1 10 EtOH 0-100 1:3 43.1 45.5 41.4 - - irregular 
9 12.0 40 1 10 EtOH 0-100 1:3 63.1 68.1 25.5 - - irregular 
10 9.0 40 1 10 Ac-EtOH 10-90 1:3 58.0 65.3 29.3 327 102 SMP 
11 9.0 40 1 10 Ac-EtOH 30-70 1:3 74.3 76.6 10.2 177 57 SMP 
12 9.0 40 1 10 Ac-EtOH 50-50 1:3 77.6 78.6 6.7 135 36 SMP 




































14 9.0 40 1 10 Ac-EtOH 90-10 1:3 90.0 89.2 0.8 51 12 NP 
15 8.0 40 1 10 Ac-EtOH 70-30 1:3 56.4 59.6 20.8 181 48 SMP 
16 12.0 40 1 10 Ac-EtOH 70-30 1:3 79.1 88.1 6.7 67 17 NP 
17 9.0 35 1 10 Ac-EtOH 70-30 1:3 89.5 94.9 5.0 72 20 NP 
18 9.0 50 1 10 Ac-EtOH 70-30 1:3 76.9 83.7 9.9 176 56 SMP 
19 9.0 40 1 5 Ac-EtOH 70-30 1:3 80.7 88.9 5.6 65 14 NP 
20 9.0 40 1 20 Ac-EtOH 70-30 1:3 80.2 90.5 6.2 117 30 SMP 
21 9.0 40 1 10 Ac-EtOH 50-50 1:10 60.7 60.2 26.3 - - CM 
22 9.0 40 1 10 Ac-EtOH 70-30 1:10 79.7 79.9 5.5 173 76 SMP 
23 9.0 40 1 10 Ac-EtOH 70-30 1:20 69.2 67.9 9.6 205 49 SMP 
24 9.0 40 0.5 10 EtOH 0-100 1:10 34.3 36.1 48.7 - - CM 
25 9.0 40 0.5 10 Ac-EtOH 10-90 1:10 47.6 50.8 24.9 - - CM 




4.5.2. Coprecipitation of CURC/PVP 
It has been demonstrated elsewhere that PVP can interfere in the crystallisation kinetics of 
some compounds by inhibiting the association of drug molecules to form crystal nuclei during 
the solvent removal from a drug-PVP solution [10,12,57,58]. 
In the second phase of this work, the SAS process was used to produce coprecipitates of 
curcumin and PVP and the effect of adjusting the solvation power of the organic solvent, 
pressure, temperature, initial solution concentration, mass ratio between drug and polymer 
and solution flow rate were explored. Five experiments were run in triplicates and the relative 
standard deviation of total product recovery and curcumin recovery was typically below 5%, 
showing that the conditions were well controlled. The results shown correspond to the mean 
values. 
4.5.2.1. Effect of solvent mixture composition 
Knowing that the relative composition of acetone in the solvent mixture affects the recovery 
of PVP particles, mixtures of acetone-ethanol with increasing acetone volume fraction from 0 
to 90% were used for the coprecipitation experiments (#8-14). Tests were carried out at the 
same conditions used for the precipitation of the single compounds (40°C, 9.0 MPa, XCO2 = 
0.98 and 10 mg/ml overall solution concentration) with drug/polymer mass ratio of 1:3. 100% 
acetone was not used because a clear solution containing both compounds could not be 
obtained at the specified concentration. The effect of adjusting the solution supersaturation 
through the manipulation of the solvent power, while keeping the overall solution 
concentration constant, is demonstrated in this section. Similarities in the vapour-liquid 





The first interesting result can be seen by comparing run #1 (PVP alone), run #5 (curcumin 
alone) and run #8 (coprecipitation) performed at the same conditions with ethanol as solvent. 
For the single compounds no powder was obtained, while in the coprecipitation the total 
product recovery was 43.1%. Similarly, in run #3 (PVP alone) and run #6 (curcumin alone) 
product recovery was 2% and 23.4%, respectively, increasing to 77.6% in run #12 when the 
materials were coprecipitated from a 50-50 Ac-EtOH solution (Table 4-1). These results 
suggest a synergistic effect in improving the supersaturation of the solution when both 
compounds are present and how the presence of two different solutes can affect the high 
pressure equilibrium of the system solvent/antisolvent, leading to different results at the same 
process conditions. Figure 4-3a reveals that two different morphologies, crystals (curcumin) 
and irregular particles (PVP), were obtained when pure ethanol was used (run #8), indicating 
that coprecipitation was unsuccessful since the compounds precipitated separately. Particle 
size could not be measured. It was considered that this behaviour may be indicative of 
precipitation outside of the supercritical region caused by the solutes elevating the critical 
pressure of the mixture. To test this, an experiment was performed at 12.0 MPa (run #9), far 
beyond the critical point of the system CO2-ethanol (8.16 MPa [51]), to ensure supercritical 
conditions. Curcumin crystals could still be seen, as shown in Figure 4-3b, suggesting that 
the separate precipitation is related to something other than effects on the CO2-ethanol 
vapour-liquid equilibrium. As the solubility in ethanol of curcumin and PVP is approximately 
5 mg/ml and 315 mg/ml, respectively, the difference in the supersaturation ratio (initial 
concentration/solubility) of the two compounds might be so high that simultaneous 
precipitation would not be achieved. On the other hand, higher pressure increased product 
recovery from 43.1% (run #8) to 63.1% (run #9), suggesting a decrease in the solute solubility 




In run #10, the addition of 10% acetone resulted in a successful coprecipitation, as shown in 
Figure 4-3c. Spherical, largely uniform particles were produced and curcumin rod/filament 
morphology could no longer be detected indicating that curcumin is well dispersed in the 
polymer matrix. A possible reason for this behaviour may be  that addition of acetone to 
ethanol simultaneously decreases the solubility of PVP and increases the solubility of 
curcumin (as it does at room temperature), leading to more similar supersaturation ratios of 
the two solutes when mixed with CO2. The composite material retained the morphology of the 
polymer as previously observed in several studies with PVP-drug [33], demonstrating that the 
precipitation behaviour is now dominated by PVP. In Figure 4-4a it is interesting to observe 
the gradual increase in the total product recovery (from 43.1 to 90.0%) and decrease in the 
mean particle size of coprecipitates (from 327 to 51 nm) by increasing the acetone content 
from 0 to 90%. SEM images shown in Figure 4-3c,d,e,f,g clearly demonstrates this tendency. 
The size range changed from sub-microparticles to nanoparticles and the particle size 
distribution narrowed (Figure 4-4b). De Marco et al. [24] explained that the variation of the 
solvent mixture composition can affect the SAS process in two different ways: by changing 
the solvation power of the solvent (ability of the solvent to dissolve the solute at fixed 
conditions) and/or the mixing behaviour of the injected solution with CO2 (large or sharp 
pressure transition range from two-phase to one-phase mixing). In terms of mixing regimes, 
ethanol and acetone have been shown to have similar behaviour (sharp transition pressure 
range) [24], therefore the decrease in the mean particle size can be explained by the decrease 
in the solvation power as acetone is added to the solvent mixture. Other authors have 
suggested that acetone repels the polymer molecules which then tend to be arranged in a more 
compact configuration, consequently decreasing particle size [24,53]. The amount of 




increased from 0 to 90% (Table 4-1). Probably, when more acetone is present in the system, 
higher supersaturation can be achieved and the material precipitates in the first centimetres of 
the precipitator. The concentration of the fluid phase decreases and less curcumin is left to 
nucleate within the thimble walls when passing through it. A decrease in the degree of particle 
coalescence was also observed with the addition of acetone, explained by the fact that acetone 
experiences a higher volume expansion than alcohols when in contact with sc-CO2 [59,60], 
being more efficiently removed from the precipitating particles. 
Figure 4-5a shows the comparison between curcumin content in the processed samples and in 
the feed solutions. For all experiments, the contents before and after processing are similar; 
therefore the values of curcumin recovery are close to the respective values of the total 
product recovery, gradually increasing from 45.5 (run #8) to 89.2% (run #14) with increasing 
acetone content. This demonstrates that the conditions selected are appropriate to precipitate 
both compounds in the designed proportion since their proportion was kept almost the same in 
the feed solution and in the coprecipitated powder. It is also interesting to observe in Figure 
4-5b that no degradation of curcumin occurred after SAS processing. Curcumin retention time 
(highest peak) was around 7.6 minutes with impurities being detected slightly before (small 
peak). By comparing the area of the peaks, curcumin concentration was determined to be 
around 90% in all samples (raw curcumin, #6 and #13). As it is not the aim of this work, the 
nature of the impurities was not determined, however curcumin is known to be found with 
other two curcuminoids (demethoxycurcumin, and bis-demethoxycurcumin) in turmeric 





Figure 4-3. SEM images of CURC/PVP processed from pure ethanol at 40°C, 1.0 ml/min, 1:3 
CURC/PVP ratio and different pressures: a) 9.0 MPa (run #8); b) 12.0 MPa (run #9); and samples 
processed at 9.0 MPa, 40°C, 1.0 ml/min, 1:3 CURC/PVP ratio from different Ac-EtOH compositions: 





Figure 4-4. Results for coprecipitates obtained from solutions with different acetone (Ac) contents at 
9.0 MPa and 40°C (run #8, #10-14, Table 4-1): a) mean diameter and total product recovery (error 
bars show standard deviation); b) particle size distribution. 
The effect of solvent can also be analysed in runs #21-22 (Figure 4-6a,b) performed at 1:10 
CURC/PVP ratio and runs #24-26 (Figure 4-6d,e,f) performed at 1:10 CURC/PVP ratio and 
0.5 ml/min. Similar trends as runs #10-14 were observed in terms of total product recovery, 
curcumin recovery (Table 4-1) and particle size (Figure 4-6), supporting the discussion 
previously presented. As curcumin recovery did not increase for acetone content higher than 
70% (Table 4-1), a 70-30 Ac-EtOH solution was selected in order to analyse the effect of 
other operational parameters on particle size and recovery. Moreover, 30% of ethanol gives 
flexibility to work with large amounts of PVP. Therefore, the next experiments will be 






Figure 4-5. a) Curcumin content as fraction of the total solute in the feed solutions and SAS-processed 
samples analysed by UV-visible spectrophotometer; b) HPLC measurements of raw curcumin and 





Figure 4-6. SEM images of CURC/PVP processed at 40°C, 9.0 MPa, 1.0 ml/min from different Ac-
EtOH compositions and CURC/PVP ratios: a) 50-50, 1:10 (run #21); b) 70-30, 1:10  (run #22); c) 70-
30, 1:20  (run #23); and processed at 0.5 ml/min: d) pure EtOH, 1:10 (run #24); e) 10-90, 1:10 (run 
#25) f) 70-30, 1:10 (run #26).   
4.5.2.2. Effect of pressure 
The effect of pressure was analysed by keeping the operational conditions the same as in run 
#13 (40°C, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 10 mg/ml overall solution 
concentration in a 70-30 Ac-EtOH solution) and changing the pressure from 9.0 MPa to 8.0 




As the critical pressures of the CO2-ethanol and CO2-acetone systems are approximately 8 
MPa at 40°C, the operational point in run #15 might be located in the biphasic region. The 
density of CO2 under these conditions (277.9 kg/m
3 
[64]) is around 43% lower than at 9.0 
MPa (485.5 kg/m
3 
[64]). This lowers the power of CO2 to solubilise the organic solvents and 
leads to a less effective supersaturation, which might explain the large increase in particle size 
from 96 nm (#13) to 181 nm (run #15, Figure 4-7a) and decrease in curcumin recovery from 
89.0 (#13) to 59.6% (#15). A high proportion (around 21%) of the curcumin injected was 
retained in the cellulose thimble probably due to the presence of liquid in the precipitator 
(operating point in the biphasic region). When the pressure was increased to 12.0 MPa (#16, 
Figure 4-7b), the CO2 density increased by 48% and the opposite effect was observed for 
particle size which decreased to 67 nm. While product recovery (curcumin + PVP, 79.1%) 
was lower than at 9.0 MPa, curcumin recovery was not much affected, indicating that at 
higher pressure the precipitation of PVP is less favourable.  
Figure 4-8 illustrates how the mean particle diameter of coprecipitates and curcumin recovery 
varies from the central experiment (#13) as a function of the variation in the CO2 density with 





Figure 4-7. SEM images of CURC/PVP processed at different conditions: a) run #15 (8.0 MPa); b) 
run #16 (12.0 MPa); c) run #17 (35°C); d) run #18 (50°C); e) run #19 (5 mg/ml); f) run #20 (20 







Figure 4-8. Values of a) mean particle diameter and b) curcumin recovery as a function of the 
variation of different operational parameters in comparison with run #13 (centre point). The standard 
deviation of curcumin recovery is below 5% and that of the mean diameter is shown in Table 4-1.  
4.5.2.3. Effect of temperature 
The effect of temperature was analysed by keeping the operational conditions the same as in 
run #13, (9.0 MPa, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 10 mg/ml overall 
solution concentration in a 70-30 Ac-EtOH solution) which was performed at 40°C, and 
changing the temperature to 35°C (#17) and 50°C (#18).  
Figure 4-7c,d shows the particles obtained at 35°C (#17) and 50°C (#18) measuring 72 and 
176 nm, respectively. At 35°C the density of CO2 is 662.1 kg/m
3
 (36% higher than 485.5 
kg/m
3 
at 40°C[64]) while at 50°C it is equal to 285.0 kg/m
3 
(41% lower than at 40°C). It is 
interesting to observe in Figure 4-8a that similar CO2 density variations from the central 
experiment (run #13) caused by temperature and pressure lead to the production of 
coprecipitates with similar particle sizes. Experiments performed at high CO2 density (low 
temperature or high pressure) yielded smaller particles due to the improved solvation power 




pressure). These results demonstrate the relevance of the fluid density in designing SAS 
experiments but it is also important to be aware that other parameters such as fluid viscosity 
and solute vapour pressure might play a role in determining particle size as the temperature is 
changed.   
Although similar particle sizes were obtained in runs #15 and #18 (low density) and runs #16 
and #17 (high density), both changes in pressure had a negative effect on curcumin recovery 
(Figure 4-8b). In contrast, at 35°C almost all curcumin was recovered, possibly because the 
vapour pressure and solubility of curcumin in the fluid phase decreased.  
4.5.2.4. Effect of solution concentration 
The effect of concentration was analysed by keeping the operational conditions the same as in 
run #13 (9.0 MPa, 40°C, 1 ml/min, XCO2 = 0.98, 1:3 CURC/PVP ratio and 70-30 Ac-EtOH 
solution) and changing the overall concentration from 10 mg/ml (run #13) to 5 mg/ml (run 
#19) and 20 mg/ml (run #20). The same amount of material was delivered to the precipitator 
but the solution volume was adjusted (doubled or halved) to obtain the desired concentration.  
A low impact on precipitation was observed. In fact, curcumin recovery changed less than 2% 
as the concentration was increased or decreased (Figure 4-8b). Particle size decreased to 65 
nm at lower concentration (Figure 4-7e) and increased to 117 nm at higher concentration 
(Figure 4-7f), also demonstrating a small influence of concentration (Figure 4-8a). Although 
higher supersaturation occurs in more concentrated solutions, particle growth by condensation 
is also intensified [50], explaining the results obtained here. 
4.5.2.5. Effect of drug/polymer mass ratio 
The effect of CURC/PVP mass ratio was studied by decreasing the ratio from 1:3 (run #13) to 




#13 (9.0 MPa, 40°C, 1 ml/min, XCO2 = 0.98, 10 mg/ml overall solution concentration in a 70-
30 Ac-EtOH solution). In order to keep the overall concentration constant, the decrease in 
CURC/PVP ratio was achieved by simultaneously decreasing the concentration of curcumin 
and increasing the concentration of PVP. 
The morphologies of the particles produced at 1:3, 1:10 and 1:20 CURC/PVP ratios are 
shown in Figure 4-3f and Figure 4-6b,c, respectively. The results in Table 4-1 demonstrate a 
gradual decrease in total product recovery from 87.1% to 79.7% and 69.2% as CURC/PVP 
ratio decreased. Similarly, curcumin recovery decreased (Figure 4-8b) since the curcumin 
content in the processed sample and feed solution were almost unchanged (Figure 4-5a) (the 
ratio between the drug and polymer remained the same in the precipitated powder). On the 
other hand, particle size increased from 96 nm to 173 nm and further to 205 nm in these 
experiments (Figure 4-8a). This behaviour has been reported before for the coprecipitation of 
PVP with other APIs [8,9]. Although the overall concentration was kept constant, the increase 
in the concentration of the polymer (from 7.5 mg/ml at 1:3 ratio to 9.5 mg/ml at 1:20 ratio) 
might have increased the viscosity of the solution, which decreases the nucleation rate and 
lead to the formation of larger and more coalescing particles [48,65,66]. It is also important to 
highlight that an increase in the concentration of PVP can additionally affect the particle-fluid 
interfacial tension. This parameter might significantly influence particle size, as demonstrated 
by Erriguible et al. [67]. 
Runs #12 (Figure 4-3e) and #21 (Figure 4-6a) performed with 50% Ac-EtOH solution can 
also be used to analyse the effect of decreasing the drug/polymer ratio from 1:3 to 1:10. Once 
again, the same trend was observed: a decrease in total product recovery and curcumin 
recovery and increase in particle size. It was also noticed that at higher PVP concentration 




coprecipitates with 1:3 CURC/PVP ratio, particles become discrete with 30% acetone (Figure 
4-3d). However, highly coalescing material is still obtained at 1:10 ratio (Figure 4-6a) when 
the acetone content was 50% (run #21), which prevented the measurement of the particle size. 
The reason for this behaviour might be that by increasing PVP concentration in the solution, 
the viscosity of the liquid phase increases, decreasing the supersaturation and nucleation rate 
and leading to a less efficient mixing and solvent removal from the particles, as previously 
explained. Therefore, the addition of acetone, which is less viscous and poorer solvent to PVP 
than ethanol, favours the formation of discrete particles. 
4.5.2.6. Effect of solution flow rate 
The effect of solution flow rate was analysed by keeping the operational conditions 
unchanged (40°C, 9.0 MPa and 10 mg/ml overall solute concentration) and decreasing the 
solution flow rate to 0.5 ml/min (XCO2 = 0.99) for a 70-30 Ac-EtOH solution and 1:10 
CURC/PVP ratio. This CURC/PVP ratio was selected because the effect of particle 
coalescence was more pronounce at 1:10 than at 1:3 and therefore we wanted to investigate 
the possibility of producing discrete particles with higher PVP content. Run #26 (0.5 ml/min) 
can be compared to run #22 (1.0 ml/min) as all other operating conditions were not changed. 
The SEM image presented in Figure 4-6f (run #26) shows the formation of discrete sub-
microparticles compared to the less discrete particles of run #22 (Figure 4-6b).  
Solution flow rate is supposed to have a minor impact on particle size [50,67,68] since it may 
cause two opposite effects in relation to the supersaturation. For instance, a decrease in the 
solution flow rate can lead to a less efficient mixing (which decreases the local 
supersaturation) and it can also decrease the solvent composition in the fluid phase which 
decreases the solute solubility and hence increases the maximum attainable supersaturation. 




liquid phase equilibrium (pressure and temperature) [50]. As particle size, morphology and 
product recovery are affected in different extent by these phenomena, it was observed a small 
increase in particle size from 173 nm (run #22) to 220 nm (run #26), while product recovery 
was not significantly affected, with values close to 80% (Table 4-1). Particle coalesce was 
reduced at lower flow rates possibly due to the fact that there is more time for the 
precipitating particles to dry before they collide with each other, as explained by Gokhale et 
al. [53]. Similar effects of the solution flow rate on particle size have been reported elsewhere 
for the precipitation of PVP alone by SAS [53].  
4.5.3. X-Ray Diffraction (XRD) 
The degree of crystallinity of the samples was analysed by XRD. Figure 4-9 shows that 
curcumin alone processed by SAS (SAS-CURC, run #7) is less crystalline than raw curcumin 
(CURC) as the intensity of the peaks decreased. The physical mixture (PM 1:3) kept all the 
curcumin characteristic peaks but with lower heights than raw CURC due to the presence of 
PVP, which is an amorphous polymer. The comparison of the PM (1:3) with the 
coprecipitates shows that amorphous formulations were formed in all coprecipitates (runs 
#11, #13, #14).  
4.5.4. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was used to access the degree of crystallinity of the 
samples and possible interactions between curcumin and PVP after processing. Figure 4-10 
shows a sharp endothermic peak corresponding to the melting point of raw curcumin at Tm = 
182°C and enthalpy of fusion of ∆Hf = 130.9 J/g, indicating the crystallinity of the compound. 
Other works have reported similar values for the melting point of unprocessed curcumin but 




differences in the purity of the sample, not always specified, and differences in the crystal 
form. PVP, on the other hand, does not show any melting point peak, demonstrating its 
amorphous structure and glass transition at Tg = 150°C (midpoint of the change in heat 
capacity). In the physical mixture (PM 1:3) the curcumin characteristic peak was slightly 
shifted to lower temperature. This behaviour has been observed by other researchers and may 
be attributable to a solvent effect of PVP [14,16]. For the SAS coprecipitate obtained in run 
#13, no endothermic peak could be detected in the region of curcumin melting point which 
indicates that amorphous curcumin was obtained after SAS processing with PVP, confirming 
the XRD results (section 4.5.3). The presence of a single Tg supports the hypothesis of a 
single phase and the decrease in Tg compared to the one of PVP is attributed to the 
plasticizing effect of the drug molecularly dispersed in the polymeric matrix [13,71]. 
4.5.5. Fourier Transform Infrared Spectroscopy (FTIR) 
The infrared spectra of the compounds before and after processing were analysed in order to 
identify possible interactions between curcumin and PVP. Figure 4-11 shows the results 
obtained. Raw curcumin (CURC) presents an absorption band at 3504 cm
-1
 corresponding to 
O-H stretching vibration. Other peaks can be identified at 1626 cm
-1
 (C=O, C=C), 1601 cm
-1
 
(C=C aromatic), 1427 cm
-1
 (C-O phenol), 1025 cm
-1
 (C-O-C), 960 cm
-1
 (benzoate trans-CH) 
and 855 cm
-1
  (C-H aromatic) [39,72]. The FTIR spectrum of PVP shows a peak at 3466 cm
-1
 
assigned to the stretching vibration of O-H and other peaks at 2883, 1651 and 1284 cm
-1
, 






Figure 4-9. XRD patterns of raw curcumin, raw PVP, 1:3 CURC-PVP physical mixture (PM), 
curcumin processed by SAS (#7) and CURC/PVP coprecipitates (#11, #13 and #14). Experiment 






Figure 4-10. DSC thermograms of raw curcumin, raw PVP, 1:3 CURC-PVP physical mixture (PM) 
and CURC/PVP coprecipitate (#13). Experiment conditions are shown in Table 4-1. 
The spectrum of the physical mixture (PM 1:3) is similar to the addition of the individual 
spectra of curcumin and PVP, which indicates that no interaction between them has occurred. 
On the other hand, for the samples of CURC/PVP processed by SAS (#10, #13, #22, #23), the 
O-H characteristic peak (3504 cm
-1
) from curcumin has disappeared. This can be ascribed to 
an intermolecular interaction, such as hydrogen bonding, between the O-H of curcumin and 
the C=O of PVP [16]. This behaviour is compatible with the observations of other researchers 
[16,39,73,74] and might explain the change in the structure of curcumin from crystalline to 
amorphous (sections 4.5.3 and 4.5.4) and the improvement in the aqueous apparent solubility 






Figure 4-11. IR spectra of raw curcumin, raw PVP, 1:3 CURC-PVP physical mixture (PM) and 
CURC/PVP coprecipitates (#10, #13, #22 and #23). Experiment conditions are shown in Table 4-1. 
4.5.6. Drug apparent solubility 
The apparent solubility of raw curcumin (CURC), SAS-processed curcumin (SAS-CURC, 
#7), CURC/PVP physical mixtures (PM) and SAS coprecipitates was determined in water at 
25°C. Unprocessed curcumin has not shown any absorbance at these conditions, while other 
authors have measured 0.006 µg/ml after dissolution for 12h in water [39] and 0.5 µg/ml after 
dissolved in saline solution and centrifuged at 12,000 rpm for 10 min (25 °C) [36]. The 
different conditions and method used explain the different results obtained. The low water 
solubility of curcumin is one of the main causes of its low bioavailability [3].  
The apparent solubility of curcumin processed by SAS alone was equal to 0.06 µg/ml, which 




the physical mixtures: 0.3 µg/ml was measured in the mixture at 1:3 CURC/PVP, while 4.4 
µg/ml was obtained at 1:10 ratio. This might be explained by a possible decrease in the 
surface tension of water in the presence of PVP, which enhances the wetting of the curcumin 
crystal surface [11,65].  
CURC/PVP coprecipitates were produced in an attempt to further increase curcumin apparent 
solubility. The apparent solubility of raw CURC, physical mixtures and curcumin 
formulations are presented in Figure 4-12a. In runs #11 and #13 the apparent solubility 
increased around 100 times compared with the physical mixture (1:3), while in run #14 an 
increase of more than 600 times was obtained.  By decreasing CURC/PVP ratio, this effect 
was even more remarkable (Figure 4-12a). In runs #22 and #26 the measured values were 
369 µg/ml and 474 µg/ml, respectively. Other authors have also reported an improvement in 
drug apparent solubility as PVP content increases [74]. This was attributed to the formation of 
a water-soluble complex between drug and PVP, which was confirmed by FTIR test (section 
4.5.5). Chhouk et al. [39] reported a curcumin apparent solubility of 2.34 µg/ml in a 
formulation with PVP while Kurniawansyah et al. [37]  obtained the highest value equal to 
77.6 µg/ml for a ternary system containing curcumin, PVP and methyl-β-cyclodextrin in a 
ratio of 1:4:4 at pH 4.5.  
4.5.7. In vitro dissolution studies 
The dissolution profile of coprecipitates (#13, #23, #26), raw curcumin (CURC), physical 
mixture (PM 1:3) and curcumin processed by SAS alone (SAS-CURC, #7) was investigated 
in water + 0.25% w/v SDS. The surfactant SDS was added to allow for a shorter dissolution 
study and minimise the impact of curcumin degradation in the results. Moreover, when no 
SDS was used, there was no discrimination among the release profiles of the raw CURC, PM 




detection limit of the UV-visible spectrophotometer used (results not shown; see Appendix 
IV).  
 
Figure 4-12. a) Apparent solubility and b) dissolution profile of raw curcumin (CURC), physical 
mixtures (PM) and processed samples. Experiment conditions are shown in Table 4-1. 
Figure 4-12b shows the dissolution profiles for the various samples in water + 0.25% w/v 
SDS. PM (1:3) releases faster than raw CURC, which is due to the improvement in curcumin 
wetting and solubility in the presence of PVP, as discussed in section 4.5.6. The release of 
SAS-CURC (#7) is faster than the physical mixture (1:3), despite having lower apparent 
solubility in water (section 4.5.6), as a result of the smaller size of the curcumin crystals 
(Figure 4-2c,d). All the coprecipitates analysed dissolved significantly faster than raw CURC 
and PM (1:3), with complete release being obtained in the first 10 minutes. In the same period 
of time, raw CURC, PM (1:3) and SAS-CURC (#7) released only 3.2%, 7.5% and 12.8% of 
curcumin, respectively. These results, in conjunction with the observations of particle 
morphology, thermal behaviour and measurements of curcumin recovery, demonstrate that 
coprecipitates with high curcumin content and improved dissolution properties were 




attributed to the formation of smaller particles with increased apparent solubility (section 
4.5.6) and reduced crystallinity compared to raw CURC (section 4.5.3).  
Two mechanisms are suggested to for the precipitation of composite materials: homogeneous 
nucleation, which produces a solid mixture in which each particle if formed by only one 
component; and heterogeneous nucleation, which generates particles composed of both 
materials (coprecipitates) [33]. By the results presented in this work, it is believed that 
heterogeneous nucleation happened, leading to the formation of composite particles. In any 
case, the aim of the work was successfully achieved, as the dissolution properties of curcumin 
were significantly improved. 
4.6. Conclusions 
In this work, the coprecipitation of curcumin and PVP by SAS was successfully achieved 
from different solvent mixtures of acetone and ethanol. The results showed that the 
composition of the solvent mixture plays a major role in determining particle size, particle 
size distribution and curcumin recovery. Particle size varied from sub-microparticles (327 – 
135 nm) to nanoparticles (96 - 51 nm) and the curcumin recovery increased from 45.5 to 
89.2% as the relative composition of acetone in the ethanol-acetone mixture was increased. 
The highest curcumin recovery (95%) was obtained at low temperature (35°C) for a 70-30 
Ac-EtOH solution. It was also observed an improvement in curcumin apparent solubility of 
around 600 times compared with the physical mixture and, consequently, a much faster 
release. These results are explained by the solid state analyses which have demonstrated the 
formation of amorphous curcumin-PVP coprecipitates. 
4.7. Supplementary material 


























Figure 4-13. Detail of the precipitation vessel (distances in millimetres). 
UV spectra of curcumin and PVP 
 





























Phase diagram and mixture critical points of the systems CO2-ethanol and CO2-acetone 
 
Figure 4-15. Vapour-liquid equilibrium of CO2-ethanol and CO2-acetone at 35°C, 40°C and 50°C. 
Table 4-2. Mixture critical points of CO2-ethanol and CO2-acetone at 40°C. 
System P (Mpa) XCO2 Reference 
CO2-acetone 7.95 0.984 [75] 
CO2-acetone 8.05 - [76] 
CO2-ethanol 8.16 0.963 [51] 
CO2-ethanol 7.8 0.985 [75] 
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5.1.  Abstract 
Graphical Abstract 
 
Common strategies to improve the dissolution properties of hydrophobic drug compounds 
include the preparation of composites with hydrophilic excipients and/or size reduction. 
However, nanoparticles have poor flowability and difficult handling. Therefore, this work 
aims to demonstrate the single-step improvement in dissolution and flow properties of 
pharmaceutical formulations. Coprecipitates of curcumin and poly (vinyl pyrrolidone) (guest 
particles) are simultaneously produced and coated onto microcrystalline cellulose (MCC, 175 
µm), corn starch (15 µm) and lactose (< 5 µm) (host particles), by combining the Supercritical 
Antisolvent process with two different configurations of fluidized bed (tapered bed and stirred 
vessel). Experiments were performed at 40°C, 9-12 MPa, 2.5-30.0% guest/host mass ratio and 
stirrer speed varying from 400 to 1200 rpm. SEM images demonstrated that nanoparticles of 
coprecipitates were obtained while DSC results showed that they were amorphous, explaining 
the remarkable improvement in dissolution achieved. Free-flowing powder was obtained 
when MCC was used as carrier. 
Keywords: supercritical antisolvent; coprecipitation; high-pressure fluidization; coating; 





 The SAS process was combined with two configurations of fluidized beds 
 Properties of fluidization in tapered beds and stirred vessels were discussed 
 Curcumin/PVP coprecipitates were produced and coated on different carrier particles 
 Curcumin release and flow properties were enhanced in a single-step process 
5.3. Introduction 
Powder technology has a major impact on the profitability of the pharmaceutical industry as 
more than 80% of drug products are solids, produced by a number of processing steps [1,2]. 
In order to improve the efficiency of manufacturing processes and to optimize formulation 
development, the current trend in the pharmaceutical industry is to develop cost-effective and 
environmental-friendly processes with fewer steps to gain better understanding and control of 
the variables [3].   
Drug solubility and dissolution rate are some crucial properties investigated in early stages of 
pharmaceutical formulation development [4]. In fact, more than 49% of drug candidates for 
oral administration have low water solubility (< 10 µg/ml) [5], which leads to poor 
bioavailability. As a consequence, the administration of high doses is required to achieve the 
therapeutic level, usually resulting in undesired side effects. The common approaches to 
improve the dissolution properties of pharmaceutical compounds are: modifying its crystalline 
structure; preparing composites with hydrophilic excipients; and/or increasing the surface area 
of the material by decreasing its size to nano-scale [6].  
Particle size reduction (micronization) techniques can be classified into two main categories: 
top-down and bottom-up. In the former, large drug particles are broken by mechanical means 




micronization processes, including milling and homogenization, require high energy input, 
which can damage the crystalline structure of the product and lead to the formation of 
electrostatically charged and cohesive powders with wide particle size distribution [7–9]. On 
the other hand, bottom-up processes such as spray drying and solvent evaporation often result 
in low precipitation yield [10–12], requiring high temperatures to dry the particles, which 
prevents the processing of thermo-sensitive compounds.  
Bottom-up processes based on the use of supercritical fluids (SCFs) are an alternative for 
these issues. In the proximity of the supercritical region (above critical pressure and critical 
temperature) a fluid has unique properties, combining liquid-like density (high solvation 
power) and gas-like compressibility and diffusivity (high mass transfer rates). By the 
manipulation of the process operating conditions (such as pressure and temperature), the fluid 
density and solvation power can be adjusted, allowing the control of the solute supersaturation 
and precipitation [13]. Therefore, particle properties can be tuned and high precipitation yield 
can be achieved [14–16]. The most used SCF, supercritical carbon dioxide (sc-CO2), is non-
toxic, non-flammable, inexpensive and considered environmental-friendly compared with 
organic solvents commonly used in the pharmaceutical industry. Its moderate critical pressure 
(7.39 MPa) and temperature (31.1°C) enable the processing of thermo-sensitive compounds 
and the production of formulations with low or no residual organic solvent content, avoiding 
product degradation and the need for further drying. Such processes have been successfully 
employed to produce uniform micro and nanoparticles and composite materials with high 
drug loading efficiency [15,17–19]. 
Although the advantages of nano-particulate systems in drug delivery are well known, the 
strong Van der Waals attraction force between dry nanoparticles leads to cohesion, 




mixed with or coated onto larger excipients or carrier particles in pharmaceutical formulations 
to avoid issues when the material flows through the manufacturing line, and also to facilitate 
the handling and delivery of the formulation to the patient.  
SCFs have been combined with fluidized beds to encapsulate particles within a film of the 
precipitating material, as detailed in a recent review [20]. More recently, particle-on-particle 
coating has been proposed to simultaneously precipitate and blend particles of active 
pharmaceutical ingredients (APIs) with larger carrier particles, hence addressing the 
aforementioned issues of fine powder flowability and handling. These processes work by 
spraying a solution of the API (in sc-CO2 or in an organic solvent) into a fluidized bed of 
carrier/excipient particles, to achieve simultaneous precipitation and coating in a single step. 
Such process integration reduces the transfer of the product between equipment, lowering the 
risk of workers’ exposure to nanoparticles since they are formed and instantaneously captured 
onto the surface of carrier particles (referred as host particles in this work). By performing the 
Supercritical Antisolvent (SAS) process (sc-CO2 acts as antisolvent) inside a stirred vessel 
containing fluidized excipient particles, Sanganwar et al. [21] reported the precipitation of 
nevirapine (18-39 μm) onto the surface of lactose (100 μm) and microcrystalline cellulose 
(MCC, 50 μm) particles by a process named Supercritical Antisolvent-Drug Excipient Mixing 
(SAS-DEM). The same group then coated lactose (100 μm) with itraconazole (0.73-1.73 μm) 
precipitated in the presence of surfactants [22], and fine lactose particles (5 μm) with 
precipitated rifampicin (~ 5 μm) [23]. Despite the fact that predominantly micro (rather than 
nano) particles of drug were obtained in these works, improvements in drug release rate were 
reported, attributed to a reduction in the drug-drug particle aggregation. Powder flowability 
was also claimed to be improved [21,22], however flow properties were not assessed by the 




(RESS) process (sc-CO2 acts as solvent) in two different setups (Wurster coater - RESS-WTS 
and fluidized bed - RESS-BFB) to precipitate nanoparticles (< 30 nm) of several APIs onto 
MCC (300 µm) [24]. Then the combination of the SAS process with a tapered fluidized bed 
(SAS-FB), in which the upward flow of CO2 is responsible for promoting the fluidization of 
the host particles, was proposed. It was employed to simultaneously precipitate and deposit 
nanoparticles of naringin (100-200 nm) onto the surface of MCC of various sizes (175-295 
µm), with great improvements in drug release achieved [25].  
In our most recent work using SAS-FB, curcumin (CURC), a hydrophobic material with 
several therapeutic properties (anticancer, antioxidant, anti-inflammatory, etc.), was selected 
as a model compound. Formulations potentially suitable for pulmonary delivery were 
prepared by coating lactose (125 µm) with curcumin crystals (0.4-12.1 μm) [14],  however, 
despite expected improvements in the flowability of the micronized crystals (due to the 
mixing with free-flowing lactose), the curcumin size reduction achieved was still not 
sufficient to give desired dissolution enhancement [15]. Our subsequent work focused on 
improving the dissolution properties of curcumin by producing coprecipitates with poly (vinyl 
pyrrolidone) (PVP), a hydrophilic polymer, by SAS [15]. Coprecipitation offers advantages 
over the precipitation of the drug alone: the drug is dispersed in the polymer matrix which can 
protect the API against degradation while also allowing drug release to be adjusted through 
polymer selection [26]. The apparent solubility of curcumin from the composite material was 
much higher (up to 600 times) than from a corresponding physical mixture of as-received 
components [15] but the nano-coprecipitates produced tended to aggregate due to high surface 
energy and would not flow.  
In order to overcome the issues identified in the previous work, this manuscript reports the 




a single step. Curcumin and PVP (guest particles) are coprecipitated and simultaneously 
coated onto the surface of free-flowing host particles (MCC, 175 µm) by using SAS-FB 
(tapered bed) and SAS-DEM (stirred vessel) processes and the characteristics of the two 
different configurations of fluidized bed (tapered bed and stirred vessel) are discussed. In 
addition, formulations potentially suitable for pulmonary delivery are prepared by coating 
smaller host particles (corn starch, 15 µm and lactose, < 5 µm) by nano CURC/PVP 
coprecipitates using SAS-DEM. For the first time, the combination of coprecipitation and 
coating under supercritical conditions is reported and novel curcumin formulations are 
produced. Since there are few reports in the literature about the use of SAS-FB and SAS-
DEM, the composites obtained from both techniques are also analysed and compared, which 
is another original aspect of this work. 
5.4. Experimental 
5.4.1. Materials 
Curcumin (purity ≥ 90%) was purchased from Cayman Chemical, UK; lactose (Lactohale® 
300, < 5 μm) was kindly provided by DFE Pharma, Germany; corn starch (15 µm [27]) was 
purchased from Argo, USA; microcrystalline cellulose (MCC - Ethispheres 150, 175 μm) was 
acquired from NP Pharm, France; poly (vinyl pyrrolidone) (PVP, Mw = 10 kg/mol) and 
sodium dodecyl sulphate (SDS) were purchased from Sigma Aldrich, UK; ethanol (EtOH, 
purity > 99.8%) and acetone (Ac, purity > 99.8%) were bought from Fisher Scientific, UK; 
carbon dioxide (CO2, purity ≥ 99.8%) was purchased from BOC, UK. The materials were 




5.4.2. SAS equipment and experimental procedure 
5.4.2.1. Particles generation by Supercritical Antisolvent (SAS) 
A schematic diagram of the SAS process and its variants, SAS-Fluidized Bed (FB) and SAS-
Drug Excipient Mixing (DEM), is shown in Figure 5-1a. A complete description of the 
experimental procedure and details of the equipment used in the SAS process has been 
presented in our previous work [14]. In summary, the precipitator (500 ml water-jacketed 
vessel) is pressurized with CO2 up to the operational pressure (9.0 or 12.0 MPa) and then a 
constant CO2 flow is set (40 g/min), while keeping pressure and temperature (40 °C) constant. 
Following this, solvent is pumped into the precipitator through a nozzle (127 µm) to establish 
a quasi-steady state composition of solvent and CO2. The pump feed is then switched to 
deliver the solution (containing curcumin or curcumin + PVP) and produce fine SAS 
particles. Once the desired volume of solution has been delivered, the liquid feed is switched 
back to solvent to purge the line (10 ml) and ensure all material has entered the vessel. The 
flow rate of the liquid was set to 0.5 ml/min in all experiments. A final washing step with CO2 
only is performed to remove any residual solvent from the precipitated powder. Once 
completed, the system can be slowly depressurized and the sample collected.  
The rig and experimental procedures employed in SAS-FB and SAS-DEM are similar to the 
SAS process, with some adaptations described in the following sections. While in SAS only 
fine particles are produced, in SAS-FB and SAS-DEM host particles are charged into the 
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Figure 5-1. Simplified diagram of: a) SAS; b) SAS-FB; c) SAS-DEM. 
5.4.2.2. Particles generation and coating by SAS-FB 
For the SAS-FB experiments, a glass tapered bed holder with tapered angle (α) of 6.7° and 
bottom internal diameter of 6.5 mm was used to fluidize the host particles. A sintered 
stainless steel gas distributor is installed on the bottom of the bed and a 127 µm nozzle is 
fixed in the middle of it  [25], allowing the fluidization of particles and simultaneous delivery 
of drug solution, as illustrated in Figure 5-1b.  
In brief, the fluidized bed holder has to be initially loaded with the material to be coated (host 
particles) and then placed inside the precipitator, which is kept at constant temperature 
(40°C). After that, the system is closed and CO2 is initially fed from the top of the vessel (not 
shown in the figure). Once the operational pressure has been reached (12.0 MPa), the CO2 
inlet is switched to the bottom of the vessel, directly into the base of the bed, and a constant 
CO2 flow is then set (40 g/min) by adjusting the outlet micrometric valve. Hence, the upward 
movement of sc-CO2 through the gas distributor promotes the fluidization of the host 
particles. A filter cap on the top of the fluidized bed prevents particles being blown out.  




following the SAS procedure previously explained, allowing simultaneous precipitation and 
coating of guest particles onto host particles. 
The minimum fluidization velocity (Umf), that is, the minimum CO2 velocity to keep particles 
supported against gravity, was estimated using Equation 5-1 valid for beds with a tapered 
angle (α) above 4.5°  [28]. 
𝑈𝑚𝑓 =  
𝑅𝑒𝑚𝑓 𝜇𝑓 
𝑑𝑝 𝜌𝑓
 Equation 5-1 




/s), ρf is the density of the fluid 
(717.8 kg/m
3
) and dp is the particle diameter (1.7 x 10
-4
 m). The Reynolds number at Umf 
(Remf) is given by Equation 5-2, where B is the bottom diameter of tapered bed (6.5 x 10
-3
 m), 
ε0 is the voidage of the stagnant bed (0.43), Øp is the particle sphericity (0.95). The 























SAS-FB experiments were performed at U/Umf = 2.8, based on the calculated value from 
Equation 5-2. Two sapphire windows in the precipitator allowed the observation of the 
behaviour of the fluidized bed during the experiments. However, precise experimental 
determination of the Umf could not be performed since the CO2 flow is oscillating (a piston 




5.4.2.3. Particles generation and coating by SAS-DEM 
In the SAS-DEM configuration, a 300 ml agitated vessel (5500 Compact Mini Bench Top 
Reactor, Parr Instrument Company) was used to promote particle fluidization. Temperature 
and stirrer speed can be set by a controller (4836 Reactor Controller, Parr Instrument 
Company) coupled with the reactor. CO2 is delivered in the axial direction 2 cm above the 
bottom of the vessel, helping the impeller to suspend the host particles, while the 
solvent/solution is delivered in the same direction, 7 cm from the bottom (Figure 5-1c).  
The experimental procedure begins by loading the host particles into the precipitator, the 
vessel is closed and the stirrer and heater are switched on. Then the same steps followed in the 
SAS process are carried out. Similarly to SAS-FB, host particles will be coated by guest 
particles precipitated from the atomized solution. Particles are maintained in the vessel by a 
filter placed in the outlet line. In the SAS-DEM experiments, the temperature was kept at 
40°C, pressure was 9.0 or 12.0 MPa, liquid solution and CO2 flow rate were respectively 
equal to 0.5 ml/min and 40 g/min.  
The stirrer speed to keep particles just suspended (Njs) depends on the geometry of the system 
and can be estimated by Equation 5-4 [29]:  











𝐼𝛿  𝑊𝜃 
Equation 5-4 
where C is the impeller off bottom clearance (m), T is the inner diameter of stirred tank (m), νf 
is the kinematic viscosity of the fluid (m
2
/s), I is the impeller diameter (m), and W is the solid 
fraction (ratio between solid mass and fluid mass multiplied by 100). For the impeller used 
here, a 45° pitched 4-blade turbine operating in down-pumping mode (PBT-D), the model 




0.35) [29]. In this type of impeller (axial flow in down pumping mode), the material is 
directed to the periphery of the vessel bottom and then lifted up from the walls [29,30]. The 
stirrer speed used in the SAS-DEM experiments varied between 1.4 and 4.3 times the Njs. As 
no sapphire window exists in the vessel, the quality of the fluidization could not be assessed 
during the experiments. 
For SAS-FB and SAS-DEM, usually 2 g of host particles were used and different amounts of 
drug solution were pumped in to achieve the desired guest/host mass ratio. The proportion 
between the mass of guest particles (mg) and host particles (mh) for 100% surface coverage of 
host particles with a monolayer of guest particles can be calculated by Equation 5-5 [27], 
assuming that guest and host particles are spherical with diameters of dg and dh and densities 










Where, N is given by Equation 5-6: 







5.4.3.1. Scanning electron microscopy (SEM) 
Scanning Electron Microscopy (SEM, model Philips XL-30 FEG) was used to access the 
morphology and size of particles at 10 kV and 10 mA. Samples were deposited on a double-
sided adhesive carbon tape and sputter coated (Emscope SC500) with gold for 3 min at 25 




5.4.3.2. Powder flow properties 
Powder flowability before and after coating was accessed by using Carr’s compressibility 
index (CI) and Hausner’s ratio (HR), obtained from the tapped and bulk densities of the 
material, as shown in Equation 5-7 and Equation 5-8, respectively: 
𝐶𝐼 =  
𝜌𝑡𝑎𝑝 −  𝜌𝑏𝑢𝑙𝑘
𝜌𝑡𝑎𝑝
 × 100% Equation 5-7 
𝐻𝑅 =  
𝜌𝑡𝑎𝑝
𝜌𝑏𝑢𝑙𝑘
 Equation 5-8 
Bulk density was estimated by transferring a certain amount of powder to a graduated 
cylinder (10 ml), weighing the sample and then dividing the mass by the volume occupied. 
After that, the cylinder was tapped until a constant volume was observed, which was used to 
obtain the tapped density. The flowability of the samples was then classified according to 
Table 5-1 [31]. 
Table 5-1. Flow behaviour of powders based on their compressibility index (CI) and Hausner’s ratio 
(HI) [31]. 
CI (%) HR Flow character 
1-10 1.00-1.11 excellent 
11-15 1.12-1.18 good 
16-20 1.19-1.25 fair 
21-25 1.26-1.34 passable 
26-31 1.35-1.45 poor 
32-37 1.46-1.59 very poor 
>38 >1.6 very, very poor 
 
5.4.3.3. Fourier Transform Infrared Spectroscopy (FTIR) 
The chemical structure of raw compounds and processed samples was assessed by Fourier 




reflectance (ATR) accessory to identify possible molecular interactions among the 
compounds. Each sample was analysed in triplicate in a range of 800-4000 cm
-1
. The spectra 
are composed of 64 scans with a resolution of 4 cm
-1
 [32,33].  
5.4.3.4. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (Discovery DSC 25, TA Instruments) was used to assess 
the thermal behaviour of unprocessed and processed materials. Each sample was initially 
deposited in an aluminium pan with a pinhole in the cover and accurately weighed. A heat-
cool-heat cycle was used: initial heating from 50°C to 160°C at 20°C/min; quench cool 
(100°C/min) back to the initial temperature; final heating to 400°C, again at 20°C/min. A 
nitrogen purge of 50 ml/min was employed during all measurements. This method has shown 
to be effective in determining the thermal transitions in formulations containing curcumin and 
PVP [15]. Tests were duplicated and the results presented here correspond to the final heating 
step. 
5.4.3.5. In vitro dissolution studies 
A USP 2 dissolution apparatus (rotating paddles) was used to analyse the in vitro dissolution 
behaviour of the samples. Accurately weighed samples containing equivalent amounts of 
curcumin (~ 1 mg) were incubated at 37 ± 0.5°C in 200 mL of water with 0.25% w/v sodium 
dodecyl sulphate (SDS), in accordance with in vitro dissolution procedures for poorly soluble 
drugs [34–37]. Paddle rotation was kept at 100 rpm and 2 ml of the solution was withdrawn 
and replaced by the same amount of fresh medium at preselected time intervals. The 
absorbance of the withdrawn solution was measured by (UV)–visible spectrophotometer 
(Jenway, Genova Plus) at 425 nm and the corresponding concentration was determined. The 




𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =   
𝑚𝑡
𝑚100%
× 100% Equation 5-9 
where mt is the mass of curcumin in solution at time t and m100% is the mass of curcumin after 
complete dissolution. All tests were carried out in triplicate. The uniformity of the 
formulations was analysed by the relative standard deviation (RSD) of drug content measured 
by the (UV)-visible spectrophotometer. 
5.5. Results and discussion 
5.5.1. Preliminary studies 
The combination of particle engineering and coating is an efficient way of preparing drug 
formulations in a single step. However, due to the number of substances (drug, polymer, 
carriers, solvents, antisolvent) and phenomena involved, particle precipitation should be 
initially separated from the fluidization and coating. In other words, first it is necessary to 
check if particles with the desired properties can be produced by SAS in the selected 
operating conditions and ensure that the solvents used will not solubilize the host particles. 
Hence, SAS precipitation and coprecipitation and investigations into solvent suitability were 
carried out as preliminary studies of this work. 
5.5.1.1. SAS precipitation and coprecipitation 
Our previous study [15] focused on understanding the coprecipitation of curcumin and PVP 
by SAS, successfully achieved from different solvent mixtures of acetone (Ac) and ethanol 
(EtOH) with product recovery as high as 90%. Based on that, the operational parameters for 
this work were selected. To maximize curcumin recovery, a 70-30 v/v Ac-EtOH solution was 
used [15], delivered at a flow rate of 0.5 ml/min. The overall (curcumin + PVP) solution 




the mass ratio between curcumin and PVP was kept at 1:3 so that the final formulation after 
coating could have fairly high drug content. The temperature was fixed at 40°C because at 
lower temperature (35°C), although curcumin recovery increases slightly, particle size 
decreases [15], leading to a decrease in the guest/host ratio required for full coverage of the 
host particles surface in the coating experiments performed in the upcoming sections, so a 
lower drug loading in the formulation would result. The CO2 flow rate was kept at 40 g/min 
(XCO2 = 0.992), while two different values of pressure were tested, 9.0 and 12.0 MPa. A 
summary of the materials and operational conditions tested is presented in Table 5-2. 
Curcumin was initially precipitated alone at 9.0 MPa (run #1, Table 5-2) and 12.0 MPa (run 
#2). For comparison, Figure 5-2a,b shows the morphology of unprocessed curcumin and 
PVP. The rectangular/rod-like shape of raw curcumin crystals with wide size distribution 
(Figure 5-2a) was changed into a combination of needle-like and some spherical particles at 
the lower pressure (9.0 MPa, Figure 5-2c). At the higher pressure (12.0 MPa, Figure 5-2d), 
curcumin precipitated as a needle/filament-like structure with smaller dimensions compared 
to the raw material.  
As the size of curcumin was not significantly reduced and it remained crystalline after SAS 
precipitation (as will be shown in more detail in section 5.5.8), a significant improvement in 
its dissolution properties was not be achieved (as demonstrated in section 5.5.9), therefore 
coprecipitation with PVP was performed by SAS in run #3 at 9.0 MPa (Table 5-2). Figure 
5-2e,f taken at different magnifications show the spherical and uniform nanoparticles of the 
composite material produced with particle size of 140 ± 63 nm (based on the measurement of 
200 particles by Image J analysis software), demonstrating the ability of PVP to inhibit the 




Table 5-2. Materials, experimental conditions and flow properties of the formulations. Other operational conditions are: temperature = 40°C, XCO2 = 
0.992, solution concentration = 20 mg/ml, solution flow rate = 0.5 ml/min and CO2 flow rate = 40 g/min. 














1 SAS - CURC 9 - - - - 
2 SAS - CURC 12 - - - - 
3 SAS - CURC/PVP 9 - - 52% 2.06 
4 SAS-DEM MCC - 12 - 800 - - 
5 SAS-DEM corn starch - 9 - 800 - - 
6 SAS-DEM lactose - 9 - 800 - - 
7 SAS-FB MCC CURC 12 2.5% - 10% 1.11 
8 SAS-FB MCC CURC/PVP 12 2.5% - 6% 1.07 
9 SAS-FB MCC CURC/PVP 12 5.0% - 8% 1.09 
10 SAS-DEM MCC CURC 12 2.5% 800 5% 1.05 
11 SAS-DEM MCC CURC/PVP 12 2.5% 800 5% 1.05 
12 SAS-DEM MCC CURC/PVP 12 5.0% 800 8% 1.08 
13 SAS-DEM corn starch CURC/PVP 9 5.0% 800 38% 1.61 
14 SAS-DEM corn starch CURC/PVP 9 10.0% 800 37% 1.58 
15 SAS-DEM corn starch CURC/PVP 9 20.0% 800 36% 1.55 
16 SAS-DEM lactose CURC 9 10.0% 800 60% 2.52 


















18 SAS-DEM lactose CURC/PVP 9 20.0% 800 54% 2.15 
19 SAS-DEM lactose CURC/PVP 9 30.0% 800 50% 2.00 
20 SAS-DEM lactose CURC/PVP 9 20.0% 400 58% 2.40 





Figure 5-2. SEM images of: a) raw curcumin; b) raw PVP; c) curcumin processed by SAS at 9.0 MPa 
(run #1); d) curcumin processed by SAS at 12.0 MPa (run #2); e) CURC/PVP coprecipitated by SAS 
at 9.0 MPa (run #3, Mag. 500X); f) CURC/PVP coprecipitated by SAS at 9.0 MPa (run #3, Mag. 
15000X). 
Once the SAS coprecipitation of CURC/PVP with the desired features (particle size, 
morphology and dissolution rate) was demonstrated to be possible at the selected operational 
conditions, the combination with coating was attempted. As the recovery of CURC/PVP 
coprecipitates and curcumin loading efficiency have been extensively discussed and 




work. Here we aim to prove the effectiveness of SAS-FB and SAS-DEM processes in 
producing formulations with improved release and flow properties in a single step. 
5.5.1.2. Compatibility between solvents and host-particles 
The first point to be taken into consideration before performing combined coating and 
coprecipitation is the compatibility between the compounds involved, that is, to ensure that 
the solvents used to dissolve the drug and the polymer would not dissolve or somehow 
interact with the host material in the bed. This could change the surface properties of the host 
particles (for example, surface roughness) and also interfere in the phase behaviour of the 
precipitating materials.  
In this work, the excipients used as host particles are: MCC (175 µm), corn starch (15 µm) 
and lactose (< 5 µm). Each was treated with solvent only (70-30 v/v Ac-EtOH with no solute 
dissolved) through SAS-DEM at 800 rpm to investigate possible changes in the surface and 
morphology of the particles. Table 5-2 shows the operational conditions used. In runs #4-6, 
the solvent was delivered for the same duration (and consequently, the same volume) as the 
solvent and solution delivered in runs #12, #15 and #18, respectively. Figure 5-3 shows the 
comparison between the host particles before (left hand side) and after solvent treatment (right 
hand side), in which no difference in particle surface, shape and size can be seen. This 
demonstrates that no interactions occurred, and also that the stirrer speed selected was suitable 
to avoid damaging particles. FT-IR analyses presented later in section 5.5.7 also confirmed 






Figure 5-3. SEM images of: a) raw MCC; b) MCC processed by 70-30 acetone/ethanol mixture; c) 
raw corn starch; d) corn starch processed by 70-30 acetone/ethanol mixture; e) raw lactose; f) lactose 
processed by 70-30 acetone/ethanol mixture. 
5.5.1.3. Guest/host mass ratio for full surface coverage 
CURC/PVP coprecipitates were then simultaneously produced and coated on the surface of 
the host particles. According to Equation 5-5 (section 5.4.2.3), for a constant mass of host 




guest particles (mg) of a certain diameter (dg) are required for complete coverage of host 
particles surface. This is illustrated in Figure 5-4, calculated for the coating of the host 
particles by 1:3 CURC/PVP coprecipitates (assuming ρg = 1224 kg/m
3
, since ρCURC = 1300 
kg/m
3
, ρPVP = 1200 kg/m
3
) with diameter (dg) varying from 10 to 200 nm.  
 
Figure 5-4. Guest/host mass ratio to cover 100% of the surface of host particles (diameter dh) as a 
function of the diameter of guest particles (dg) (Equation 5-5).  












CURC/PVP guest 1224 0.14 - - 
MCC host 1400 175 0.3% 2.5 - 5.0% 
corn starch host 1550 15 3.0% 5.0 - 20.0% 
lactose host 1540 1 - 5 9.4 - 57.8% 10.0 - 30.0% 
For guest particles of 140 nm (representing the coprecipitates obtained in run #3), the 
calculated mass ratios for complete surface coverage are given in Table 5-3, together with the 
properties of the materials and the range of guest to host mass ratio used in the experiments. 
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Equation 5-5, it is possible that the quantity of guest particles required is higher than 
predicted; therefore, the values calculated were used only as a starting point to select the 
minimum amount of guest material to be used. Values below 2.5% for guest/host ratio were 
not used as drug content in the formulations would be too low (< 0.6%). 
5.5.1.4. SAS-FB operational conditions 
In tapered beds, the inclination of the walls offers unique hydrodynamic properties, resulting 
in a vigorous circulation of particles [39], which is beneficial in applications that require good 
mixing and high heat and mass transfer [40]. Although cylindrical beds are more common, the 
tapered geometry is largely employed in the pharmaceutical, food and chemical industries in 
processes where a reduction in particle size, due to attrition or chemical reactions, would lead 
to particle entrainment, channelling and slugging, and hence reduce the efficiency of the 
fluidization [28]. Since the cross-section area increases with height, the gas velocity is higher 
in the bottom of the bed, keeping larger particles in movement, while the lower velocity 
towards the top prevents the elutriation of smaller particles [39,40]. This is advantageous in 
SAS-FB coating since guest and host particles have very different diameters.  
In early exploratory experiments with SAS-FB for MCC coating by CURC/PVP 
coprecipitates (not shown here), two reasons were identified as the cause of the fluidization to 
stop: the presence of liquid in the bed and a high proportion of guest/host particles added. In 
the first case, the operational point (40°C, 9.0 MPa, XCO2 = 0.992) was probably below the 
critical pressure of the mixture 70:30 Ac-EtOH in CO2, as it has been observed that PVP 
enlarges the biphasic region of the phase diagram of the CO2/solvent mixture [41]. In this 
situation, as the operational point is located within the biphasic region, gas and liquid phases 
coexist inside the vessel, wetting the host particles. Therefore, they become sticky and lumps 




Sometimes the lumps were broken into smaller ones but, still, the top of the bed would 
usually stop moving. In the second situation, if the ratio guest/host was too high, the strong 
attraction force between the submicron guest particles also led to the formation of lumps, 
stopping the fluidization. Taking as reference the reported mixture critical point of the system 
PVP (with initial concentration of 20 mg/ml) in 50% Ac-EtOH mixture + CO2 at 40°C (Pc = 
9.34, Xc(CO2) = 0.982 [41]), 12.0 MPa was selected to be used in all SAS-FB experiments to 
make sure that the operating point is located far above the mixture critical point in fully 
developed supercritical conditions [42], avoiding the presence of liquid in the bed and 
consequent particle agglomeration. 
In SAS-FB, the fluidization of particles is promoted by the upwards flow of CO2 and the 
solution jet. Therefore, the CO2 flow rate selected has to be above the minimum fluidization 
velocity and at the same time satisfy thermodynamic requirements to favour particle 
precipitation (molar fraction of CO2 higher than that of the mixture critical point). The 
minimum fluidization velocity was calculated according to Equation 5-1 for MCC particles in 
a tapered bed (tapered angle α = 6.7° and bottom diameter B = 6.5 mm) at 40°C and 12.0 
MPa, resulting in 1.0 cm/s or 14.1 g/min of CO2. In order to ensure the experiments were 
performed in the supercritical region, a CO2 molar fraction above 99% (XCO2 = 0.992) was 
used, based on the delivery of solution at 0.5 ml/min and CO2 at 40 g/min, which gives U/Umf 
= 2.8.  
Due to the cohesive nature of the finer particles (“Group C” in Geldart’s classification [43]), 
the fluidization of corn starch (d50 = 15 µm) and lactose (d50 < 5 µm) was not possible so 
only MCC particles (d50 = 175 µm) were coated by SAS-FB. SAS-DEM was then used to 




5.5.1.5. SAS-DEM operational conditions 
For very small particles, sticky or wet materials, the inter-particle forces are stronger than the 
hydrodynamic forces exerted by the fluid, leading to channelling, so “normal” fluidization is 
extremely hard. However, it can be improved by employing stirrers or vibrators [43,44]. In 
SAS-DEM, the additional energy required to fluidize fine particles is provided by a 
mechanical stirrer (45° pitched 4-blade turbine). Using an agitated vessel makes the combined 
coating and coprecipitation process more versatile since the requirement of a minimum CO2 
flow rate to fluidize the particles no longer exists (although the delivery of CO2 close to the 
bottom of the vessel helps to keep particles suspended). Moreover, if the operational point 
falls into the biphasic region, the fluidization should not stop. From the precipitation point of 
view, the stirrer speed could potentially be adjusted to tune particle size, since it will influence 
the mass transfer in the system [45]. However, the additional energy requirement and the 
possibility of damage to the particles need to be taken into account.  
The stirrer speed required to have the host particles just suspended (Njs) was calculated using 
Equation 5-4, at the operating conditions shown in Table 5-2. In Table 5-4, the values 
obtained are summarized, and the proportion between the stirrer speed used in the 
experiments (N) and the just suspended speed (NJs) are shown for the different host particles 
tested. 
5.5.2. Coating of MCC by SAS-FB and SAS-DEM 
The first coating experiments were performed by precipitating curcumin alone onto MCC 
particles by SAS-FB (run #7) and SAS-DEM (run #10) with a guest/host mass ratio of 2.5%. 




#2), given in Table 5-2. For SAS-DEM, a stirrer speed of 800 rpm (N/Njs = 2.2, Table 5-4) 
was employed. 
Table 5-4. Comparison between the just suspended stirrer speed (Njs) and the speed used in the 
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The SEM images in Figure 5-5a,c (SAS-FB) and Figure 5-5b,d (SAS-DEM) show that the 
morphology of curcumin crystals obtained by both coating processes was similar (rod/needle-
like). However, they are smaller and less aggregated than curcumin produced by SAS, 
presented in Figure 5-2d (for comparison, Figure 5-5a,b and Figure 5-2d are given in the 
same magnification). This size decrease following coating has been previously observed, 
explained by the collection of the precipitating curcumin close to its point of origin on the 
surface of the host particles, preventing further growth and aggregation [14]. The behaviour of 
fluidization was observed during the SAS-FB experiment (run #7) through the sapphire 
windows located in the high-pressure vessel. As predicted by Equation 5-1 (Umf = 1.0 cm/s, 
corresponding to 14.1 g/min), the CO2 flow rate used (40 g/min) was high enough to fluidize 
the MCC particles but not so high to blow them out of the bed, even when the solution jet was 
injected. During the entire experiment, a fully fluidized bed was observed, with bubbles being 






Figure 5-5. SEM images of MCC coated samples using SAS-FB (left-hand side) and SAS-DEM 
(right-hand side): a) run #7, Mag. 500X; b) run #10, Mag. 500X; c) run #7, Mag. 5000X; d) run #10, 
Mag. 5000X; e) run #8, Mag. 500X; f) run #11, Mag. 500X; g) run #9, Mag. 500X; h) run #12, Mag. 





In the following tests, curcumin and PVP were coprecipitated and simultaneously coated onto 
the surface of MCC particles by SAS-FB (runs #8-9) and SAS-DEM (runs #11-12) under the 
same operational conditions (Table 5-2) with two different guest/host mass ratios (2.5% and 
5.0%). Samples containing 2.5% guest/host ratio are presented in Figure 5-5e (SAS-FB, run 
#8) and Figure 5-5f (SAS-DEM, run #11) while those of 5.0% ratio are shown in Figure 
5-5g,i (SAS-FB, run #9) and Figure 5-5h,j (SAS-DEM, run #12). As the guest/host ratios 
used were much higher than the calculated value required for full surface coverage of MCC 
(0.3%, Table 5-3), complete surface coverage was achieved in all experiments. Owing to the 
aggregated nature of the CURC/PVP nanoparticles, a multi-layered coating was obtained 
(Figure 5-5i,j). Pictures taken at higher magnification also reveal that the particle size of the 
coprecipitates produced by SAS-DEM (Figure 5-5j) is considerably smaller than the ones 
produced by SAS-FB (Figure 5-5i) which suggests improved mass transfer. 
5.5.3. Coating of corn starch by SAS-DEM 
For some pharmaceutical applications, fine excipients are used since they might inhibit the 
tendency of powder segregation due to differences in particle size between the API and 
excipient, while also improving compaction properties of tablets [47]. Hence, taking 
advantage of the additional agitation provided by the stirrer in the SAS-DEM process, fine 
corn starch particles (15 µm) were fluidized and coated with CURC/PVP coprecipitates using 
a stirrer speed of 800 rpm (N/Njs = 2.3, Table 5-4) while keeping the same conditions as in 
the preliminary studies of SAS coprecipitation (run #3). Three different guest/host ratios were 
tested: 5% (run #13, Figure 5-6a,b), 10% (run #14, Figure 5-6c,d) and 20% (run #15, Figure 
5-6e,f). Although 3% was the calculated guest/host ratio required for full surface coverage of 
corn starch particles (Table 5-3), due to the aggregated nature of the coprecipitates, the 




material was required to cover the surface of the host particles. At 20% mass ratio, the 
coverage seemed to be almost complete (Figure 5-6f), in contrast to the large uncoated areas 
observed at 5% (Figure 5-6b) and 10% ratio (Figure 5-6d). Since the attraction force existing 
between the nanoparticles of coprecipitates is very strong, the stirrer speed used (800 rpm) 
was not capable of promoting their de-agglomeration. 
 
Figure 5-6. SEM images of corn starch coated with CURC/PVP by SAS-DEM at Mag. 1500X (left-
hand side) and 5000X (right-hand side) and different guest/host mass ratios: a), b) 5% (run #13); c), d) 




5.5.4. Coating of lactose by SAS-DEM 
Fine lactose particles (d < 5 µm) were also selected to be coated by SAS-DEM in order to 
produce formulations potentially suitable for pulmonary delivery. Lactose is an excipient 
approved by most regulatory agencies for such application and its size range (1-5 µm) is 
appropriate for lung deposition [48,49]. As nanoparticles of coprecipitates would be easily 
exhaled after inhalation, the combination with carrier particles with the desired properties can 
be a novel formulation strategy for the delivery of curcumin, which preserves the advantages 
of delivering nanoparticles to the lungs [50,51].  
The coating was performed at a fixed stirrer speed of 800 rpm (N/Njs = 2.9, Table 5-4) and 
varying the guest/host ratio in runs #16-19. SEM images showing the formulations obtained 
are presented in two different magnifications (5000X in the left-hand side and 15000X in the 
right hand-side) in Figure 5-7. In run #16, curcumin alone was used as the guest material, at 
10% guest/host ratio. Hence, the typical rod-like crystal morphology of precipitated curcumin, 
indicated by the red arrows in Figure 5-7a,b, can be identified among irregular lactose 
particles.  
In the following experiments, CURC/PVP coprecipitates were used as guest material for the 
simultaneous coprecipitation and coating of lactose by SAS-DEM. Considering lactose 
particles with a size range of 1-5 µm (according to the supplier, d50 < 5 µm), the guest/host 
mass ratio required for full lactose surface coverage with a monolayer of CURC/PVP particles 
would be between 9.4% and 57.8% (Table 5-3). The coating experiments were then 
performed at mass ratios of 10% (run #17, Figure 5-7c,d), 20% (run #18, Figure 5-7e,f) and 
30% (run #19, Figure 5-7g,h). Because the size of the coprecipitates is much smaller than the 




coating the irregular lactose particles and aggregates in the SEM images taken at higher 
magnification (right hand-side of Figure 5-7).  
 
Figure 5-7. SEM images of lactose coated with CURC and CURC/PVP by SAS-DEM at 800 rpm, 
Mag. 5000X (left-hand side) and 15000X (right-hand side) and different guest/host mass ratios: a) and 
b) 10% CURC (run #16); c) and d) 10% CURC/PVP (run #17); e) and f) 20% CURC/PVP (run #18); 




As the size of the carrier/host particles become smaller, it gets more difficult to obtain a 
uniform surface coating since the host particles also tend to be aggregated. As observed in the 
SEM images (Figure 5-7), the stirrer speed used (800 rpm), was not capable of providing 
enough energy to break all lactose agglomerates. To investigate the impact of the stirrer 
speed, two additional experiments were performed: run #20 at 400 rpm (N/Njs = 1.4, Table 
5-4) and run #21 at 1200 rpm (N/Njs = 4.3, Table 5-4), both at 20% guest/host ratio. As 
expected, due to the higher energy input, at 1200 rpm (Figure 5-8c,d) there seems to be a 
reduction in the size of the lactose agglomerates in comparison with the sample obtained at 
400 rpm (Figure 5-8a,b).  
 
Figure 5-8. SEM images of lactose coated with 20% CURC/PVP by SAS-DEM at Mag. 5000X (left-
hand side) and 15000X (right-hand side) and different stirrer speeds: a) and b) 400 rpm (run #20); c) 




5.5.5. Product uniformity 
Since curcumin is coloured and all host particles are white (Figure 5-9), the colour change of 
host particles after coating can be used as an initial evidence of the success of the process. 
Figure 5-9 shows digital pictures of raw materials and some processed samples. As observed, 
curcumin precipitated by SAS alone (run #2) exhibited an orange colour, but more vivid than 
that of raw curcumin, probably because of differences in the particle size and in the crystal 
form produced (section 5.5.8). MCC coated by curcumin (run #7) presents a lighter orange 
shade, as one would expect from the mixture of orange and white powders. All samples 
containing CURC/PVP coprecipitates, on the other hand, are yellow due to the change in size 
and molecular structure of curcumin (section 5.5.8) when dispersed within the matrix of PVP. 
The colours observed in the coated samples are uniform at this scale, suggesting that the API 
is uniformly distributed in the formulation. In fact, the relative standard deviation (RSD) of 
curcumin content varied from 2.2-4.6% for SAS-FB samples and from 1.1-5.7% for SAS-
DEM. These values are within the range recommended by FDA (RSD < 6%) [52], 
demonstrating the ability of both coating processes in producing pharmaceutical formulations 
in a single-step. 
 
Figure 5-9. Digital pictures of raw materials and processed samples. Experimental conditions are 




5.5.6. Powder flow properties 
The flow properties of raw excipients and processed samples were accessed by the 
measurement of the Carr’s compressibility index (CI) and Hausner’s ratio (HR) from bulk and 
tapped density measurements. For raw MCC, corn starch and lactose, the values of CI are, 
respectively: 7%, 33% and 48%, while the values of HR are: 1.08, 1.48 and 1.90. Therefore, 
based on Table 5-1, these excipients present excellent, very poor and very, very poor 
flowability, respectively.  
The values of CI and HR for the processed samples are shown in Table 5-2. As expected, due 
to the high surface energy of nanoparticles, the coprecipitates produced by SAS (run #3) have 
even worse flow properties, with CI = 52% and HR = 2.06. By simultaneously precipitating 
and coating curcumin (run #7, SAS-FB and run #10, SAS-DEM) and CURC/PVP 
coprecipitates (runs #8-9, SAS-FB and runs #11-12, SAS-DEM) onto the surface of free-
flowing MCC particles, the resulting coated materials retained the excellent flowability of the 
host (5% <CI< 10% and 1.05<HR<1.11) in the range of guest/host ratio tested (up to 5%). 
This demonstrates the applicability of SAS-FB and SAS-DEM to produce pharmaceutical 
formulations with improved dissolution (section 5.5.9) and flow properties in a single step by 
combining fine particles containing the active material with free-flowing host particles.  
Formulations with corn starch (36% <CI< 38% and 1.55<HR<1.61) and lactose (50% <CI< 
60% and 2.00<HR<2.52) retained the poor flow character of the uncoated carriers. This could 
be improved by adding very small amounts of flow additives to the formulation, which act as 
spacers [53] between the host particles, thus reducing inter-particle forces and agglomeration 
[47,54]. Therefore, future work would aim to explore different mixtures of host particles and 




formulations with tailored release and flow properties could be produced for direct use in dry 
powder inhalers [55,56], and to prepare tablets by direct compression [47,57].  
5.5.7. Fourier Transform Infrared Spectroscopy (FTIR) 
In order to investigate possible interactions between the host particles and solvents, MCC, 
corn starch and lactose were treated by solvent (70-30 v/v Ac-EtOH mixture) in runs #4-6, for 
the same duration (same amount delivered) as solvent and solution were pumped in runs #12, 
#15 and #18, respectively. A qualitative analysis of the IR spectra of compounds before and 
after solvent treatment (Figure 5-10a) revealed that no interactions occurred between solvents 
and host particles since the same peaks are found comparing the spectra of the materials 
before and after processing (peak intensity is related to the area of material in contact with the 
surface of the ATR crystal and the distribution of the sample). Hence, these results confirm 
that the solvents selected were appropriate for the coating experiments, as previously 
discussed.  
Since the properties of the host particles were unchanged after solvent treatment, the spectra 
of the coated samples should show a combination of the spectra of raw host particles and 
guest particles precipitated by SAS (curcumin or CURC/PVP). This can be observed in 
Figure 5-10a, which also shows the chemical similarities between samples produced by SAS-
FB (runs #7-8) and SAS-DEM (runs #10-11). 
5.5.8. Differential Scanning Calorimetry (DSC) 
The thermal behaviour of processed samples and raw materials was analysed by Differential 
Scanning Calorimetry (DSC). In Figure 5-10b it is possible to see that raw curcumin presents 
an endothermic peak at around 187°C, corresponding to its melting point. After SAS 




indicates a change in the crystal form of curcumin [58]. Such crystal modification following 
supercritical fluid micronization of curcumin has been previously observed [59]. When 
coprecipitated with PVP, the complete amorphization of curcumin (run #3) is evidenced by 
the absence of melting point peaks. Only the glass transition temperature of the composite 
material can be seen at 139°C, close to the glass transition temperature of the pure PVP 
(150°C), as discussed in more detail elsewhere [15].  
 
Figure 5-10. a) IR spectra and b) DSC thermograms of raw materials and processed samples. 




No thermal transitions for MCC and corn starch could be observed in the temperature range 
tested, while lactose showed its melting point close to 219°C. In the formulations containing 
curcumin alone as guest material (runs #10 and #16), one or two melting point peaks were 
detected, confirming that curcumin maintained a crystalline structure after precipitation and 
coating. Obviously, formulations with lower curcumin content generated peaks with lower 
intensity. When CURC/PVP coprecipitates were used as guest material (exemplified by runs 
#8, #11 and #15 in Figure 5-10b), curcumin melting point peaks disappear, showing again the 
amorphous structure of the coprecipitates.   
5.5.9. In vitro dissolution studies 
In vitro dissolution studies were performed to analyse the effect of coprecipitation and coating 
on the release rate of curcumin. Figure 5-11 shows that the release rate of unprocessed 
curcumin and 1:3 mass ratio physical mixture (PM) of curcumin and PVP was much slower 
than the other samples. After 60 minutes of test, only approximately 11% and 15% of 
curcumin, respectively, was dissolved. This clearly justifies the need of using other 
approaches to improve curcumin dissolutions properties.  
The size reduction accomplished by SAS (run #2) led to a faster release than raw curcumin 
and physical mixture. However, as SAS-processed curcumin maintained its crystallinity 
(section 5.5.8), further improvement was prevented and hence the release reached only 60% 
in 60 minutes. Simultaneous precipitation and coating of curcumin onto host particles in run 
#7 (SAS-FB) and #10 (SAS-DEM) yields similar behaviour to SAS curcumin (run #2) with 
no perceived improvement (Figure 5-11). In fact, the SAS-processed sample showed an 
initially faster release probably because thinner crystals (Figure 5-2d) were produced 




In contrast, coprecipitation with PVP demonstrated remarkable improvement in the 
dissolution rate of curcumin. Even though differences in the particle size of coprecipitates 
produced by SAS-FB (Figure 5-5i), and SAS-DEM (Figure 5-5j) were observed, the 
formulations exhibited similar dissolution behaviour. For all samples containing 
coprecipitates (runs #3, #8, #11, #17 in Figure 5-11), a complete release was achieved in the 
first 5 minutes of the test whereas, at the same time interval, raw curcumin released just 3% 
and SAS-processed curcumin (run #2) around 20%. The superior dissolution properties of the 
coprecipitates are explained by the dispersion of curcumin within the matrix of PVP, which 
lead to the formation of amorphous particles (section 5.5.8) and consequent improvement in 
curcumin solubility [15]. 
 
Figure 5-11. In vitro dissolution profile of raw curcumin, curcumin/PVP physical mixture (1:3) and 
processed samples. Experimental conditions are detailed in Table 5-2. 
5.6. Conclusions 
Curcumin coprecipitation with PVP and simultaneous coating onto host particles was 
performed in a single step by combining the SAS process with two different configurations of 


































inside of a tapered bed by the upward CO2 flow and in a stirred vessel. By employing a 
systematic exploration of the processes, particle coprecipitation and coating was attempted 
and successfully achieved for the first time, allowing significant improvement in the release 
and flow properties of curcumin formulations: the particle size and amorphous nature of the 
coprecipitated curcumin provided solubility while the size of the host particles contributed 
flowability.  
SAS-FB was demonstrated to be effective for the coating of large MCC (175 µm) particles 
while fine and cohesive particles of corn starch (15 µm) and lactose (< 5 µm) required the aid 
of the stirrer in SAS-DEM.  As the coated samples retained the flow character of the uncoated 
host particles, in the range of guest/host ratio tested, excellent flowability was maintained for 
all MCC formulations which combined the advantages of nano-particulate systems in a free-
flowing powder. Fine host particles, on the other hand, would require the addition of flow 
enhancers, which is the aim of future work. 
The integrated SCF-based processes described here benefit from a reduction in the number of 
processing steps, minimising the requirement to transfer product between process units and 
lowering the risk of workers’ exposure to nanoparticles. They present a great potential for 
application in other powder processing industries in which the release of the active needs to 
be controlled.  
5.7. Acknowledgements 
The authors would like to thank the National Council for Scientific and Technological 






5.8. Competing interests 
The authors would like to declare that there are no competing interests. 
5.9. References 
[1] M. Jivraj, L.G. Martini, C.M. Thomson, C.M. Thomson, An overview of the different 
excipients useful for the direct compression of tablets, Pharm. Sci. Technolo. Today. 3 
(2000) 58–63. 
[2] F.J. Muzzio, T. Shinbrot, B.J. Glasser, Powder technology in the pharmaceutical 
industry : the need to catch up fast, 124 (2002) 1–7. 
[3] I. Pasquali, R. Bettini, Are pharmaceutics really going supercritical?, Int. J. Pharm. 364 
(2008) 176–187. doi:10.1016/j.ijpharm.2008.05.014. 
[4] M. Gibson, Pharmaceutical Preformulation and Formulation: A Practical Guide from 
Candidate Drug Selection to Commercial Dosage Form, 2005. doi:10.1021/op050157h. 
[5] M.S. Ku, W. Dulin, M.S. Ku, W. Dulin, A biopharmaceutical classification-based 
Right- First-Time formulation approach to reduce human pharmacokinetic variability 
and project cycle time from First-In-Human to clinical Proof-Of-Concept, Pharm. Dev. 
Technol. 17 (2012) 285–302. doi:10.3109/10837450.2010.535826. 
[6] S. Jain, N. Patel, S. Lin, Solubility and dissolution enhancement strategies: current 
understanding and recent trends, Drug Dev. Indusrial Pharm. 41 (2015) 875–887. 
doi:10.3109/03639045.2014.971027. 
[7] J. Zhang, L. Wu, H.K. Chan, W. Watanabe, Formation, characterization, and fate of 
inhaled drug nanoparticles, Adv. Drug Deliv. Rev. 63 (2011) 441–455. 
doi:10.1016/j.addr.2010.11.002. 
[8] M. D. Ticehurst, P. A. Basford, C. I. Dallman, T. M. Lukas, P. V. Marshall, G. 
Nichols, D. Smith, Characterisation of the influence of micronisation on the 
crystallinity and physical stability of revatropate hydrobromide, Int. J. Pharm. 193 
(2000) 247–259. doi:10.1016/S0378-5173(99)00347-6. 
[9] N. Rasenack, B.W. Müller, Micron-Size Drug Particles: Common and Novel 





[10] R. Kaur, T. Garg, B. Malik, U.D. Gupta, P. Gupta, G. Rath, A.K. Goyal, Development 
and characterization of spray-dried porous nanoaggregates for pulmonary delivery of 
anti-tubercular drugs, Drug Deliv. 23 (2016) 882–887. 
doi:10.3109/10717544.2014.920428. 
[11] D.F. Bain, D.L. Munday, A. Smith, Solvent influence on spray-dried biodegradable 
microspheres, J. Microencapsul. 16 (1999) 453–474. doi:10.1080/026520499288915. 
[12] C. Bosquillon, C. Lombry, V. Préat, R. Vanbever, Influence of formulation excipients 
and physical characteristics of inhalation dry powders on their aerosolization 
performance, J. Control. Release. 70 (2001) 329–339. doi:10.1016/S0168-
3659(00)00362-X. 
[13] R.B. Gupta, Supercritical fluid technology for particle engineering, in: R.B. Gupta, 
U.B. Kompella (Eds.), Nanoparticle Technol. Drug Deliv., 1st ed., Taylor and Francis 
Group, New York, 2006: pp. 53–84. 
[14] R.L. Matos, T. Lu, C. McConville, G. Leeke, A. Ingram, Analysis of curcumin 
precipitation and coating on lactose by the integrated supercritical antisolvent-fluidized 
bed process, J. Supercrit. Fluids. 141 (2018) 143–156. 
doi:10.1016/j.supflu.2017.12.013. 
[15] R.L. Matos, T. Lu, V. Prosapio, C. McConville, G. Leeke, A. Ingram, Coprecipitation 
of curcumin/PVP with enhanced dissolution properties by the supercritical antisolvent 
process, J. CO2 Util. 30 (2019) 48–62. doi:10.1016/j.jcou.2019.01.005. 
[16] A. Tandya, H.Q. Zhuang, R. Mammucari, N.R. Foster, Supercritical fluid 
micronization techniques for gastroresistant insulin formulations, J. Supercrit. Fluids. 
107 (2016) 9–16. doi:10.1016/j.supflu.2015.08.009. 
[17] E. Reverchon, R. Adami, G. Caputo, I. De Marco, Spherical microparticles production 
by supercritical antisolvent precipitation: Interpretation of results, J. Supercrit. Fluids. 
47 (2008) 70–84. doi:10.1016/j.supflu.2008.06.002. 
[18] E. Reverchon, I. De Marco, E. Torino, Nanoparticles production by supercritical 





[19] V. Prosapio, E. Reverchon, I. De Marco, Formation of PVP/nimesulide microspheres 
by supercritical antisolvent coprecipitation, J. Supercrit. Fluids. 118 (2016) 19–26. 
doi:10.1016/j.supflu.2016.07.023. 
[20] R.L. Matos, S.A.B. Vieira, D. Melo, E.C.M. Cabral, N.R. Foster, Dense CO2 
technology : Overview of recent applications for drug processing / formulation / 
delivery, Chem. Eng. Process. Process Intensif. 140 (2019) 64–77. 
doi:10.1016/j.cep.2019.04.009. 
[21] G.P. Sanganwar, S. Sathigari, R.J. Babu, R.B. Gupta, Simultaneous production and co-
mixing of microparticles of nevirapine with excipients by supercritical antisolvent 
method for dissolution enhancement, Eur. J. Pharm. Sci. 39 (2010) 164–174. 
doi:10.1016/j.ejps.2009.11.011. 
[22] S.K. Sathigari, C.A. Ober, G.P. Sanganwar, R.B. Gupta, R.J. Babu, Single-Step 
Preparation and Deagglomeration of Itraconazole Microflakes by Supercritical 
Antisolvent Method for Dissolution Enhancement, J. Pharm. Sci. 100 (2011) 2952–
2965. doi:10.1002/jps.22524. 
[23] C.A. Ober, L. Kalombo, H. Swai, R.B. Gupta, Preparation of rifampicin/lactose 
microparticle composites by a supercritical antisolvent-drug excipient mixing 
technique for inhalation delivery, Powder Technol. 236 (2013) 132–138. 
doi:10.1016/j.powtec.2012.04.057. 
[24] G.A. Leeke, T. Lu, R.H. Bridson, J.P.K. Seville, Application of nano-particle coatings 
to carrier particles using an integrated fluidized bed supercritical fluid precipitation 
process, J. Supercrit. Fluids. 91 (2014) 7–14. doi:10.1016/j.supflu.2014.03.012. 
[25] Q. Li, D. Huang, T. Lu, J.P.K. Seville, L. Xing, G.A. Leeke, Supercritical fluid coating 
of API on excipient enhances drug release, Chem. Eng. J. 313 (2017) 317–327. 
doi:10.1016/j.cej.2016.12.066. 
[26] V. Prosapio, I. De Marco, E. Reverchon, Supercritical antisolvent coprecipitation 
mechanisms, J. Supercrit. Fluids. 138 (2018) 247–258. 
doi:10.1016/j.supflu.2018.04.021. 
[27] J. Yang, A. Sliva, A. Banerjee, R.N. Dave, R. Pfeffer, Dry particle coating for 





[28] M.H. Khani, Models for prediction of hydrodynamic characteristics of gas-solid 
tapered and mini-tapered fluidized beds, Powder Technol. 205 (2011) 224–230. 
doi:10.1016/j.powtec.2010.09.018. 
[29] R. Jafari, P.A. Tanguy, J. Chaouki, Characterization of Minimum Impeller Speed for 
Suspension of Solids in Liquid at High Solid Concentration , Using Gamma-Ray 
Densitometry, 2012 (2012). doi:10.1155/2012/945314. 
[30] M. Schafer, M. Yianneskis, P. Wachter, F. Durst, Trailing Vortices around a 45 " 
Pitched-Blade Impeller, 44 (1998) 1233–1246. 
[31] R. L. Carr, Evaluating flow properties of solids, Chem. Eng. 72 (1965) 163–168. 
[32] J. Li, I.W. Lee, G.H. Shin, X. Chen, H.J. Park, Curcumin-Eudragit® e PO solid 
dispersion: A simple and potent method to solve the problems of curcumin, Eur. J. 
Pharm. Biopharm. 94 (2015) 322–332. doi:10.1016/j.ejpb.2015.06.002. 
[33] M. Anwar, I. Ahmad, M.H. Warsi, S. Mohapatra, N. Ahmad, S. Akhter, A. Ali, F.J. 
Ahmad, Experimental investigation and oral bioavailability enhancement of nano-sized 
curcumin by using supercritical anti-solvent process, Eur. J. Pharm. Biopharm. 96 
(2015) 162–172. doi:10.1016/j.ejpb.2015.07.021. 
[34] V.P. Shah, A. Noory, C. Noory, B. McCullough, S. Clarke, R. Everett, H. Naviasky, 
B.N. Srinivasan, D. Fortman, J.P. Skelly, In vitro dissolution of sparingly water-soluble 
drug dosage forms, Int. J. Pharm. 125 (1995) 99–106. doi:10.1016/0378-
5173(95)00123-Z. 
[35] S.M.H. Rahman, T.C. Telny, T.K. Ravi, S. Kuppusamy, Role of Surfactant and pH in 
Dissolution of Curcumin., Indian J. Pharm. Sci. 71 (2009) 139–142. doi:10.4103/0250-
474X.54280. 
[36] K. Gowthamarajan, S.K. Singh, Dissolution testing for poorly soluble drugs: A 
continuing perspective, Dissolution Technol. 17 (2010) 24–32. 
doi:10.14227/DT170310P24. 
[37] P. Knöös, S. Onder, L. Pedersen, L. Piculell, S. Ulvenlund, M. Wahlgren, Surfactants 




Results Pharma Sci. 3 (2013) 7–14. doi:10.1016/j.rinphs.2013.08.001. 
[38] H. Sekikawa, M. Nakano, T. Arita, Inhibitory Effect of Polyvinylpyrrolidone on the 
Crystallization of Drugs, Chem. Pharm. Bull. 26 (1978) 118–126. 
doi:10.1248/cpb.26.118. 
[39] F. Depypere, J.G. Pieters, K. Dewettinck, PEPT visualisation of particle motion in a 
tapered fluidised bed coater, J. Food Eng. 93 (2009) 324–336. 
doi:10.1016/j.jfoodeng.2009.01.042. 
[40] M. Rasteh, F. Farhadi, A. Bahramian, Hydrodynamic characteristics of gas-solid 
tapered fluidized beds: Experimental studies and empirical models, Powder Technol. 
283 (2015) 355–367. doi:10.1016/j.powtec.2015.06.002. 
[41] R. Campardelli, E. Reverchon, I. De Marco, PVP microparticles precipitation from 
acetone-ethanol mixtures using SAS process: Effect of phase behavior, J. Supercrit. 
Fluids. 143 (2019) 321–329. doi:10.1016/j.supflu.2018.09.010. 
[42] I. De Marco, M. Rossmann, V. Prosapio, E. Reverchon, A. Braeuer, Control of particle 
size, at micrometric and nanometric range, using supercritical antisolvent precipitation 
from solvent mixtures: Application to PVP, Chem. Eng. J. 273 (2015) 344–352. 
doi:10.1016/j.cej.2015.03.100. 
[43] D. Geldart, Types of gas fluidization, Powder Technol. 7 (1973) 285–292. 
doi:10.1016/0032-5910(73)80037-3. 
[44] D. Geldart, N. Harnby, A.C. Wong, Fluidization of cohesive powders, Powder 
Technol. 37 (1984) 25–37. doi:10.1016/0032-5910(84)80003-0. 
[45] A. Martín, M.J. Cocero, Numerical modeling of jet hydrodynamics, mass transfer, and 
crystallization kinetics in the supercritical antisolvent (SAS) process, J. Supercrit. 
Fluids. 32 (2004) 203–219. doi:10.1016/j.supflu.2004.02.009. 
[46] Y. Peng, L.T. Fan, Hydrodynamic characteristics of fluidization in liquid-solid tapered 
beds, Chem. Eng. Sci. 52 (1997) 2277–2290. doi:10.1016/S0009-2509(97)00061-4. 
[47] Z. Huang, J. V Scicolone, X. Han, R.N. Davé, Improved blend and tablet properties of 





[48] A.S. Silva, M.T. Tavares, A. Aguiar-Ricardo, Sustainable strategies for nano-in-micro 
particle engineering for pulmonary delivery, J. Nanoparticle Res. 16 (2014) 1–17. 
doi:10.1007/s11051-014-2602-0. 
[49] D.I. Daniher, J. Zhu, Dry powder platform for pulmonary drug delivery, Particuology. 
6 (2008) 225–238. doi:10.1016/j.partic.2008.04.004. 
[50] C. Loira-Pastoriza, J. Todoroff, Delivery strategies for sustained drug release in the 
lungs, Adv. Drug Deliv. Rev. 75 (2014) 81–91. doi:10.1016/j.addr.2014.05.017. 
[51] I.M. El-sherbiny, N.M. El-baz, M.H. Yacoub, Inhaled nano- and microparticles for 
drug delivery, Glob. Cardiol. Sci. Pract. (2015) 1–14. doi:10.5339/gcsp.2015.2. 
[52] C.J.S. BRIAN R. ROHRS, GREGORY E. AMIDON, RICHARD H. MEURY, 
PAMELA J. SECREAST, HARRY M. KING, Particle Size Limits to Meet USP 
Content Uniformity Criteria for Tablets and Capsules, J. Pharm. Sci. 95 (2006) 1049–
1059. doi:DOI 10.1002/jps. 
[53] C. Bresges, N.A. Urbanetz, Determination of the minimum number of spacer particles 
ensuring non-contact between host particles - A new approach by numerical modelling, 
Powder Technol. 187 (2008) 260–272. doi:10.1016/j.powtec.2008.03.002. 
[54] L. Qu, Q. Zhou, J.A. Denman, P.J. Stewart, K.P. Hapgood, D.A. V Morton, Influence 
of coating material on the flowability and dissolution of dry-coated fine ibuprofen 
powders, Eur. J. Pharm. Sci. 78 (2015) 264–272. doi:10.1016/j.ejps.2015.07.016. 
[55] Q.T. Zhou, D. a V Morton, Drug-lactose binding aspects in adhesive mixtures: 
Controlling performance in dry powder inhaler formulations by altering lactose carrier 
surfaces, Adv. Drug Deliv. Rev. 64 (2012) 275–284. doi:10.1016/j.addr.2011.07.002. 
[56] M. Gera, V. a Saharan, M. Kataria, V. Kukkar, Mechanical methods for dry particle 
coating processes and their applications in drug delivery and development., Recent Pat. 
Drug Deliv. Formul. 4 (2010) 58–81. doi:10.2174/187221110789957200. 
[57] M.C. Gohel, P.D. Jogani, A review of co-processed directly compressible excipients, J. 
Pharm. Pharm. Sci. 8 (2005) 76–93. 
[58] P. Sanphui, N.R. Goud, U.B.R. Khandavilli, S. Bhanoth, A. Nangia, New polymorphs 




[59] F. Kurniawansyah, R. Mammucari, N.R. Foster, Polymorphism of curcumin from 
dense gas antisolvent precipitation, Powder Technol. 305 (2017) 748–756. 
doi:10.1016/j.powtec.2016.10.067. 
 
    
Chapter 6 - 
GENERAL DISCUSSION AND 
















6.1.  Main findings and recommendations for future work 
This work has demonstrated the steps taken towards the development of curcumin 
formulations with improved dissolution and flow properties using supercritical fluids. Several 
formulation strategies and processing methods were reviewed in Chapter 2 and the 
combination of SAS precipitation and coating in a tapered fluidized bed (SAS-FB) and stirred 
vessel (SAS-DEM) were found to be suitable means to achieve the aims of the project. 
Therefore, in Chapter 3, curcumin was precipitated onto the surface of free-flowing lactose 
particles (125 µm) by SAS-FB with the aim of improving curcumin dissolution (by size 
reduction) and flowability (by association with larger carrier particles). The investigation of 
several operational parameters contributed to a better understanding of the precipitation 
behaviour of curcumin from two different solvents and, for the first time, in the presence of 
fluidized particles. It was shown that formulations with uniform curcumin content were 
obtained, practically free of residual organic solvent while keeping the chemical structure of 
the raw materials. Moreover, SAS-FB particles were found to be smaller and less aggregated 
than SAS particles, so the formulation obtained would potentially be suitable for inhalation. 
Additional tests in a Twin Stage Impinger (TSI) [1,2] and Andersen Cascade Impactor (ACI) 
[3,4], for example, would have to be performed to check the amount of drug reaching the 
different regions of the respiratory tract and hence, confirm the suitability of the formulation 
for the suggested delivery route.  
The progress of the research showed that, although a reduction in the size and crystallinity of 
curcumin was previously achieved, this was insufficient to significantly improve its 
dissolution properties (dissolution tests only presented in Chapters 4 and 5). Chapter 4 then 
focused on that issue. Curcumin was coprecipitated with PVP by SAS, exploring again in the 




mixture, which were shown to affect product recovery and particle size. Even greater effect 
on that properties were observed when different solvent mixtures of ethanol and acetone 
where employed due to their high impact on the degree of supersaturation achieved (more 
acetone added in the mixture leads to a decrease in particle size and increase in product 
recovery). It was found that ethanol alone was not capable of producing coprecipitates of 
curcumin and PVP at the experimental conditions tested, explained by the great difference in 
the supersaturation ratio (concentration/solubility [5]) of the two compounds. It would be very 
interesting in future work to investigate this hypothesis by testing other solvent mixtures and 
solutes to better understand how the difference in the supersaturation ratio of the solutes 
affects the coprecipitation results. Other important findings were that low solution flow rate 
(0.5 ml/min) reduced particle coalescence of coprecipitates and low temperature (35°C) 
increased curcumin recovery. Testing higher overall concentration of the organic solution 
would be desirable to intensify the process, so other solvents and solvent mixture could be 
employed.  
The objective of Chapter 4 was achieved, with coprecipitates showing an improvement in 
water solubility of up to 600 times compared to the physical mixture of the raw materials, due 
to amorphization and size reduction of curcumin. Dissolution tests were presented in a 
mixture of water and SDS (0.25%) to demonstrate the differences in the release profile of raw 
curcumin, curcumin-PVP physical mixture, curcumin processed by SAS alone and 
CURC/PVP coprecipitates. However, in order to optimize the formulation produced in terms 
of curcumin release rate, dissolution tests in a medium capable of discriminating among 
different coprecipitates (using less SDS or other buffer solutions, as exemplified in Appendix 
IV) would be required. Since SDS significantly changes the release rate of curcumin 




in the formulation (coprecipitation of the three compounds – CURC/PVP/SDS). The analysis 
of the samples after some storage time could also provide important information about the 
stability of the formulation to prevent curcumin degradation and recrystallization. Naturally, 
bioavailability tests would be the next stage on the formulation development process.  
Chapter 5 then brings together the enhancement in solubility and flowability in the same 
formulation and a more comprehensive description of the characteristics of the integrated 
processes (SAS-FM and SAS-DEM), and requirements for successful coprecipitation and 
coating were given. It was shown that when MCC (175 µm) was used as carrier, the 
formulation produced maintained the excellent flow properties of MCC. It would be 
interesting to identify the maximum guest/host mass ratio possible while keeping the 
formulation in a flowable form. Smaller carriers (corn starch, 15 µm and lactose, < 5 µm) 
were employed as an attempt to produce novel nano-on-micro formulations for pulmonary 
delivery; however the flowability of the powder was very poor. Future work would aim to 
improve the flow properties of the formulation by adding small amounts of flow additives 
[6,7] (such as magnesium stearate and silica) in the precipitator to be mixed with the carrier 
prior to precipitation. After that, lung deposition measurements by TSI and ACI would be 
necessary for further development of the formulation. The use of a more robust experimental 
design (based on Response Surface Methodology [8,9], for example) would also be beneficial 
to evaluate a wider range of conditions and interactions of different process parameters on the 
dissolution and flow properties of the samples.  
In terms of process improvements, some changes in the rig are suggested, such as having CO2 
delivered from a larger tank kept outside the Lab. Besides being safer, this would eliminate 
the inconvenience of recording the total CO2 mass used since the last cylinder replacement 




replaced before being completely used). Moreover, it was observed that the check valves of 
some cylinders were not working properly, creating some kind of resistance to the flow of 
CO2. Many times, during experiments, even though the conditions were stable, the pressure 
would start to decrease and then rapidly increase again after a noise was heard from the 
cylinder. Such variations in pressure, and consequently in the flow rate, led to the loss of 
many experiments (stopped before the end), so having a larger tank would be highly 
beneficial with a well-maintained check valve in the inlet line. The recycling of CO2 is also 
desirable; however it is necessary to ensure that the separation system (middle pressure vessel 
and cyclone) for the mixture that leaves the precipitator is efficient to avoid recycling solvent 
and solute to the precipitator. Currently, the control of the CO2 flow rate is done manually by 
adjusting the opening of a micrometric valve. Having a pump with automatic flow control 
would definitely increase the reproducibility of the process (less dependent on the experience 
of the operator). Another desirable improvement in safety is having the rig within an enclosed 
system (fume cupboard), allowing the processing of more dangerous compounds.  
A better understanding of the combined fluidization and precipitation at different conditions 
could be possible if the window of the high-pressure vessel was bigger to allow the 
observation/recording of the solution jet entering the vessel. Different nozzle 
configurations/positions (top and bottom [11]) could also be tested. Moreover, measurements 
of the pressure drop across the bed are highly desirable to allow a more precise calculation of 
the minimum fluidization velocity for future scaling up of the equipment. 
Despite all advantages of SCF-based processing techniques described throughout this work, 
the elevated costs of high-pressure equipment, difficulties in scaling up throttling devices and 
incomplete understanding of all factors and interactions of factors affecting supercritical 




limit the applicability of such techniques in an industrial scale. However, the need of finding 
more environmentally friendly technologies and preparing highly engineered particulate 
structures will probably drive pharmaceutical research towards a deeper understanding and 
improvement of such process for future widespread industrial application [12]. Hopefully, this 
thesis will have given some contribution towards that.   
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APPENDIX I - SAS-FB Detailed Experimental 
Procedure 
 
A detailed experimental procedure for SAS-FB is presented here, with equipment and 
instruments shown in Figure 1-I. 
 
Figure I-1. Diagram of the experimental setup. 
ABREVIATIONS 
V - valve 
HE – heat exchanger 
HPV – high pressure vessel 
MPV – middle pressure vessel 
PRV – pressure relief valve 





 1. Turn on all heat exchangers (HE-01, HE-02 and HE-03); 
 2. Weigh carrier particles and prepare drug/polymer solution; 
 3. Transfer carrier particles to the bed holder and place them inside the HPV. 
 4. Fill the pipettes with solvent and drug/polymer solution 
 5. Close the vessel and connect the pipes (solvent and CO2). 
 6. Close V2, V3, V7 and V8; 
 7. OpenV1, V4, V5 and V6 to pressurize the HPV; 
 8. Wait until the pressure in PT-01 (inside the HPV) is equal to the pressure in PT-02 
(inside the cylinder, approx. 60 bar if the cylinder is full and approx. 40 bar if the 
cylinder needs replacement); 
 9. Open V9 (compressed air) to star the CO2 pump. 
 10. When the pressure in PT-01 reaches the set point (adjusted in BPR-01), close V6; 
 11. Open V8 and V2 to start the fluidization; 
 12. Open V3 to adjust the CO2 flow rate by watching FT-01; 
 13. When the flow is stable, turn on the HPLC pump to deliver pure solvent, then drug 
solution and finally flush the pipe with more pure solvent; 
 14. Turn off the HPLC pump; 
 15. Let pure CO2 running throughout the vessel to remove residual solvent; 
 16. Close V9 to stop CO2 pump; 
 17. Close V1 and wait for the pressure in the HPV to decrease to ambient (check PT-01); 
 18. Open V7 to collect the recovered organic solvent in the MPV and dispose it in the 
solvent waste bottle; 
 19. Disconnect pipes (solvent and CO2) and open the HPV to remove the bed holder with 
the coated particles; 
 20. Collect sample from the bed holder with a spatula. 




APPENDIX II - Pictures of the experimental setup 
 
  





Figure II-2. Lid of high-pressure vessel (500 ml) with detail of solution and CO2 injection for SAS. 
  
Figure II-3. a) Glass connector and cellulose thimble containg sample of coprecipitate obtained in run 
#22 (Chapter 4); b) cellulose thimbles obtained from several experiments showing that the amount of 











APPENDIX III - Residence Time Calculations 
 
III.1. Residence time in the precipitator 
The theoretical mean residence time of the mixture solvent-CO2 inside precipitator can be 
calculated according to Equation 6-1 [1]. 
𝑡𝑅 =  
𝑉
𝑣
 Equation 6-1 
where V is the volume of the fluid (volume of cellulose thimble and glass connector, where 
the precipitation happens) and v is the constant volumetric flow rate of the fluid mixture (flow 
rate of solvent + flow rate of CO2). 
III.1.1. Time to reach quasi-steady state (tSS) 
It has been demonstrated that in the SAS process the precipitator is self-mixed by the 
injection of the liquid solution and sc-CO2, behaving like a well-mixed reactor [2]. Therefore, 
the mass balance for the organic solvent is given by Equation 6-2, where CIN is the constant 
concentration of solvent in the inlet stream, and C represents the concentration of the solvent 
in the outlet, which varies with time t (Figure III-1). 
𝐶𝐼𝑁 −  𝐶 = 𝑡𝑅
𝑑𝐶
𝑑𝑡
 Equation 6-2 
 





In the beginning of the SAS process, pure solvent is pumped inside the precipitator in order to 
reach a quasi-steady state composition of solvent and CO2. For a step input, if t ≤ 0 => C = CIN 
= 0, and if t > 0 => CIN is constant (≠ 0) and C = C(t). Then the integration of Equation 6-2 
gives: 
𝑡 =  − 𝑡𝑅 ln (1 −
𝐶
𝐶𝐼𝑁
)  Equation 6-3 
Equation 6-3 was then used to calculate the time required to reach quasi steady state 
composition of organic solvent and CO2 in the precipitator, assuming C = 95%CIN and V = 
261.4 ml, CO2 flow rate of 40 g/min (which gives different values of v, depending on the 
pressure p and temperature T inside the vessel). The calculated values are shown in Table III-
1. 
Table III-1. Mean residence time (tR), time for reaching quasi-steady state composition of organic 
solvent in the fluid mixture (tSS) and required flushing time to remove residual solvent from the 



















8 40 0.278 143.9 1.0 144.9 1.8 5.4 9.6 
9 40 0.486 82.3 1.0 83.3 3.1 9.4 16.6 
12 40 0.718 55.7 1.0 56.7 4.6 13.8 24.4 
9 35 0.662 60.4 1.0 61.4 4.3 12.7 22.5 
9 50 0.285 140.4 1.0 141.4 1.8 5.5 9.8 
9 40 0.486 82.3 0.5 82.8 3.2 9.5 16.7 
9 40 0.486 82.3 1.5 83.8 3.1 9.3 16.5 
 
III.1.2. Flushing time to remove residual solvent (tF) 
To finish the precipitation process, pure CO2 is run through the vessel to remove residual 
organic solvent. It has been shown that the precipitator behaves as a well-mixed reactor if 
CO2 is introduced from the bottom, and behaves as a plug flow reactor when introduced from 




experiments, sc-CO2 was introduced in the vessel from the top, while introduced from the 
bottom during SAS-FB and SAS-DEM.  
As a longer flushing time is required in the case of a well-mixed reactor [2], this was 
considered for the calculations. In the beginning of the flushing step (t = 0), CIN = 0 (no more 
solvent enters the vessel). Therefore, the time required to achieve C = 0.5%C0 was calculated 
based on the integration of Equation 6-2, where C0 is the concentration of solvent in the outlet 
stream at the beginning of the flushing step: 
𝑡 =  − 𝑡𝑅 ln (
𝐶
𝐶0
)  Equation 6-4 
The calculated values required of CO2 flushing are shown in Table III-1 but usually it was 
run for longer periods (30 minutes).   
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APPENDIX IV -  Dissolution Method Development 
 
Dissolution of raw and processed samples in different media (samples produced in Chapter 
4). 
 
Figure IV-1. Release rate of raw curcumin and formulations in 0.05M phosphate buffer solution (pH 
4.5).  
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